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GenerAL inTroduCTion
11
ACuTe LeuKeMiA
Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow characterized 
by impaired maturation of myeloid progenitor cells and increased proliferation of these 
ineffective myeloid precursors.1 AML patients have impaired normal hematopoiesis by 
replacement of immature cells resulting in cytopenias of the different peripheral blood cell 
types. The majority of patients present with signs of bone marrow failure including anemia, 
neutropenia, or thrombocytopenia. Fatigue, infections, and hemorrhage are the most 
common clinical manifestations at presentation of AML patients, whereas enlargement of 
the spleen and liver are frequent clinical signs of the rapid proliferation of the abnormal 
myeloid precursors.  
epidemiology 
AML is the most common form of acute leukemia in adults, accounting for approximately 
80% of the cases.2 The overall incidence of AML ranges from 3 to 5 cases per 100.000 persons 
in large registries,2-4 and estimated around 3 per 100.000 persons in the Netherlands.5 The 
annual incidence of AML increases with age, estimating >20 cases per 100.000 in persons 
above the age of 70 years.4,5 AML is a disease of the elderly population with a median age 
at diagnosis of 65 to 70 years. Relative survival of patients with AML decreases with age but 
may not be generalized as survival also greatly depends on the underlying characteristics of 
the leukemia.
etiology and pathophysiology
AML can be secondary to other hematological disorders such as myelodysplastic 
syndrome or myeloproliferative neoplasms, and may also be related to previous therapy 
including treatment with topoisomerases II inhibitors (anthracyclines), alkylating agents or 
radiotherapy.6 However, the majority of patients develop a de novo AML. The development 
of AML from normal myeloid stem cells has been suggested to occur along a gradual, 
“evolutionary” path, whereby myeloid precursor cells with a proliferative advantage 
ultimately prevail. Leukemogenesis consists of the stepwise acquisition of mutations 
affecting key cellular programs, including proliferation, differentiation, cell cycle physiology, 
and/or apoptosis. Earlier, a two-hit hypothesis was proposed, consisting of class I mutations 
(eg, FLT3-ITD or K/N-RAS) conferring a proliferative advantage resulting in clonal expansion 
of myeloid progenitors, and class II mutations resulting in impaired differentiation (eg, 
NPM1 or CEBPA).7,8 However, advances in DNA sequencing of leukemic cells of individual 
patients resulted in the discovery of many genetic events, which may have a complex 
interaction. Clonal hematopoiesis with somatic mutations may occur as early events in the 
development of hematological malignancies.9,10 These mutations are gradually acquired and 
may ultimately result in coexisting malignant clones with usually one dominant clone and 
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multiple subclones harboring different genetic mutations.11,12 Studies have shown that these 
clones may evolve during the development of leukemia, but also during or after treatment, 
with clones emerging or disappearing depending on their proliferative advantage and the 
supportive or counteracting effects exerted by their (micro)environment and therapeutic 
pressure.12,13 Genetic mutations are identified in the vast majority (>95%) of patients with de 
novo AML, commonly without the presence of chromosomal abnormalities.11,14-16 The most 
frequently observed genetic alterations are mutated NPM1, FLT3-ITD, mutated DNMT3A, 
or mutated IDH, and genetic mutations may frequently co-occur with different impact 
on outcome of the individual patient.11,14-16 Coinciding with these genomic discoveries, 
molecular aberrations were demonstrated to identify subgroups of AML patients with 
distinct prognostic features, increasingly necessitating tailored treatment approaches. As a 
result, molecular analysis has become pivotal in the diagnosis and risk classification of AML 
patients. The applied techniques are rapidly evolving and were recently summarized.16,17
diagnosis and risk classification
Morphology of peripheral blood and bone marrow smears is still the cornerstone of 
diagnosing AML.18 A bone marrow or peripheral blood blast count of more than 20% is 
required for the diagnosis of AML according to the latest European LeukemiaNET (ELN) 
guideline.18 In addition to morphology, the evaluation of patients with AML should also 
include immunophenotyping, cytogenetics and molecular analysis of the leukemic blasts 
as the WHO classification of myeloid neoplasm is increasingly based on molecular genetic 
diagnostics. The latest WHO 2016 classification includes AML with BCR-ABL1 and mutated 
RUNX1 as two new provisional entities.18 In addition, a new category called “myeloid 
neoplasm with germ line predisposition” was added, recognizing myeloid malignancies being 
associated with inherited or de novo germ line mutations.18 The increased and extensive use 
of genetic data for patients with AML has provided the opportunity to address the predictive 
capacity of specific genetic mutations.14-16,19 Previously, conventional cytogenetics and 
mutations of NPM1, FLT3-ITD and CEBPA were included in the ELN 2010 risk classification 
of AML patients.20 The current ELN 2017 AML risk classification has added mutations in 
three genes including RUNX1, ASXL1, and TP53 (Table 1).18 Similar to the previous risk 
classification, the ELN 2017 risk classification is advocated to be used for risk-stratifying AML 
and to a risk-adapted treatment approach of patients with AML.  
induction treatment
The first goal of treatment of patients with AML is to obtain a complete hematological 
remission (CR), which is defined as a blast count of less than 5% in the bone marrow and 
recovery of peripheral neutrophils and platelets. Since the early 1980s, the backbone of AML 
induction treatment has been the “7 + 3” regimen, which is a combination of cytarabine and 
an anthracycline.21,22 Cytarabine is generally dosed as 100-200 mg/m2 daily as a continuous
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Table 1  European LeukemiaNET 2017 AML risk classification*
risk category Genetic or molecular abnormality
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow†
Biallelic mutated CEBPA
Intermediate Mutated NPM1 and FLT3-ITDhigh†
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow† (without adverse risk genetic lesions)
t(9;11)(p21.3;q23.3); MLLT3-KMT2A‡
Cytogenetic abnormalities not classified as favorable or adverse
Adverse t(6;9)(p23;q34.1); DEK-NUP214
t(v;11q23.3); KMT2A rearranged
t(9;22)(q34.1;q11.2); BCR-ABL1
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)
–5 or del(5q); –7; –17/abn(17p)
Complex karyotype,§ monosomal karyotype||
Wild-type NPM1 and FLT3-ITDhigh†
Mutated RUNX1{
Mutated ASXL1{
Mutated TP53
*   Table adapted from Dohner et al. Diagnosis and management of AML in adults: 2017 ELN recommendations 
from an international expert panel. Blood. 2017;129(4):424-47; Table 5.17
†    Low, low allelic ratio (<0.5); high, high allelic ratio (≥0.5); semi quantitative assessment of FLT3-ITD allelic ratio
     (using DNA fragment analysis) is determined as ratio of the area under the curve “FLT3-ITD” divided by area    
      under the curve “FLT3-ITD wild-type”
‡   The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations.
§   Three or more unrelated chromosome abnormalities in the absence of 1 of the WHO-designated recurring 
translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); 
AML with BCR-ABL1
||   Defined by the presence of 1 single monosomy (excluding loss of X or Y) in association with at least 1 additional 
monosomy or structural chromosome abnormality (excluding core-binding factor AML)
{  These markers should not be used as an adverse prognostic marker if they co-occur with favorable risk AML 
subtypes
infusion for seven days for induction, whereas intensified cytarabine has been the 
cornerstone of consolidation chemotherapy. The HOVON approach was established as 
induction chemotherapy consisting of cytarabine 200 mg/m2 daily for seven days and 
idarubicin 12 mg/m2 for three days, followed by consolidation therapy with an anthracycline 
and high-dose cytarabine, which dosage has currently been established at 1000 mg/m2.23-35 
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Higher dosing of cytarabine up to 3000 mg/m2 has been associated similar CR rates, whereas 
increased toxicity has been reported.32,36,37 The anthracycline in the induction regimens 
may be three days of either idarubicine 12 mg/m2 daily or daunorubicine 60 mg/m2 
daily. Different doses of anthracyclines have been investigated, with daunorubicine 90 mg/m2 
being associated with higher response rates as compared with daunorubicine 45 mg/m2,29,38,39 
whereas a recent randomized study found increased early mortality compared with a 
dosage of 60 mg/m2.40 The ELN 2017 guideline has recommended a dose of 60 mg/m2 
daunorubicine as the minimum dose.18 Other groups have compared idarubicine 12 mg/m2 
with daunorubicine either dosed at 50 mg/m2 or 80 mg/m2 and found no significant 
differences in response rate or outcome parameters.41,42 Thus the “7 + 3” regimen with 
cytarabine and an anthracycline  (either daunorubicine or idarubicine) has been adopted as 
the backbone of induction chemotherapy. That regimen may result in an hematological CR 
in 60 to 90% of patients aged 60 years and younger, whereas CR rates are lower (40 to 60%) 
in elderly patients above the age of 60 years.29,32,35-42 Decreased CR rates and shorter duration 
of CR in elderly patients may be related to the disease itself harboring more high-risk 
features resulting in a higher incidence of refractory disease, but also to increased mortality 
following induction treatment due to concurrent diseases.43 
A number of drugs have been added to the backbone of AML treatment in prospective 
phase 3 trials of younger and elderly patients to improve the response rate and outcome 
of AML induction treatment.44 These drugs include etoposide,45,46 nucleoside analogues 
(ie, fludarabine, cladribine, or clofarabine),28,35,37,47-50 or the anti-CD33 antibody-drug conjugate 
gemtuzumab ozogamicin.30,51-55 The latter drug was initially withdrawn because of negative 
results, but has regained interest after a meta-analysis was published, which reported lower 
relapse rates and improved survival in patients with favorable or intermediate risk AML.56 
A number of FLT3 inhibitors (ie, sorafenib, midostaurin, lestaurtinib) have also been studied 
in randomized phase 3 trials as additive drug to the backbone induction treatment of AML 
patients.57-60 Recently, midostaurin was associated with improved overall survival (OS) 
compared with placebo in patients with AML harboring a FLT3 mutation, which resulted 
in approval for midostaurin in AML patients with FLT3 mutations.60 Currently, multiple 
new drugs are being investigated, including drugs targeting specific molecular mutations, 
hypomethylating agents, and new chemotherapeutic drug formulations.61 These drugs 
are currently primarily used in the setting of relapsed or refractory AML patients, but may 
proceed to the induction treatment of AML within the next years. 
Post-remission treatment
The majority of patients obtain a first hematological CR after induction treatment, but the 
risk of a relapse without further treatment is considerably high. Post-remission treatment 
may reduce the risk of relapse and may consist of continued chemotherapy, autologous 
hematopoietic stem cell transplantation (HSCT) and allogeneic HSCT (alloHSCT). The clinical 
Chapter 1
15
decision for post-remission treatment is primarily based on the risk of the leukemia, but 
also on other factors, including the potential to harvest stem cells, the availability of an 
allogeneic donor, and patients performance status or concurrent morbidity. 
Continued chemotherapy 
Post-remission chemotherapy has been associated with acceptable toxicity profiles and 
may be specifically applied in patients who appear chemotherapy sensitive.62 The HOVON 
approach has been to continue chemotherapy in such patients with mitoxantrone and 
etoposide,27,32 whereas other groups have used post-remission cytarabine. The optimal dose 
of cytarabine has been addressed by different study groups, although a dose of 1500 mg/m2 
has been associated with less toxicity and similar OS compared with higher doses of 
cytarabine.37,63 Different other chemotherapeutic regimens did also not yield better outcome 
compared with high doses of cytarabine (ie, >2000 mg/m2).64-66 Although subgroups of AML 
patients may have profited from higher doses of cytarabine, no convincing evidence is 
currently available that higher doses of cytarabine are preferred over a dose of >1000 mg/m2 
as post-remission chemotherapy.67 
Autologous hematopoietic stem cell transplantation 
Autologous HSCT consists of high dose chemotherapy followed by the infusion of autologous 
hematopoietic progenitor cells to ensure hematopoietic recovery. Initially, autologous 
HSCT was performed using autologous bone marrow,68,69 with randomized studies and 
their meta-analyses reporting better relapse-free survival (RFS) following autologous bone 
marrow transplantation, but similar OS compared with chemotherapeutic post-remission 
treatment or no further treatment.70-73 Autologous HSCT with peripheral blood stem 
cells was increasingly being used as from the early 1990s, which transplants contain a 
significantly higher number of stem cells compared with bone marrow resulting in improved 
hematological recovery and less mortality from infectious or bleeding complications.74-77 
The comparative value of autologous peripheral blood HSCT and chemotherapeutic 
consolidation has not been studied extensively. The HOVON-SAKK group has performed 
a prospective randomized study of autologous peripheral blood HSCT compared with 
chemotherapeutic consolidation and found significantly less relapse, a trend towards better 
RFS, but similar OS compared with post-remission chemotherapy.31 Retrospective studies 
have also compared autologous HSCT with alloHSCT following sibling donors. These studies 
showed less non-relapse mortality (NRM) following autologous HSCT, but an increased 
cumulative incidence of relapse which resulted in similar outcome in good and intermediate 
risk patients.78-80 Although autoHSCT provides a stronger cytotoxic anti-leukemic effect 
than continued chemotherapy, the application of autoHSCT may be limited to subgroups 
of patients, including patients lacking an appropriate stem cell donor or being ineligible for 
alloHSCT, but having a sufficient autologous stem cell harvest.81,82 
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Allogeneic hematopoietic stem cell transplantation
AML has become the most dominant indication for alloHSCT worldwide.83,84 AlloHSCT was 
originally developed with an intensive cytotoxic conditioning regimen for leukemic ablation, 
but also to provide an immunosuppressive effect preventing graft rejection of allogeneic bone 
marrow cells.85 The anti-leukemic effect was initially attributed to high dose chemotherapy 
and radiotherapy, but was subsequently largely ascribed to the immunological graft-versus-
leukemia (GVL)-effect, initially based on the observation of an inverse relation of relapse 
rates and grades of graft-versus-host disease (GVHD).86 T-cells were found to be largely 
responsible for GVL, with alloreactivity resulting from recognition of disparate allogeneic 
antigens. These disparities were later found to involve minor and major human leucocyte 
antigens (HLA) as well as some specific tumor antigens.87-91 Retrospective studies confirmed 
the observation of an increased relapse rate in patients who received an alloHSCT with either 
T-cell depletion of the donor graft or patients who received intensified immunosuppressive 
regimens for prevention of GVHD. These strategies resulted in less GVHD at the expense of 
increased relapse, indicating that the GVL-effect was abrogated upon elimination of donor 
T-cells.92-94 The GVL-effect has been extensively investigated since these observations, and 
it was subsequently exploited with the development of donor lymphocyte infusions after 
transplantation.95,96 
Although alloHSCT was shown to offer the most effective anti-leukemic therapy in AML, 
counterbalancing NRM compromised that favorable effect compared with chemotherapy 
or autologous HSCT.72 As randomized studies proved to be difficult to perform, comparative 
studies evaluated alloHSCT by donor availability in so-called donor-versus-no-donor studies. 
The HOVON-SAKK group also performed such a donor-versus-no-donor analysis and found 
no benefit of myeloablative conditioning (MAC) alloHSCT in patients with a favorable risk 
AML, whereas improved OS and RFS were reported in patients with an intermediate or poor 
risk AML.97 These results were confirmed by others and also documented in several meta-
analysis of these studies.97-99 However, the meta-analysis by HOVON-SAKK suggested that 
the survival benefit of MAC alloHSCT was limited to patients below the age of 40 years, due 
to increased NRM in older patients.97 These and other studies highlighted the need to reduce 
NRM associated with alloHSCT.97-102 As the beneficial effect of alloHSCT depended on GVL 
rather than on intensive chemotherapy and radiotherapy, attempts were made to reduce the 
toxicity of the fully myeloablative regimens. Reduced intensity conditioning (RIC) regimens 
were developed, which were associated with decreased toxicity and mortality.103-109 The 
GVL-effect of alloHSCT following RIC regimens was still present and was found to be stronger 
in patients who experienced chronic GVHD, whereas patients who received a T-cell depleted 
graft had a higher incidence of relapse.110-112 One of the least intensive nonmyeloablative 
conditioning regimen was developed by the Seattle group consisting of fludarabine and 
a low dose of total body irradiation, which was associated with effective engraftment 
and limited early mortality.109 However, the anti-leukemic effects of these less intensive 
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conditioning regimens were questioned in patients with high risk leukemias in which patient 
groups higher relapse rates were observed.113 Therefore, others added intermediate dose 
alkylating agents (ie, busulfan, treosulfan, melphalan) to the conditioning to enhance the 
anti-leukemic efficacy.114-119 These RIC regimens were suggested to be associated with less 
relapse compared with nonmyeloablative regiments, but no randomized prospective studies 
have been conducted so far comparing these regimens. Nevertheless, these less intensive 
conditioning regimens broadened the application of alloHSCT, particularly for elderly 
patients or for patients with concurrent morbidity. Meanwhile, the increased availability 
of alternative donors has allowed to offer alloHSCT to the majority of AML patients for 
whom transplantation is indicated. Increased availability of stem cell donors resulted from 
an enormous increase of potential volunteer unrelated donors in the larger registries, 
including the American and several European and Asian registries.83,84,120 In addition, 
unrelated cord blood was developed as an alternative stem cell source, whereas haplo-
identical family donors have regained interest more recently.121-126 Although the degree of 
antigen disparity is greater using alternative donors, most transplants with the use of these 
donors are currently performed following RIC and with more intensive immunosuppressive 
approaches.124-126 Collectively, studies in AML with alloHSCT following RIC confirmed the 
potency of the immunotherapeutic GVL-effect of alloHSCT, but GVHD related toxicity and 
mortality of alloHSCT have remained a major challenge, especially following transplants 
with alternative donors.103,126-130 
AiMS And ouTLine oF THe THeSiS
This thesis addresses the value of post-remission therapy with alloHSCT and weighs the 
beneficial anti-leukemic effects of alloHSCT versus toxicity and non-relapse mortality. 
The first part of the thesis addresses the comparative value of alloHSCT as post-
remission treatment in subgroups of patients. In Chapter 2, post-remission treatment with 
chemotherapy, autologous HSCT, or alloHSCT following RIC of MAC regimens was compared 
in patients aged 40 to 60 years. The comparative value of these post-remission therapies 
were considered in three leukemia risk groups with different effects of alloHSCT on OS, RFS 
and the cumulative incidence of relapse. Outcome of elderly patients who receive intensive 
treatment for AML may be worse as compared with younger patients. Chapter 3 addresses 
outcome following post-remission treatment in elderly patients above the age of 60 years, 
comparing no further post-remission treatment with chemotherapy, autologous HSCT or 
alloHSCT following RIC. The outcome of post-remission treatment was again compared 
in different AML risk groups. Post-remission treatment has been specifically debated in 
patients with an intermediate risk AML, especially taking molecular markers (eg, NPM1 and 
FLT3-ITD) into account. We addressed the impact of NPM1 and FLT3-ITD including the FLT3-
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ITD allelic ratio on the outcome in patients with cytogenetically normal AML in Chapter 4. 
Patients were classified based on these molecular markers and outcome of post-remission 
treatment with alloHSCT vs autologous HSCT or chemotherapy was compared. A risk-
adapted approach of AML may be further developed taking minimal residual disease (MRD) 
into account. Chapter 5 addresses whether and to what extent the GVL-effect of alloHSCT 
was present in patients with or without MRD to provide further risk- and MRD-adapted 
recommendations for post-remission treatment with alloHSCT.
The second part of the thesis focuses on complications and toxicity of alloHSCT. In Chapter 6, 
the preferred type of donor for patients with poor risk AML in first CR was investigated in a 
large cohort of alloHSCT recipients. Outcome was compared for patients receiving alloHSCT 
with matched related donors, matched unrelated donors, mismatched unrelated donors, 
cord blood grafts, or haplo-identical donors. Secondly, outcome and mortality following 
alloHSCT may be predicted before transplantation using transplant risk scores. Chapter 7 
addresses the prediction of NRM in recipients of RIC alloHSCT. Previous established risk 
scores were evaluated and the variables of these scores were subsequently reassessed and 
combined into a new NRM risk score for AML patients proceeding to RIC alloHSCT. Chapter 8 
describes the incidence and sequelae of hepatitis E virus as an opportunistic pathogen in 
recipients of alloHSCT having clinical implications.
Finally, Chapter 9 summarizes the most important findings of this thesis and provides a 
risk-adapted approach for a personalized post-remission treatment of AML patients taking 
into account the risk of relapse, but also the risk of mortality.
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AbSTrACT 
The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia 
(AML) in first complete remission (CR1) is a subject of continued debate, especially in 
patients at higher risk of non-relapse mortality (NRM), including patients >40 years of age. 
We report results of a time-dependent multivariable analysis of allogeneic hematopoietic 
stem cell transplantation (alloHSCT) (n = 337) versus chemotherapy (n = 271) or autologous 
HSCT (autoHSCT) (n = 152) in 760 patients aged 40-60 years with AML in CR1. Patients 
receiving alloHSCT showed improved overall survival (OS) as compared with chemotherapy 
(respectively 57 ± 3% vs 40 ± 3% at 5 years, P < 0.001). Comparable OS was observed 
following alloHSCT and autoHSCT in patients with intermediate risk AML (60 ± 4% vs 54 ± 
5%). However, alloHSCT was associated with less relapse (hazard ratio [HR] 0.51, P < 0.001) 
and better relapse-free survival (RFS) (HR 0.74, P = 0.029) as compared with autoHSCT in 
intermediate risk AMLs. AlloHSCT was applied following myeloablative conditioning (n = 
157) or reduced intensity conditioning (n = 180), resulting in less NRM, but comparable 
outcome with respect to OS, RFS and relapse. Collectively, these results show that alloHSCT 
is to be preferred over chemotherapy as PRT in patients with intermediate and poor risk 
AML aged 40-60 years, whereas autoHSCT remains a treatment option to be considered in 
patients with intermediate risk AML. 
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Although hematological first complete remissions (CR1) may be achieved in ~80% of 
younger patients with newly diagnosed acute myeloid leukemia (AML), the relapse rate 
is still unacceptably high and varies according to age and the underlying cytogenetic and 
molecular profile of the leukemia.1-5 Post-remission therapy (PRT) is applied for prevention 
of relapse and may include either consolidation chemotherapy or hematopoietic stem cell 
transplantation (HSCT) using either allogeneic (alloHSCT) or autologous (autoHSCT) stem 
cell grafts. Although alloHSCT offers the most effective antileukemic therapy, enhanced 
non-relapse mortality (NRM) may compromise that favorable effect. As a result, alloHSCT is 
no longer indicated for favorable risk AML,6 and currently being discussed in patients with 
intermediate risk AML.7-9
NRM following myeloablative conditioning (MAC) alloHSCT increases with age and/or 
comorbidities,10-12 as a result of which a net survival benefit of alloHSCT in AML patients 
beyond 40 years could not be demonstrated in a meta-analysis of the earlier studies by 
HOVON, MRC, EORTC and the French BGM group.6,13-16 Following that observation, several 
HOVON centers introduced reduced intensity conditioning (RIC) alloHSCT in patients beyond 
40 years of age to reduce NRM, while maintaining graft versus leukemia (GVL) effects.17,18 
Meanwhile, by virtue of the use of peripheral blood stem cells instead of bone marrow, 
results of autoHSCT gradually improved in AML.19 These developments, as well as results of 
more recent retrospective and prospective studies,20-22 urged us to readdress the question 
of preferred PRT in a more recent cohort of AML patients, aged 40-60 years. Particularly 
this age-cohort allowed us to compare PRT by alloHSCT, using either RIC or MAC, versus 
chemotherapy or autoHSCT. We evaluated these PRT modalities by time-dependent analysis, 
a method that has lately increasingly been applied for evaluation of alloHSCT, as the sibling 
donor versus no-donor methodology can no longer be applied with the increased use of 
unrelated donors.7,23-26 The method allows for comparing patients actually transplanted 
versus non-transplanted patients without the bias caused by the time to transplant.27 
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PATienTS And MeTHodS
Patients
A total of 760 patients between 40 and 60 years of age with newly diagnosed AML receiving 
PRT in CR1, who participated in two consecutive, prospective HOVON-SAKK phase III trials 
(AML42/42A, and AML92), were included.19,28,29 Patients were classified for leukemia risk, 
based on the cytogenetic and molecular profile of the underlying AML, according to the 
latest European LeukemiaNET (ELN) AML risk classification.1 In the present analysis, the 
intermediate-I and intermediate-II risk groups of the ELN risk classification were combined 
because of similar outcome of these subgroups (Supplementary Figure 1). Both AML42/42A 
and AML92 had been approved by ethics committees of participating institutions and were 
conducted in accordance with the Declaration of Helsinki. All participants had given written 
informed consent. Detailed description of the inclusion and exclusion criteria of these 
studies are previous reported.28,29 
Treatment protocols
Treatment in the AML42/42A and AML92 studies involved a maximum of two remission 
induction cycles, including anthracyclin with cytarabine chemotherapy, as previously 
described.28,29 Three different types of PRT were applied in patients in CR1 according to a 
predefined strategy as outlined in the AML42 and AML 92 protocol, including a third cycle 
of chemotherapy with mitoxantrone and etoposide, high-dose chemotherapy with busulfan 
and cyclophosphamide followed by autoHSCT, or alloHSCT following either RIC or MAC. These 
different therapeutic modalities were applied according to a risk-adapted strategy.19,28,29 
(1) Patients with AML classified as favorable risk, according to cytogenetic and available 
molecular analysis, were planned for a third cycle of chemotherapy; (2) intermediate risk 
patients were preferentially treated by alloHSCT using a human leukocyte antigen (HLA) 
matched sibling donor or a fully HLA-matched unrelated donor if available; and (3) patients 
with poor risk AML proceeded to alloHSCT using either a sibling or unrelated donor, using 
7/8 or 8/8 matched donors. Patients alternatively received an autoHSCT or a third cycle of 
chemotherapy if no suitable donor was available.19 
Transplantation protocols
Patients received either a MAC or RIC regimen followed by the infusion of donor cells. RIC-
alloHSCT was introduced in patients below 60 years as from 2001, whereby the indication 
for RIC or MAC was selectively determined by age and consistently adhered to by the 
individual center throughout the AML42/42A and AML92 studies. Whereas some centers 
maintained their policy of MAC-alloHSCT for all patients up to the age of 60, a number of 
centers changed their policy by setting the age limit for MAC at <40 and RIC for patients 
of 40 years and beyond. The degree of HLA-matching for unrelated donors was 8/8 allele 
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match for HLA-A, B, C, and DRB1 for intermediate risk patients and ≥ 7/8 allele match for 
poor risk patients. The MAC regimen contained high-dose cyclophosphamide with total 
body irradiation (TBI) in 110 (70%) patients, whereas the remainder received busulfan with 
cyclophosphamide. T-cell depletion was only performed in recipients of MAC-alloHSCT, 
whereby partial T-cell depletion was performed by CD34-selection and add-back of T-cells 
to the graft to ensure 1 × 105 T-cells/kg bodyweight of the recipient, as described earlier.30 
Although RIC regimens varied, the majority contained 2.0 Gy TBI preceded by fludarabine (n 
= 126, 70%), as described earlier.17 A calcineurin inhibitor (either ciclosporin or tacrolimus) 
plus mycophenolate mofetil or methotrexate was given as prophylaxis for graft versus 
host disease (GVHD). Recipients of a T-cell depleted MAC-alloHSCT received a calcineurin 
inhibitor (either ciclosporin or tacrolimus) plus methotrexate as GVHD prophylaxis. 
endpoints
The primary endpoint of the study was overall survival (OS), according to the type of PRT 
received. OS and relapse-free survival (RFS) were measured from the date of start of PRT. The 
event for OS was death whatever the cause, and patients were censored at the date of last 
contact, if alive. The events for RFS were death in CR1, designated as NRM or hematological 
relapse. The cumulative risks of relapse and NRM over time were calculated as competing 
risks with actuarial methods where patients alive in continuing CR1 were censored at the 
date of last contact.
Statistical methods
A time-dependent analysis of PRT was performed as described previously,24 by applying 
multivariable Cox regression with time-dependent covariates autoHSCT and alloHSCT. The 
multivariable analysis is conceptually similar to a Mantel-Byar analysis,31 but more general as 
it allows for adjustment for other factors. Some patients received PRT with chemotherapy (n 
= 39) or autoHSCT (n = 3) first before they proceeded to alloHSCT. In both the multivariable 
analysis and the estimation of the survival curves, these patients were counted as at risk in 
the chemotherapy or autoHSCT group from the start of PRT until alloHSCT and after that 
as at risk in the alloHSCT group. Multivariable Cox regression analysis for OS, RFS, relapse 
and NRM was applied with stratification for leukemia risk and adjustment for late CR (after 
cycle II instead of I), time from CR to PRT, age, sex and year of treatment before or after 
2006. Year of treatment before or after 2006 was included to adjust for a possible overall 
difference in outcomes between these two periods. Moreover, time from start induction to 
start post-remission treatment and T-cell depletion were added as factors to the model, but 
showed no significant effects on OS, RFS, relapse or NRM. A similar analysis restricted to 
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alloHSCT patients was done for a direct comparison of RIC-alloHSCT and MAC-alloHSCT, with 
stratification by leukemia risk and adjustment for late CR, time from CR to transplantation, 
age, sex, donor type and year of transplantation before or after 2006. In addition, time 
from start induction to transplantation, number of induction cycles, stem cell source, TBI, 
patient/donor gender mismatch and cytomegalovirus mismatch were not included in the 
model because of no significant effect on outcome. All P-values were based on log likelihood 
ratio tests, except when explicitly stated otherwise. Log likelihood ratio tests were also used 
to test for interactions. The proportional hazard assumption was tested on the basis of 
Schoenfeld residuals.32 P-values have not been adjusted for multiple testing. All analyses 
were done with Stata Statistical Software: Release 13 (2013, College Station, TX, USA: Stata 
Corporation). 
received no post- 
remission treatment 
51  early death
35  AML progression
33  excessive toxicity
11  no compliance
  8  hypoplasia
39  unknown reasons
1,196  patients aged 40-60 years included in two consecutive  
           HOVON-SAKK studies (AML42/42A, AML 92)
   937  patients obtained CR after 1 or 2 chemotherapy induction cycles
 760  patients received post-remission treatment
177
259  no CR after 2 cycles
 
310  received chemo
        followed by*  
        alloMAC    in 13 pts  
        alloRIC      in 26 pts
155  received autoHSCT
        followed by*  
        alloMAC    in 2 pts  
        alloRIC      in 1 pt
157  received alloMAC
        (including 13+2 pts)
180  received alloRIC
        (including 26+1 pt)
Figure 1  Consort diagram
*Counted as at risk in the transplantation group as from the day of transplant, according to time-dependent analysis
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reSuLTS
Characteristics of the patients
Between January 2001 and February 2010, induction chemotherapy was started in 1196 
patients aged 40-60 years (Figure 1). CR after induction (2 cycles) was obtained in 937 (78%) 
patients, of whom 760 proceeded to PRT with either chemotherapy (n = 271), autoHSCT (n 
= 152), MAC-alloHSCT (n = 157) or RIC-alloHSCT (n = 180). One hundred and seventy seven 
patients in CR1 did not receive PRT, because of toxicity (n = 33), early death (n = 51), AML 
progression (n = 35) or other reasons (Figure 1). Patient characteristics are presented in 
Table 1. Owing to the preferred application in poor risk patients, more patients proceeding to 
alloHSCT exhibited adverse risk features. A higher percentage of alloHSCT recipients needed 
two cycles of chemotherapy instead of one cycle to obtain CR. AutoHSCT and alloHSCT were 
more frequently applied in recent years. The median follow-up of patients still alive was 
79 months and differed between patients receiving chemotherapy (83 months), autoHSCT 
(71 months), MAC-alloHSCT (88 months) and RIC-alloHSCT (75 months). Table 2 presents 
transplantation characteristics of alloHSCT recipients, comparing the groups of RIC and MAC. 
Recipients of RIC-alloHSCT were significantly older and were transplanted more frequently 
in the recent years. Grafts were not manipulated in all RIC-alloHSCT patients, whereas 24% 
of MAC-alloHSCT patients received grafts, partially depleted of T-cells. Patients receiving 
RIC-alloHSCT and MAC-alloHSCT had similar donor source, stem cell source, CMV-serology 
status, female donors/male recipient’s ratio and similar distributions of their leukemia risk 
profile1 and EBMT-risk scores10 (Tables 1 and 2).
Treatment outcome
OS appeared to be clearly different in the favorable, intermediate-I/intermediate-II, adverse 
leukemia risk groups as categorized by the ELN AML risk classification,1 with OS at 5 years 
of 74 ± 4% in favorable risk, 51 ± 3% in intermediate-I risk, 47 ± 6% in intermediate-II risk 
and 33 ± 4% in adverse risk AMLs (Supplementary Figure 1). Because of similar survival 
in the ELN intermediate I and II risk subcategories, these patients were analyzed as one 
single intermediate risk group. Outcome estimates at 5 years for each type of PRT by ELN 
risk group can be found in Supplementary Table 1. Figure 2a and 2b show OS and RFS of all 
patients by type of PRT, stratified for leukemia risk. Improved OS was found for alloHSCT 
recipients as compared with patients receiving chemotherapy as PRT (57 ± 3% versus 40 ± 
3% at 5 years, P<0.001, Figure 2a). In addition, OS was significantly improved in recipients of 
autoHSCT as compared with recipients of chemotherapy (54 ± 3% versus 40 ± 3% at 5 years, 
P = 0.02, Figure 2a). 
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Table 1  Patient characteristics 
Post-remission treatment p-value
(CT vs Auto)
p-value
(CT vs Allo)
CT
(n=271)
Auto
(n=152)
Allo
(n=337)
Gender 
Male 151 56% 83 55% 181 54% .83 .62
Female 120 44% 69 45% 156 46%
Age (years)
Median                     52 52 51 .72 .14
Range                      40–60 40–60 40-60
wbC at diagnosis (x109/l)
Median                     14 16 7 .55 .005
Range                      1–400 1–220 0-300
Karyotype classification 
t(8;21)                    18 7% 4 3% 3 1% .002 <.001
inv(16)                    30 11% 3 2% 4 1%
CN-X-Y                      149 55% 91 60% 171 51%
CA Rest                    45 17% 33 22% 106 31%
MK                         15 6% 4 3% 40 12%
Missing 14 5% 17 11% 13 4%
Molecular classification (positive patients)*
NPM1                    64 24% 43 28% 61 18% .078 .15
CEBPα dm                    4 1% 7 5% 5 1% .052 .91
FLT3-ITD ratio < 0.60           22 8% 21 14% 37 11% .33 .23
FLT3-ITD ratio > 0.60 9 3% 3 2% 5 1%
EVI1 8 3% 4 3% 15 4% .97 .20
risk AML†
Favorable 86 32% 39 26% 29 9% .28 <.001
Intermediate               150 55% 93 61% 161 48%
Adverse                       35 13% 20 13% 147 44%
Cr reached after
Cycle 1 (early CR) 220 81% 130 86% 245 73% .26 .014
Cycle 2 (late CR) 51 19% 22 14% 92 27%
Time from start induction to start post-remission treatment (months)
Median                     3.3 3.6 3.8 .002 <.001
IQ range                      3–4 3–4 3–4
Time from Cr to start post-remission treatment (months)
Median                     2.1 2.3 2.3 <.001 .039
IQ range                      1–3 1–3 1–3
year of start treatment 
<2006                      169 62% 73 48% 162 48% .004 <.001
≥2006                     102 38% 79 52% 175 52%
Abbreviations: CT indicates chemotherapy; Auto, autologous hematopoietic stem cell transplantation; Allo, 
allogeneic hematopoietic stem cell transplantation; WBC, white blood cell count; CN-X-Y, cytogenetically normal or 
only loss of X or Y chromosome; CA, cytogenetically abnormal; MK, monosomal karyotype; NPM1, nucleophosmin 1; 
CEBPα dm, CCAAT/enhancer-binding protein alpha double mutations; FLT3-ITD, Fms-like tyrosine kinase 3 internal 
tandem duplication; EVI1, ecotropic virus integration site 1; AML, acute myeloid leukemia; CR, complete remission; 
and IQ, interquartile range; * Molecular analysis was available in 62% of the patients for NPM1 and Flt3-ITD, and in 
54% of the patients for CEPBα and EVI1; † According to the European LeukemiaNET AML risk classification
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Table 2  Characteristics of alloHSCT recipients
Conditioning p-value
AlloMAC 
(n=157)
AlloriC 
(n=180)
Age (years) 
Median 48 54
<.001
Range 40–59 40–60
risk AML*
Favorable 16 10% 15 8%
.81Intermediate               92 59% 110 61%
Adverse                       49 31% 55 31%
Cr reached after
Cycle 1 (early CR) 108 69% 137 76%
.13
Cycle 2 (late CR) 49 31% 43 24%
year of start treatment 
<2006                      92 59% 70 39%
<.001
≥2006                     65 41% 110 61%
donor type 
HLA-identical sibling 117 75% 131 73%
.42VUD 29 18% 41 23%
Other 11 7% 8 4%
T-cell depletion 
Yes 38 24% 0
<.001
No 119 76% 180 100%
Stem cell source 
PB 141 90% 170 94%
.11
BM 16 10% 10 6%
Tbi given 
Yes 110 70% 131 73%
.092No 41 26% 31 17%
Unknown 6 4% 18 10%
Female donor to male recipient 
Yes 35 22% 33 18%
.37
No 122 78% 147 82%
CMv match patient/donor 
-/- 59 38% 57 32%
.36
-/+ 13 8% 25 14%
+/- 37 24% 44 24%
+/+ 48 31% 54 30%
ebMT-score
1 point 3 2% 2 1%
.85
2 points 90 57% 103 57%
3 points 56 36% 68 38%
4 points 8 5% 7 4%
Abbreviations: AlloMAC indicates myeloablative conditioned allogeneic hematopoietic stem cell transplantation; 
alloRIC, reduced intensity conditioned allogeneic hematopoietic stem cell transplantation; AML, acute myeloid 
leukemia; CR, complete remission; HLA, human leukocyte antigen; VUD, voluntary unrelated donor; PB, peripheral 
blood; BM, bone marrow; TBI, total body irradiation; CMV, cytomegalovirus; and  EBMT, European Group for Blood 
and Marrow  Transplantation; * According to the European LeukemiaNET AML risk classification                                                   
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Intermediate risk AMLs
In intermediate risk patients, alloHSCT and autoHSCT significantly improved OS as compared 
with chemotherapy (60 ± 4% and 54 ± 5%, respectively, versus 36 ± 4% at 5 years, P<0.001, 
Figure 2c), while OS after alloHSCT versus autoHSCT was not significantly different. In 
contrast, improved RFS was found in patients with intermediate risk AML receiving PRT 
with alloHSCT as compared with autoHSCT (56 ± 4% versus 39 ± 5% at 5 years, respectively, 
P = 0.04, Figure 2d). Trends toward improved OS and RFS were found for alloHSCT and 
autoHSCT as compared with chemotherapy in the relatively small subgroups of favorable 
and unfavorable risk leukemia’s (Supplementary Figure 2). 
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Figure 2  OS and RFS in all patients and intermediate-risk patients by post-remission treatment 
Kaplan-Meier estimates of OS (A) and RFS (B) of patients with AML in first complete remission from start of post-
remission treatment, according to post-remission treatment and with direct adjustment for differences in leukemia 
risk category among the treatment groups by the method of Gail and Byar.55 Kaplan-Meier estimates of OS (C) and 
RFS (D) in intermediate risk patients. Of note, numbers of patients at risk (indicated below the x axis) differ from the 
patient numbers (indicated in Table 1 and within the figure) because of the time-dependent nature of this analysis, 
which allows for time to transplantation by switching patients at the time of allograft in CR1 to the transplantation 
curve. Abbreviations: CT, chemotherapy; Auto, autologous hematopoietic stem cell transplantation; Allo, allogeneic 
hematopoietic stem cell transplantation; F, number of failures (that is, death whatever the cause for OS, and death 
or relapse for RFS); N, number of patients; and Cox LR, Cox likelihood ratio
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Second complete remission
A total of 358 patients developed a relapse after having received PRT. Two hundred and 
five patients proceeded to salvage chemotherapy and 125 (35%) entered a second CR. 
Ultimately, only 75 out of 358 relapsing patients proceeded to alloHSCT in second CR and 6 
patients received an autoHSCT in second CR. Overall outcome of all relapsing patients was 
12 ± 2% at 5 years from relapse.
Multivariable analysis
Table 3 shows the results of the multivariable analysis with stratification for leukemia risk 
and with adjustment for sex, age, late CR, time from CR to PRT, year of start of PRT before 
or after 2006 and PRT type. Both OS and RFS were significantly better after alloHSCT as 
compared with chemotherapy with HRs of 0.64 (P<0.001) and 0.51 (P<0.001), respectively 
(Supplementary Figure 2). Relapse was significantly reduced following alloHSCT as compared 
with chemotherapy (HR 0.33, P<0.001). AutoHSCT was also associated with significantly 
improved RFS (HR 0.69, P = 0.005) and a reduced risk of relapse (HR 0.66, P = 0.003) as 
compared with chemotherapy. OS was not significantly different comparing alloHSCT 
with autoHSCT (HR 0.83, P = 0.19), while RFS was significantly improved after alloHSCT as 
compared with autoHSCT (HR 0.74, P = 0.029). 
Intermediate risk AMLs
With respect to OS and RFS in intermediate risk patients, the HRs comparing alloHSCT with 
chemotherapy were 0.54 (95% CI: 0.40-0.72, P<0.001) and 0.47 (95% CI: 0.35-0.63, P<0.001), 
respectively. The HRs comparing autoHSCT with chemotherapy in intermediate risk patients 
were 0.72 (95% CI: 0.51-1.02, P = 0.058) for OS and 0.73 (95% CI: 0.52-1.00, P = 0.048) for RFS. 
A trend was found toward improved OS comparing alloHSCT with autoHSCT in intermediate 
risk patients (HR 0.74, 95% CI: 0.52-1.06, P = 0.10), whereas RFS was significantly better for 
alloHSCT in intermediate risk patients (HR 0.65, 95% CI: 0.46-0.90, P = 0.011). 
Tests for interaction
We tested for interactions between the type of PRT with age, time from CR to post-remission 
treatment, year of treatment (< or ≥ 2006), sex, late CR1 and leukemia risk. Only between 
age and PRT significant interactions were found, indicating that autoHSCT recipients 
experienced an increased event rate with age for all endpoints (details not shown). We have 
also tested for the interaction between the type of PRT and center size (above or below the 
median number of patients per center). No interaction was found between type of PRT and 
center size for all outcome parameters. 
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AlloHSCT conditioning: riC versus MAC
We additionally performed a direct comparison of patients receiving RIC-alloHSCT with 
MAC-alloHSCT. Figures 3a and 3b show OS and RFS, respectively, of alloHSCT recipients by 
conditioning type stratified for leukemia risk. NRM was significantly increased for recipients 
of MAC-alloHSCT as compared with recipients of RIC-alloHSCT (23 ± 3% versus 11 ± 2% 
at 5 years, P = 0.009, Figure 3d), whereas the cumulative incidence of relapse comparing 
RIC-alloHSCT with MAC-alloHSCT was not significantly different (37 ± 4% versus 29 ± 4% 
at 5 years, Figure 3c), resulting in no significant different OS (57 ± 4% versus 51 ± 4% at 5 
years) and RFS (52 ± 4% versus 48 ± 4% at 5 years) for RIC-alloHSCT recipients compared 
with MAC-alloHSCT patients. Multivariable analysis with stratification for leukemia risk and 
adjustment for covariates including donor type (Table 4), showed decreased NRM following 
RIC-alloHSCT (HR 0.44, P = 0.004). Of note, within the group of patients receiving MAC-
alloHSCT, NRM was increased in recipients of partially T-cell depleted MAC-alloHSCT (HR 
4.00, 95% CI: 2.04-7.84, P<0.001), but relapse was not increased. No patients receiving RIC-
alloHSCT received grafts that were depleted of T-cells. Relapse did not differ between MAC-
alloHSCT and RIC-alloHSCT with an HR of 1.24 (P = 0.34). It resulted in similar OS (HR 0.78, 
P = 0.16) and RFS (HR 0.85, P = 0.34) between RIC-alloHSCT and MAC-alloHSCT. The similar 
outcome following either RIC or MAC was also observed in subgroups of patients, according 
to underlying leukemia risk. Specifically, the advantage of RIC- or MAC-alloHSCT versus 
chemotherapy in terms of RFS was observed in both intermediate and poor risk subgroups 
to a similar degree (Supplementary Figure 3). 
GVHD
Incidences of grade II-IV acute GVHD after RIC-alloHSCT and MAC-alloHSCT were 9% and 26%, 
respectively. Incidences of chronic limited and chronic extensive GVHD were, respectively, 
19% and 36% in RIC-alloHSCT and 32% and 29% in MAC-alloHSCT patients.
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Figure 3  Outcome of allogeneic transplantation by conditioning type
Kaplan-Meier estimates of OS (A) and RFS (B) and cumulative incidence of relapse (C) and NRM (d) of patients 
with AML in first CR form start of transplantation, according to conditioning type and with direct adjustment for 
differences in leukemia risk category among the treatment groups by the method of Gail and Byar.55 The cumulative 
incidences of relapse and NRM over time were calculated as competing risks with actuarial methods, where 
patients alive in continuing CR1 were censored at the date of last contact. Abbreviations: F, number of failures (that 
is, death whatever the cause); N, number of patients; and Cox LR, Cox likelihood ratio
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diSCuSSion
The preferred type of PRT in younger patients with AML in CR1 is a subject of continued 
debate. While the GVL effect exerted by alloHSCT strongly reduces relapse irrespective 
of cytogenetic subcategory,24 counterbalancing NRM may attenuate a favorable effect on 
OS, which is especially evident in good risk patients.6,13-16,26 More recently, alloHSCT is also 
being discussed in intermediate risk patients,7-9 especially in patients at higher risk of NRM. 
We and others previously observed increased NRM in alloHSCT recipients over the age of 
40 years, which resulted in similar outcome for AML CR1 patients receiving alloHSCT as 
compared with conventional PRT using chemotherapy or autoHSCT.6,13-16 Following the latter 
observations, several HOVON centers introduced RIC-alloHSCT for patients as from the age 
of 40 years, but adhered to alloHSCT as preferred PRT in intermediate risk patients. The 
latter approach signified the basis for the current study, addressing the value of alloHSCT 
versus conventional PRT and comparing recipients of a MAC-alloHSCT versus RIC-alloHSCT. 
Here, by time-dependent analysis, we observed improved OS by alloHSCT as compared with 
chemotherapeutic PRT in patients aged 40 to 60 years with AML in CR1. Of note, alloHSCT 
and autoHSCT did not significantly differ with respect to OS in intermediate risk patients, 
although RFS was better following alloHSCT. In addition, the intensity of the conditioning 
regimen did not significantly affect the rate of relapse after alloHSCT, thereby questioning 
the necessity of MAC in this category of patients.
Currently, it is generally accepted that patients with favorable risk AML do not qualify 
for alloHSCT as preferred PRT, because of a high probability of obtaining a second CR and 
subsequent favorable outcome upon proceeding to alloHSCT in second CR.7,26,33 More 
recently, that policy was also advocated for intermediate risk patients,7 although remission 
rates in relapsing intermediate risk patients are generally lower and also the percentage 
of patients actually proceeding to alloHSCT in second CR is compromised.9,34 Younger 
patients with adverse risk AML are currently recommended for an alloHSCT in CR1 using 
sibling or alternative donors, provided the risk of NRM is not excessively high.12 However, 
these recommendations are continuously evolving, because of a number of developments, 
including better results following autoHSCT,19-22 less NRM following RIC-alloHSCT17,18 and 
improved possibilities for risk-adapted therapy,12 using at one hand better prognostic scores 
for leukemia risk,1 better scores to predict NRM10,11,35 and incorporation of quantified minimal 
residual disease (MRD) in decision making.36-39 These developments urged us to readdress 
PRT, especially focusing on the place of alloHSCT in intermediate risk patients aged 40-
60 years, for whom RIC-alloHSCT had been introduced in recent years. In contrast to our 
earlier observations,13 the present study clearly showed an overall advantage for alloHSCT 
recipients as compared with patients proceeding to chemotherapeutic PRT. NRM following 
alloHSCT in the present study estimated 17 ± 2% at 5 years as compared with 25 ± 4% at 4 
years in the earlier HOVON-SAKK study,13 which thereby largely accounted for the observed 
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improvement. Improved outcome following alloHSCT as compared with chemotherapy in 
the present study was apparent in both MAC-alloHSCT and RIC-alloHSCT recipients, with 
fairly similar outcome. These results are in accordance with a recent German study, exploring 
PRT by prospective matched pair analysis.40 That study showed significantly better OS for 
alloHSCT in non-favorable risk patients and especially in patients 45-59 years of age, which 
compares well with the present report. Also in their study, an increasing number of patients 
received an alloHSCT preceded by non-MAC or RIC, but recipients of RIC and MAC were 
not compared. In addition, the option of autoHSCT was not included as a PRT option in the 
AMLCG99 study.40 Stelljes et al.40 performed a prospective matched pair analysis, whereas 
alloHSCT was evaluated by time-dependent methodology in the present study. In the past, 
we and others evaluated the effect of transplantation by ‘biological randomization’ through 
so-called (sibling) donor versus no-donor studies.6,13 These studies allow for an intention 
to treat analysis and thereby to approximate real randomized studies, although variable 
numbers of patients with a donor in those studies actually proceeded to transplantation. 
With the advent of MUDs and their increasing application in AML, sibling donor versus no-
donor studies have become obsolete. Therefore, other statistical methods were introduced, 
including landmark analysis, matched pair analysis and multivariable models that include a 
particular type of PRT as a time-dependent covariate.41 Although only a real randomization 
would more rigorously rule out selection, the methodology does allow for approximating a 
prospective comparison without the bias caused by the time to transplant and by including 
a multivariate analysis corrects for the most important, but not all, characteristics affecting 
relapse and NRM.23,27 
Results with autografting have improved following the introduction of peripheral blood 
stem cells,19-22 and a recent retrospective study by the Center for International Blood and 
Marrow Transplant Research suggested similar outcome for younger AML CR1 patients 
receiving either alloHSCT from an HLA-identical sibling or an autograft using peripheral 
blood stem cells.21 Although recipients of alloHSCT exhibited more high risk features, had 
longer follow-up and experienced a lower risk of treatment failure, no significant difference 
in OS was noted. Better possibilities for salvage may have accounted for improved survival 
after autoHSCT. Salvage by MAC-alloHSCT after autologous bone marrow transplantation 
appeared associated with considerable NRM in the past,42,43 but currently RIC-alloHSCT using 
either sibling or alternative donors may provide for better possibilities for PRT in second CR, 
as was suggested in the present study by a better RFS following alloHSCT but similar OS for 
autoHSCT and alloHSCT recipients. 
RIC-alloHSCT is generally associated with reduced NRM as compared with MAC 
regimens, but concern has been raised that a reduction of NRM by RIC-alloHSCT is achieved 
at the expense of its antileukemic activity.17,18 Although our study is not a prospective 
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randomized study by design and individual conditioning choice is poorly controllable, the 
methodology applied allowed to limit the bias associated with time to transplant, while 
including a multivariable analysis.23,24,31,44 With a mature follow-up of >6 years (median) in 
recipients of RIC-alloHSCT, we found that the reduction of relapse by RIC-alloHSCT did not 
significantly differ from what was observed in recipients of MAC-alloHSCT, suggesting overall 
equivalent antileukemic efficacy. These results are in contrast with earlier observations of a 
possible higher relapse rate after RIC-alloHSCT.45-51 A recent, prematurely closed prospective 
randomized study between RIC-alloHSCT and MAC-alloHSCT did not find major differences 
in outcome.52 The RIC regimen in the latter study, however, involved a more intensive, near 
ablative conditioning with 8 Gy TBI.52 The potent antileukemic effect of RIC-alloHSCT that 
we observed may be explained by a strong GVL-effect given the relatively high incidence of 
chronic extensive GVHD, which correlates with ongoing GVL.53,54 Also, the strong antileukemic 
effects of dose-intensive remission-induction chemotherapy28,29 may have obviated the need 
for further intensified chemoradiotherapy as part of the conditioning regimen. Therefore, 
our results suggest that reducing the intensity of the conditioning regimen before alloHSCT 
may result in less NRM without a significant increase of relapse in this group of intensively 
treated AML patients in CR1. 
Collectively, our results suggest that alloHSCT is to be preferred over chemotherapy as 
PRT in patients with intermediate and poor risk AML aged 40-60 years, whereas autoHSCT 
remains a treatment option to be considered in patients with intermediate risk AML. Further 
refinement of decision making might result from taking into account at one hand evolving 
leukemia risk factors and at the other hand risk factors that predict for NRM.12 In addition, risk 
factors that evolve during treatment such as MRD currently gain importance.36-39 A number 
of recent studies have suggested that especially intermediate risk patients may be further 
subclassified on the basis of MRD, which might thereby allow for further optimization of 
personalized PRT in AML. Last, given the potent GVL activity and limited toxicity profile of 
RIC-alloHSCT, further evaluation of RIC alloHSCT in younger AML patients below the age of 
40 years appears warranted.
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SuPPLeMenTAry APPendix
Supplementary Table 1  Outcome estimates at 5 years following post-remission treatment in each AML risk group
outcome after treatment (% at 5 years)
Post-remission treatment no. of patients oS rFS Relapse nrM
All patients*
CT 271 40 ± 3 30 ± 3 60 ± 3   1 ± 1
Auto 152 54 ± 4 44 ± 4 47 ± 4   5 ± 2
Allo 337 57 ± 3 54 ± 3 36 ± 3 17 ± 2
Favorable-risk†
CT   86 76 ± 5 56 ± 6 43 ± 6   1 ± 1
Auto   39 73 ± 7 73 ± 7 21 ± 6   6 ± 4
Allo   29 70 ± 8 70 ± 8 10 ± 5 20 ± 7
intermediate-risk†
CT 150 36 ± 4 28 ± 4 70 ± 4   2 ± 1
Auto   93 54 ± 5 39 ± 5 56 ± 5   5 ± 2
Allo 161 60 ± 4 56 ± 4 29 ± 3 15 ± 3
Adverse-risk†
CT   35 19 ± 7 11 ± 6 89 ± 6   0
Auto   20  35 ± 11  31 ± 10  69 ± 10   0
Allo 147 37 ± 5 30 ± 5 51 ± 5 19 ± 4
Abbreviations: OS indicates overall survival; RFS, relapse-free survival; NRM, non-relapse mortality; CT, chemo-
therapy; Auto, autologous hematopoietic stem cell transplantation; and Allo, allogeneic hematopoietic stem cell 
transplantation
* Stratified for leukemia risk
† According to the European LeukemiaNET AML risk classification
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Supplementary Figure 1  Overall survival by European LeukemiaNET AML risk classification 
Kaplan-Meier estimates of overall survival of patients with AML in first complete remission from start of post-
remission therapy, according to European LeukemiaNET (ELN) AML risk classification.1 Abbreviations: F, number of 
failures (i.e, death whatever the cause); N, number of patients; and Cox LR, cox likelihood ratio
Supplementary Figure 2 Forest plots of overall survival and relapse-free survival by post-remission therapy
Forest plots of pooled and individual estimates of the relative reduction (hazard ratio (HR) and 95% confidence 
interval (CI)) of overall survival (OS) and relapse-free survival (RFS) in each AML risk group, comparing autologous 
hematopoietic stem cell transplantation (Auto) versus chemotherapy (CT) (A and C), and allogeneic hematopoietic 
stem cell transplantation (Allo) versus CT (B and d). Multivariable cox regression analysis was applied with 
stratification for leukemia risk and adjustment for late CR (after cycle II instead of I), time from CR to PRT, age, sex, and 
year of treatment before or after 2006. Some patients received post-remission treatment with CT or Auto first before 
they proceeded to Allo. These patients were counted as at risk in the CT or Auto group from start of post-remission 
treatment until Allo and after that as at risk in the Allo group. Therefore the numbers in the Events/Patients table are 
different from the numbers reported in Table 1. Tests for heterogeneity were not significant for all comparisons (A-d).
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 OS: AutoHSCT vs Chemotherapy
 Study
 Events/Patients
 Chemotherapy  AutoHSCT
 HR & 95% CI 
 (Chemotherapy : AutoHSCT)
 Reduction
 (SD)
 Risk class
 Favorable  22 / 89  12 / 39
 Intermediate  101 / 170  51 / 95
 Adverse  30 / 51  13 / 21
 Total  153 / 310  76 / 155
 (49%)  (49%)
 23%(11)
 reduction 
 2P=0.07 0  0.5  1.0  1.5  2
 AutoHSCT  CT
 better  better
 OS: AlloHSCT vs Chemotherapy
 Study
 Events/Patients
 Chemotherapy  AlloHSCT
 HR & 95% CI 
 (Chemotherapy : AlloHSCT)
 Reduction
 (SD)
 Risk class
 Favorable  22 / 89  10 / 31
 Intermediate  101 / 170  87 / 202
 Adverse  30 / 51  68 / 104
 Total  153 / 310  165 / 337
 (49%)  (49%)
 36%(8)
 reduction 
 2P<0.001 0  0.5  1.0  1.5  2
 AlloHSCT  Chemotherapy
 better  better
 RFS: AutoHSCT vs Chemotherapy
 Study
 Events/Patients
 Chemotherapy  AutoHSCT
 HR & 95% CI 
 (Chemotherapy :  AutoHSCT)
 Reduction
 (SD)
 Risk class
 Favorable  36 / 89  12 / 39
 Intermediate  109 / 170  59 / 95
 Adverse  32 / 51  14 / 21
 Total  177 / 310  85 / 155
 (57%)  (55%)
 31%(9)
 reduction 
 2P=0.006 0  0.5  1.0  1.5  2
 AutoHSCT  Chemotherapy
 better  better
 RFS: AlloHSCT vs Chemotherapy
 Study
 Events/Patients
 Chemotherapy  AlloHSCT)
 HR & 95% CI 
 (Chemotherapy : AlloHSCT))
 Reduction
 (SD)
 Risk class
 Favorable  36 / 89  10 / 31
 Intermediate  109 / 170  92 / 202
 Adverse  32 / 51  73 / 104
 Total  177 / 310  175 / 337
 (57%)  (52%)
 49%(6)
 reduction 
 2P<0.001 0  0.5  1.0  1.5  2
 AlloHSCT  Chemotherapy
 better  better
A
B
C
D
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 RFS: MAC vs Chemotherapy
 Risk class
 Favorable  36 / 89  4 / 16
 Intermediate  109 / 170  45 / 92
 Adverse  32 / 51  38 / 49
 Total  177 / 310  87 / 157
 (57%)  (55%)
 46%(8)
 reduction 
 2P<0.001 0  0.5  1.0  1.5  2
 AlloMAC  Chemotherapy
 better  better
 RFS: RIC vs Chemotherapy
 Risk class
 Favorable  36 / 89  6 / 15
 Intermediate  109 / 170  47 / 110
 Adverse  32 / 51  35 / 55
 Total  177 / 310  88 / 180
 (57%)  (49%)
 51%(7)
 reduction 
 2P<0.001 0  0.5  1.0  1.5  2
 AlloRIC  CT
 better  better
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 HR & 95% CI 
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 (SD)
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 (SD)
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Supplementary Figure 3  Forest plots of relapse-free survival by post-remission therapy 
Forest plots of pooled and individual estimates of the relative reduction (hazard ratio (HR) and 95% confidence 
interval (CI)) of relapse-free survival (RFS) in each AML risk group, comparing chemotherapy (CT) versus 
myeloablative conditioned allogeneic hematopoietic stem cell transplantation (alloMAC) (A), and CT versus reduced 
intensity conditioned allogeneic hematopoietic stem cell transplantation (alloRIC) (B). Multivariable cox regression 
analysis was applied with stratification for leukemia risk and adjustment for late CR (after cycle II instead of I), 
time from CR to PRT, age, sex, and year of treatment before or after 2006. Some patients received post-remission 
treatment with CT first before they proceeded to Allo. These patients were counted as at risk in the CT group from 
start of post-remission treatment until Allo and after that as at risk in the Allo group. Therefore the numbers in 
the Events/Patients table are different from the numbers reported in Table 1. Tests for heterogeneity were not 
significant for both comparisons (A-B).
Chapter 2
3
PoST-reMiSSion TreATMenT wiTH ALLo- 
GeneiC STeM CeLL TrAnSPLAnTATion in  
PATienTS AGed 60 yeArS And oLder  
wiTH ACuTe MyeLoid LeuKAeMiA:  
A TiMe-dePendenT AnALySiS
J Versluis, CLE Hazenberg, JR Passweg, WLJ van Putten, J Maertens,  
BJ Biemond, M Theobald, C Graux, J Kuball, HC Schouten, T Pabst, B Löwenberg,  
G Ossenkoppele, E Vellenga, JJ Cornelissen, on behalf of the HOVON and  
SAKK Leukemia Groups
Lancet Haematol. 2015;2(10):e427-36. 
AbSTrACT
background Acute myeloid leukaemia mainly affects elderly people, with a median age 
at diagnosis of around 70 years. Although about 50-60% of patients enter first complete 
remission upon intensive induction chemotherapy, relapse remains high and overall 
outcomes are disappointing. Therefore, effective post-remission therapy is urgently needed. 
Although often no post-remission therapy is given to elderly patients, it might include 
chemotherapy or allogeneic haemopoietic stem cell transplantation (HSCT) following 
reduced intensity conditioning reduced-intensity conditioning. We aimed to assess the 
comparative value of allogeneic HSCT with other approaches, including no post-remission 
therapy, in patients with acute myeloid leukaemia aged 60 years and older. 
Methods For this time-dependent analysis, we used the results from four successive 
prospective HOVON-SAKK acute myeloid leukaemia trials. Between May 3, 2001, and Feb 5, 
2010, a total of 1155 patients aged 60 years and older were entered into these trials, of whom 
640 obtained a first complete remission after induction chemotherapy and were included 
in the analysis. Post-remission therapy consisted of allogeneic HSCT following reduced-
intensity conditioning (n=97), gemtuzumab ozogamicin (n=110), chemotherapy (n=44), 
autologous HSCT (n=23), or no further treatment (n=366). Reduced-intensity conditioning 
regimens consisted of fludarabine combined with 2 Gy of total body irradiation (n=71), 
fludarabine with busulfan (n=10), or other regimens (n=16). A time-dependent analysis was 
done, in which allogeneic HSCT was compared with other types of post-remission therapy. 
The primary endpoint of the study was 5-year overall survival for all treatment groups, 
analysed by a time-dependent analysis. 
Findings 5-year overall survival was 35% (95% CI 25-44) for patients who received an 
allogeneic HSCT, 21% (17-26) for those who received no additional post-remission therapy, 
and 26% (19-33) for patients who received either additional chemotherapy or autologous 
HSCT. Overall survival at 5 years was strongly affected by the European LeukemiaNET acute 
myeloid leukaemia risk score, with patients in the favourable risk group (n=65) having better 
5-year overall survival (56% [95% CI 43-67]) than those with intermediate risk (n=131; 
23% [19-27]) or adverse risk (n=444; 13% [8-20]) acute myeloid leukaemia. Multivariable 
analysis with allogeneic HSCT as a time-dependent variable showed that allogeneic HSCT 
was associated with better 5-year overall survival (HR 0.71 [95% CI 0.53-0.95], p=0.017) 
compared with non-allogeneic HSCT post-remission therapies or no post-remission therapy, 
especially in patients with intermediate risk (0.82 [0.58-1.15]) or adverse risk (0.39 [0.21-
0.73) acute myeloid leukaemia.
interpretation Collectively, the results from these four trials suggest that allogeneic 
HSCT might be the preferred treatment approach in patients of 60 years of age and older 
with intermediate risk and adverse risk acute myeloid leukaemia in first complete remission, 
but the comparative value should ideally be shown in a prospective randomised study.
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inTroduCTion
Acute myeloid leukaemia (AML) mainly affects older adults, with a median age at diagnosis 
of between 67 and 71 years.1 Intensive remission induction chemotherapy can be initiated 
in patients with a favourable performance status and without substantial comorbidities. A 
first complete remission (CR1) is obtained in around 50-60% of patients.2,3 Poor outcome of 
elderly patients can be explained by an increased incidence of relapse caused by a composite 
of poor risk AML characteristics. Thus, outcome is still disappointing in these patients, with 
5-year overall survival (OS) of 15-30% after intensive induction chemotherapy.2,3 Therefore, 
effective post-remission therapy (PRT) in elderly patients is urgently needed. PRT can include 
continued chemotherapy, autologous haemopoietic stem cell transplantation (HSCT), or 
allogeneic HSCT (alloHSCT), although maintenance treatment has never been proven to be 
effective. The issue of post-remission chemotherapy in older patients with AML has not been 
resolved, with equivalent outcomes reported for one cycle of chemotherapy compared with 
more than one cycle of post-remission chemotherapy.4 An earlier study by the HOVON-SAKK 
consortia5 did not show improved outcome following PRT with the monoclonal antibody 
gemtuzumab ozogamicin (GO), but the efficacy of this treatment has been the subject of 
ongoing debate.5-8 AlloHSCT is the most effective PRT for the prevention of relapse in young 
patients with AML in CR1.9-12 However, non-relapse mortality (NRM) can compromise these 
favourable effects on OS, especially in patients with advanced age, comorbidities, or both. 
Reduced intensity conditioning (RIC) regimens have been developed to reduce NRM, while 
maintaining graft-versus-leukaemia effects.13 AlloHSCT following RIC has been shown to 
be feasible and is increasingly used in older patients with newly diagnosed AML.14,15 Two 
comparative retrospective trials showed improved outcome by alloHSCT following RIC as 
compared with chemotherapy in elderly patients.16,17 In the present study, we aimed to 
compare alloHSCT following RIC with other PRT approaches, including no further PRT in 
patients with AML aged 60 years or older, who were entered into four successive, prospective 
HOVON-SAKK AML trials. 
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MeTHodS
Study design and participants
Patients aged 60 years and older with newly diagnosed AML were included, who participated 
in consecutive, prospective HOVON-SAKK phase 3 trials (AML42/42A, AML43, AML81, and 
AML92) and who obtained CR1 after one or two induction cycles of chemotherapy and 
were alive at day 30 after the second cycle of treatment.3,5,18 Detailed descriptions of the 
inclusion and exclusion criteria of these studies have been previously published.3,5,18 Patients 
were classified by leukaemia risk, based on the cytogenetic and molecular profile of the 
underlying AML, according to the latest European LeukemiaNET (ELN) risk classification.19 
The intermediate-I and intermediate-II risk groups of the ELN classification were combined, 
on the basis of previous observations of similar outcome in patients 60 years of age and 
older.20 All studies had been approved by the ethics committees of the participating 
institutions and were done in accordance with the Declaration of Helsinki. All participants 
had provided written informed consent. The results of the AML81 and AML92 trials have not 
yet been published, but trial information for both studies is available in the Netherlands Trial 
Register (NTR904 and NTR1446, respectively).
Procedures
Treatment in the AML42/42A, AML43, AML81, and AML92 studies involved a maximum of 
two remission induction cycles consisting of anthracycline with cytarabine chemotherapy, as 
previously described.3,5,18 No further PRT was viewed as standard of care in patients aged 60 
years or older (AML43 and AML81). Patients included in the AML43 study who had reached 
CR could be randomly allocated between GO 6 mg/m2 every 4 weeks for three cycles or 
no PRT.5 In the AML42/42A and AML92 studies, patients who were younger than 61 and 
66 years, respectively, were eligible for PRT in a similar way as were younger patients. For 
patients treated with additional chemotherapy, they received a third cycle of chemotherapy 
with mitoxantrone 10 mg/m2 per day intravenously for 5 days and etoposide 100 mg/m2 
per day intravenously for 5 days. For patients treated with autologous HSCT, they received 
high-dose chemotherapy with busulfan 1 mg/kg orally (or, alternatively busilvex 0.8 mg/
kg intravenously) four times daily for 4 days and cyclophosphamide 60 mg/kg per day 
intravenously for 2 days followed by an autologous HSCT. Patients proceeded to alloHSCT 
after the identification of an human leukocyte antigen (HLA)-identical sibling or matched 
unrelated donor. Patients received a RIC regimen followed by the infusion of donor cells. 
The degree of HLA-matching for unrelated donors was eight out of eight alleles for HLA-A, 
HLA-B, HLA-C, and DRB1 for intermediate risk patients and at least seven out of eight alleles 
for adverse risk patients. RIC regimens mostly consisted of fludarabine 30 mg/m2 per day 
intravenously for 3 days and 2 Gy of total body irradiation or fludarabine 30 mg/m2 per day 
intravenously for 5 days combined with busulfan 1 mg/kg orally (or, alternatively busilvex 
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0.8 mg/kg intravenously) four times daily for 2 days. Rabbit antithymocyte globulin 2 mg/
kg per day intravenously for 4 days was added to the RIC regimens in recipients of unrelated 
donors. Graft-versus-host disease (GVHD) prophylaxis was given with a calcineurin inhibitor 
(ie, ciclosporin or tacrolimus) based on serum trough levels (with a target of 250-350 
μg/L for ciclosporin and 5-15 ng/mL for tacrolimus) combined with orally administered 
mycophenolate mofetil 15 mg/kg three times daily.
Outcomes
The primary endpoint of the study was 5-year OS for all treatment groups. OS and RFS were 
measured from day 30 after cycle 2, or from CR1 in cases where CR1 was obtained after day 
30 of cycle 2. The event for OS was death whatever the cause, and patients were censored at 
the date of last contact if alive. Secondary endpoints were RFS, relapse and NRM. The events 
for RFS were death in CR1 (designated as NRM) or haematological relapse (recurrence of 
blasts in the marrow of ≥5% [excluding increased blasts in the context of regenerating 
marrow]). The cumulative risks of relapse and NRM over time were calculated as competing 
risks with actuarial methods, wherein patients alive in continuing CR1 were censored at the 
date of last contact. 
Statistical analysis
We used the Kaplan-Meier method to estimate survival and the reverse Kaplan-Meier 
method to calculate the median time to follow-up. We did a time-dependent analysis of PRT 
as described previously,12 taking into account the change in an individual’s covariate status 
over time. We compared alloHSCT with non-alloHSCT PRT (ie, chemotherapy, autologous 
HSCT, or GO) and no PRT by applying multivariable Cox regression with the time-dependent 
covariate alloHSCT; we used this time-dependent covariate to avoid selectively favouring 
the alloHSCT group by attributing the favourable time period (since no relapse occurred) 
from CR to transplant to the alloHSCT group. The multivariable analysis is conceptually 
similar to a Mantel-Byar analysis,21 but more general because it allows for adjustment for 
other factors. All patients initially received no PRT before proceeding to any type of PRT. Six 
patients received chemotherapy before alloHSCT. In both the multivariable analysis and the 
estimation of the survival curves, these patients were counted as at risk in the no PRT or 
non-alloHSCT group from start of the analysis until they received alloHSCT, and after that 
as at risk in the alloHSCT group. We applied a multivariable Cox regression analysis for OS, 
RFS, relapse, and NRM, with adjustment for the different types of non-alloHSCT treatment, 
leukaemia risk, white blood cell count (WBC) at diagnosis (<20 × 10⁹ cells per L vs ≥20 × 
10⁹ cells per L), late CR (after cycle 2 instead of cycle 1), age, sex, and year of treatment 
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(before 2006 vs 2006 or later). We included year of treatment (ie, before 2006 vs 2006 or 
later) to adjust for a possible overall difference in outcomes between these two periods. All 
p-values were based on log likelihood ratio tests, except when explicitly stated otherwise. 
We also used log likelihood ratio tests to test for interactions. The proportional hazards 
assumption was tested on the basis of Schoenfeld residuals.21,22 The test of the assumption 
of proportionality indicated non-proportionality in the variable alloHSCT for all endpoints 
with increased HRs being limited to the early follow-up period, which would be expected 
because of the early toxicity of alloHSCT (Supplementary Table 1). We have not adjusted p 
values for multiple testing. All analyses were done with Stata version 13.1. 
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reSuLTS
Between May 3, 2001, and Feb 5, 2010, induction chemotherapy was started in 1155 
patients aged 60 years and older with AML in the four successive prospective HOVON-SAKK 
trials (Figure 1). 515 (45%) of 1155 patients were excluded from the analyses, because 
of refractory disease or death without achieving CR1 (427 [37%] of 1155 patients), death 
during cycle 2 of chemotherapy after an early CR (50 [4%] patients), or because they did not 
receive a second cycle of treatment due to toxicity (38 [3%] patients). CR after two cycles 
of induction therapy was obtained in 640 (55%) patients, of whom 274 (43%) proceeded to 
PRT with either GO (110 [17%] of 640), chemotherapy (44 [7%]), autologous HSCT (23 [4%]), 
or alloHSCT (97 [15%]).  According to protocol, 366 (57%) of 640 patients who achieved 
a first complete remission did not receive further PRT after having received two cycles of 
chemotherapy, including 274 (75%) of 366 patients who obtained haematological remission 
after their first course of chemotherapy and 92 (25%) of 366 who did so after the second 
course of chemotherapy.
1155 patients aged ≥60 years included in
         HOVON-SAKK phase 3 trials (AML42/42A,
         AML43, AML81, and AML92)
515 excluded
      427 no complete remission
             after 2 cycles of
             chemotherapy
        50 died in cycle 2
        38 did not start cycle 2
             (because of toxicity)
640 patients obtained complete remission
       after 1 or 2 chemotherapy induction cycles
543 did not receive allogeneic HSCT
       366 no treatment
       110 gemtuzumab ozogamicin
         44 chemotherapy
         23 autologous HSCT
97 received allogeneic HSCT
Figure 1  trial profile 
Patients aged 60 years and older with acute myeloid leukaemia in the four consecutive HOVON-SAKK studies 
(AML42/42A, AML43, AML81, and AML92) included in this analysis. HSCT=haemopoietic stem cell transplantation.
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Table 1  Patient characteristics
Post-remission treatment
no PrT
(n=366)
non-allo PrT
(n=177)
alloHSCT
(n=97)
p-value
Gender 
Male 195 53% 99 56% 52 54%
.84
Female 171 47% 78 44% 45 46%
Age (years)
Median                     68 65 64
<.0001
Range                      60–82 60–78 60–74
wbC at diagnosis (x109/l)
Median                     3.6 6.4 4.4
.18
Range                      0.7-236 0.4-510 0.7-380
Karyotype classification 
t(8;21)                    15 4% 7 4% 0 0%
.40
inv(16)                    9 2% 6 3% 1 1%
CN-X-Y                      188 51% 81 46% 53 54%
CA Rest                    92 25% 55 31% 30 31%
MK                         28 8% 15 8% 8 8%
Missing 34 9% 13 7% 5 5%
risk AML*
Favorable 33 9% 24 14% 8 8%
.15
Intermediate-I 213 58% 83 47% 51 53%
Intermediate-II 51 14% 33 19% 13 13%
Adverse 69 19% 37 21% 25 26%
Cr reached after
Cycle 1 (early CR) 274 75% 120 68% 64 66%
.10
Cycle 2 (late CR) 92 25% 57 32% 33 34%
Time from Cr to start post-remission treatment (months)
Median                     NA 2.1 2.5
<.0001
IQ range                      NA 1.3–3.0 1.6–3.7
year of start post-remission treatment
<2006                      224 61% 140 79% 43 44%
<.0001
≥2006                     142 39% 37 21% 54 56%
Abbreviations: AlloHSCT indicates allogeneic haematopoietic stem cell transplantation; WBC, white blood cell count; 
CN-X-Y, cytogenetically normal or only loss of X or Y chromosome; CA, cytogenetically abnormal; MK, monosomal 
karyotype; AML, acute myeloid leukaemia; CR, complete remission; IQ, interquartile range; and NA, not applicable
* According to the European LeukemiaNET AML risk classification
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Table 1 shows the patient characteristics. Recipients of PRT were younger than patients 
who did not receive PRT. Most of the AMLs were classified as intermediate risk according to 
the ELN risk classification, and this did not differ significantly across the three groups. About 
a third of the patients in both PRT groups needed two cycles of chemotherapy to achieve 
CR. In patients who received PRT, time from CR to receiving alloHSCT was significantly longer 
than time from CR to receiving other types of PRT. Additionally, the number of patients 
receiving PRT in the form of alloHSCT has increased since 2006. The estimated median 
follow-up time was 69 months (interquartile range (IQR): 57-99) for patients receiving 
alloHSCT, 104 months (74-120) for patients receiving other types of PRT, and 82 months (54-
100) for those who received no PRT.
Table 2 shows the transplantation characteristics of the patients who received alloHSCT. 
Grafts from HLA-identical siblings were used in 69 (71%) of 97 transplants. The majority 
of patients had a low European Group for Blood and Marrow Transplantation (EBMT) risk 
score.23 
OS seemed to be strongly affected by the ELN AML risk classification. A small favourable 
risk group was identified, in which patients had better 5-year OS (56% [95% CI 43-67]), 
whereas the intermediate-I (23% [18-28]), intermediate-II (24% [16-34]), and adverse risk 
groups (13% [8-20]) had quite poor OS (Figure 2A). We subsequently pooled intermediate 
I and II patients together for further analyses (23% [19-27]).  Figure 2B and 2C show OS 
and RFS of all patients by type of PRT. OS was better for alloHSCT recipients than patients 
receiving no PRT (5-year OS 35% [95% CI 25-44] vs 21% [17-26]; p=0.033), whereas the 
difference between alloHSCT and other types of PRT was not significant (26% [95% CI 19-33], 
p=0.43, Figure 2B). Similarly, RFS was significantly improved in patients receiving alloHSCT as 
compared with those who received no further treatment (5-year RFS 32% [95% CI 23-41] vs 
14% [11-18], p=0.007, Figure 2C). 5-year RFS for patients receiving other types of PRT was 
20% (95% CI 15-27). The cumulative incidence of relapse was 50% (95% CI 40-61) at 5 years 
in the patients who received alloHSCT, compared with 77% (72-81) in those who received 
no PRT, and 66% (57-74) in those who received non-alloHSCT PRT (Figure 3A). The 5-year 
cumulative incidence of NRM after alloHSCT was 18% (95% CI 12-27), compared with 14% 
(95% CI 8-25) in patients receiving no alloHSCT and 9% (6-12) in those patients receiving 
non-alloHSCT PRT (Figure 3B). Treatment outcomes for the different types of non-alloHSCT 
PRTs are shown in Supplementary Table 2. Both patients who received alloHSCT and those 
who did not, did not show significant improvement in OS over time (Supplementary Table 
3). Extensive toxicity data for the different types of PRT were not available in detail for 
comparison between the different types of treatment, but Supplementary Table 4 provides 
information about the cause of death by type of PRT. 
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Table 2  Transplantation characteristics
alloHSCT (n=97)
donor type 
HLA-identical sibling 69 71%
Matched unrelated donor 20 21%
Other 8   8%
Stem cell source 
Peripheral blood 87 90%
Bone marrow 7   7%
Cord blood 3   3%
T-cell depletion
In vitro 3   3%
Ex vivo 1   1%
None 93 96%
Conditioning 
Fludarabin / TBI 71 73%
Fludarabin / Busulfan 10 10%
Fludarabin / Cyclophosphamide / TBI 3   3%
Fludarabin / Cyclophosphamide 2   2%
Unknown 11 11%
Antithymocyte globulin used
Yes 19 20%
No 55 57%
Unknown 23 24%
Female donor to male recipient 
Yes 5   5%
No 92 95%
Graft-versus-host disease prophylaxis
Ciclosporin 6   6%
Ciclosporin / mycophenolate mofetil 70 72%
Tacrolimus / mycophenolate mofetil 2   2%
Unknown 19 20%
Cytomegalovirus status of patient/donor
+/- 24 25%
+/+ 36 37%
-/+ 5   5%
-/- 18 19%
Unknown 14 14%
ebMT-score 
2 points 64 66%
3 points 30 31%
4 points 3   3%
Abbreviations: alloHSCT indicates allogeneic haematopoietic stem cell transplantation; HLA, human leukocyte 
antigen; TBI, total body irradiation; and  EBMT, European Group for Blood and Marrow Transplantation
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Figure 2  Overall survival and relapse-free survival
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(A) Overall survival by 
acute myeloid leukaemia 
risk category. (B) Overall 
survival by post-remission 
therapy. (C) Relapse-free 
survival by post-remission 
therapy. All estimates are 
for patients aged 60 years 
and older with acute mye-
loid leukaemia in first com- 
plete remission, from start 
of post-remission treat-
ment. Patients were classi-
fied by leukaemia risk, 
based on the cytogenetic 
and molecular profile of 
the underlying acute mye- 
loid leukaemia, according to 
the latest European Leuke-
miaNET risk classification.19 
Non-allogeneic postremis-
sion therapy refers to che-
motherapy, autologous 
HSCT, or gemtuzumab ozo-
gamicin. Notably, numbers 
of patients at risk differ 
from the patient numbers 
in table 1 and within the 
figure because of the time-
dependent nature of this 
analysis, which allows for 
time to transplantation by 
switching patients at the 
time of allograft in first 
complete remission.
N=number of patients; 
F=number of failures (ie, 
death, whatever the cause)
PRT=post-remission therapy 
HSCT=haemopoietic stem 
cell transplantation
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Figure 3  Cumulative incidence of relapse and non-relapse mortality 
(A) Cumulative incidence of relapse by type of post-remission therapy. (B) Cumulative incidence of non-
relapse mortality by type of post-remission therapy. All estimates are for patients aged 60 years and older with 
acute myeloid leukaemia in first complete remission, from start of post-remission treatment. Non-allogeneic 
postremission therapy refers to chemotherapy, autologous HSCT, or gemtuzumab ozogamicin. Notably, numbers 
of patients at risk differ from the patient numbers in table 1 and within the figure because of the time-dependent 
nature of this analysis, which allows for time to transplantation by switching patients at the time of allograft in first 
complete remission to the transplantation curve. N=number of patients. F=number of failures. PRT=postremission 
therapy. HSCT=haemopoietic stem cell transplantation.
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Multivariable analysis
Table 3 shows the results of the multivariable analysis with adjustment for type of non-
alloHSCT PRT, sex, age, leukaemia risk, WBC, late CR, and year of treatment. Both OS and 
RFS were significantly improved by alloHSCT compared with no PRT (Table 3). Relapse was 
significantly reduced by alloHSCT compared with no PRT; this effect was exerted similarly 
among the intermediate and adverse risk groups (Figure 4C). Women had a significantly 
better OS  and RFS than did men (Table 3). Intermediate risk and adverse risk AMLs were 
associated with a highly significant HR for reduced OS and RFS, and increased rate of relapse 
compared with favourable AMLs (Table 3). Furthermore, patients with a WBC higher than 
20 × 10⁹ cells per L at diagnosis had a significant HR for worse OS and RFS, and significantly 
increased risk of relapse compared with those with a WBC of up to 20 × 10⁹ cells per L. Minor 
differences in outcome were recorded between centres, but the multivariable analysis 
stratified by centre did not change OS (Supplementary Table 5). Figure 4 shows the forest 
plots of the HRs for OS, RFS, and relapse split by leukaemia risk group for a comparison of 
alloHSCT with non-alloHSCT (ie, patients who received other types of PRT and those who 
received no PRT). With respect to OS, the pooled estimates of the HR comparing alloHSCT 
versus non-alloHSCT was 0.71 (95% CI 0.53-0.95, p=0.014, Figure 4A), which seemed to 
be most prominent in adverse risk patients. With respect to RFS and relapse, the pooled 
estimates of the HR comparing alloHSCT with non-alloHSCT were 0.63 (95% CI 0.47-0.73; 
p=0.001) for RFS (figure 4B), and 0.46 (0.33-0.64; p<0.0001) for relapse (figure 4C), which 
were similarly improved by alloHSCT in patients with intermediate risk and adverse risk 
AMLs.
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Figure 4  Forest plots of AlloHSCT versus non-alloHSCT 
Forest plots of pooled and individual estimates of the relative reduction (HR) and 95% CI of overall survival (A), 
relapse-free survival (B), and relapse (C) in each acute myeloid leukaemia risk group, comparing allogeneic HSCT 
versus no allogeneic HSCT (non-allogeneic HSCT, which includes patients who received no post-remission therapy 
and those who received other types of post-remission therapy). Multivariable Cox regression analysis was used, 
with adjustment for the different types of non-allogeneic HSCT treatment, leukaemia risk, white blood cell count 
at diagnosis, late complete remission, age, sex, and year of treatment. To avoid bias, all patients started in the 
nonallogeneic HSCT group at the moment of first complete remission. In case patients proceeded to allogeneic 
HSCT, these patients were censored in the non-allogeneic HSCT group and switched to the allogeneic HSCT group 
at the very moment they received a transplant. Therefore, all patients were counted as at risk in the non-allogeneic 
HSCT group from start of follow-up until allogeneic HSCT and after that as at risk in the allogeneic HSCT group. 
Therefore the numbers in the events/patients table differ from those in table 1. HSCT=haemopoietic stem cell 
transplantation. HR=hazard ratio 
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At present, outcome in older patients with AML remains poor compared with that in younger 
patients because of an increased frequency of adverse cytogenetics,24 more concurrent 
comorbidities,25 and less fewer potentially curative treatment options.26 In our analysis, we 
recorded improved RFS by alloHSCT compared with no further treatment and non-alloHSCT 
PRT in intermediate risk and adverse risk patients, and the latter subgroup also showed 
improved OS. PRT in the form of GO, chemotherapy and autologous HSCT, did not differ 
significantly from no further therapy beyond two cycles of chemotherapy for all patients. 
The cytogenetic and molecular profile of the leukaemia is the most important factor 
affecting outcome and treatment decisions are largely based on the risk profile of the 
AML.19 Younger patients with a favourable risk profile generally do not qualify for PRT by 
alloHSCT, but that issue remains unsolved in older patients with AML. Because the number 
of favourable risk patients was small in our study, we were not able to show a survival 
benefit for alloHSCT in that particular subgroup. In intermediate risk AMLs, alloHSCT 
significantly improved RFS compared with other types of PRT, although we did not observe 
a significant difference in OS. Salvage treatment by alloHSCT in second CR might account for 
that observation, since alloHSCT in second CR could be done in 25% of relapsing patients 
(data not shown). A clear survival benefit for alloHSCT was noted in patients with adverse 
risk AMLs. The latter observation may support the application of alloHSCT in that particular 
subgroup, if eligible. In addition to the risk profile of the AML, peripheral blood cell count 
recovery and especially minimal residual disease are often used for predicting the risk of 
relapse, but information of both cell count recovery and minimal residual disease after CR 
was not available in the present analysis.
NRM may compromise the favourable effects of alloHSCT on relapse, especially in elderly 
patients with comorbidities. Although NRM following alloHSCT was increased compared 
with other types of PRT in the present study, the cumulative incidence of NRM of 18% (95% 
CI 12-27) following alloHSCT might support the feasibility of this treatment following RIC in 
patients aged 60 years and older. However, this observation cannot easily be generalised, 
since our results are from a selected group of elderly patients, who were eligible for 
transplant and who had a well matched sibling or unrelated donor. The use of risk scores to 
estimate the risk of NRM pre-transplantation and the selection of only those patients with 
an acceptable NRM-score could further reduce NRM. Several risk scores are available with 
patient-related and transplantation-related parameters,23 comorbidities,27 or combination 
of parameters.25 In particular, NRM risk assessment for patients with AML who qualify for 
RIC can be improved by a dedicated score, as was developed for AML in CR1 patients by 
the EBMT Acute Leukemia Working Party.25 Information about specific comorbidities was 
not available in the present study, but the included patients had quite a low EBMT-score, 
suggesting that transplanted patients were thereby devoid of an excessive risk for NRM.
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In our study, reduction of relapse and the acceptable toxicity of alloHSCT resulted in 
a survival benefit of alloHSCT compared with other types of PRT in adverse risk patients 
aged 60 years and older with AML in CR1. Although the present study is not a prospective 
randomised trial, the time-dependent nature of the analysis enables the comparison with no 
treatment, while avoiding the bias of time to transplantation by attributing that favourable 
time period to the no-transplant recipients (ie, control group).21,28,29 Nevertheless, our study 
is hampered by selection of a relatively small group of 97 transplanted patients out of 640 
patients in CR1, who met the eligibility criteria of the respective transplant centres, had 
a well matched donor, and actually underwent transplantation. Only a true randomised 
study will address those problems, and therefore results of a randomised study comparing 
alloHSCT with non-alloHSCT treatment, which is currently being done by cooperative groups 
in Europe (NCT00766779), are eagerly awaited.
In conclusion, our results show that alloHSCT following RIC is a feasible PRT in patients 
aged 60 years and older with AML in CR1. Survival was improved with alloHSCT compared 
with other types of PRT, especially in patients with adverse risk AML. Although transplant 
decisions should be based on a careful pre-transplant risk assessment of relapse and NRM,30 
these results suggest that the early search and identification of a compatible donor should 
also be pursued in elderly patients with an adverse AML risk profile.
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reSeArCH in ConTexT
evidence before this study
We searched PubMed before submission (final search on March 8, 2015) for original research 
articles published since 2001 about RIC alloHSCT versus chemotherapy in patients aged 60 
years and older with AML in CR1, using the search terms “AML”, “allogeneic”, “reduced 
intensity”, and “elderly” or “60 years”. Although several studies showed the feasibility of 
alloHSCT following RIC in elderly patients with AML in CR1, no prospective randomised trials 
comparing alloHSCT versus chemotherapy have been reported in these elderly patients with 
AML. We identified two comparative retrospective trials that included patients with AML 
aged 60 years and older and compared alloHSCT with chemotherapeutic PRT. Both studies 
suggested improved outcome by alloHSCT compared with other PRTs, which was mostly 
present in intermediate risk and adverse risk AML subgroups. Similarly, in patients younger 
than 60 years of age with AML in CR1, we and others have reported improved survival with 
alloHSCT compared with chemotherapeutic PRT, especially in patients with intermediate 
risk and adverse risk AMLs.
Added value of this study
Our study included a large number of patients with long follow-up who all received induction 
treatment for AML in prospective phase 2 and 3 trials. Our results of a time-dependent 
analysis show that, in patients of 60 years and older with AML in CR1, alloHSCT might provide 
improved outcome compared with a non-alloHSCT PRT approach, especially in patients with 
intermediate risk and adverse risk AML. 
implications of all the available evidence 
As outlined recently, tailoring of PRT in elderly patients depends not only on disease related 
risk factors, such as the underlying cytogenetic or molecular risk of the AML, but also on 
patient risk factors, including comorbidity status and performance status. Outcome of 
PRT in patients with AML, especially those aged 60 years and older, might benefit from a 
personalised treatment approach that takes into account both patient and disease factors, 
with the assessment of AML risk status, comorbidities, and performance status. Although 
alloHSCT might improve outcome in subgroups of elderly patients with AML, these results 
need to be confirmed in a prospective trial, which is currently ongoing (NCT00766779).
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SuPPLeMenTAry APPendix
Supplementary Table 1  Tests of proportional hazards assumption
Total cohort <=12 months >12 monhts Schoenfeld residuals
HR 95% Ci Hr1 95% Ci Hr2 95% Ci p-value* rho p-value
Overall survival
AlloHSCT 0.71 0.53-0.95 1.02 0.68-1.53 0.55 0.36-0.84 .038 -0.083 .058
CT/auto 1.02 0.73-1.43 1.01 0.63-1.62 1.02 0.63-1.66 .98 -0.026 .54
GO 0.80 0.62-1.03 0.77 0.51-1.16 0.80 0.58-1.11 .87 -0.024 .60
WBC>20 1.33 1.09-1.63 1.71 1.29-2.26 1.10 0.81-1.48 .036 -0.104 .019
Relapse-free survival
AlloHSCT 0.63 0.47-0.83 0.86 0.60-1.22 0.44 0.27-0.72 .031 -0.075 .075
CT/auto 0.99 0.72-1.38 1.17 0.80-1.72 0.61 0.32-1.17 .089 -0.044 .29
GO 0.85 0.67-1.09 0.94 0.69-1.28 0.71 0.48-1.05 .28 -0.011 .80
WBC>20 1.33 1.09-1.62 1.51 1.19-1.91 0.99 0.68-1.43 .058 -0.101 .018
Relapse
AlloHSCT 0.46 0.33-0.64 0.60 0.40-0.90 0.35 0.20-0.61 .12 -0.090 .053
CT/auto 0.86 0.60-1.24 0.95 0.62-1.45 0.58 0.28-1.20 .25 -0.002 .97
GO 0.83 0.65-1.08 0.87 0.63-1.21 0.75 0.50-1.13 .57 0.014 .76
WBC>20 1.42 1.15-1.76 1.67 1.29-2.15 1.02 0.68-1.52 .041 -0.148 .0015
non-relapse mortality
AlloHSCT 3.10 1.59-6.02 7.38 3.08-17.7 1.20 0.42-3.42 .009 -0.139 .18
CT/auto 2.70 1.24-5.84 5.74 2.27-14.5 0.90 0.19-4.40 .048 -0.165 .096
GO 0.89 0.36-2.23 1.82 0.58-5.79 0.32 0.07-1.49 .077 -0.109 .33
WBC>20 0.86 0.50-1.49 0.81 0.43-1.55 0.84 0.30-2.37 .95 0.023 .83
Abbreviations: HR, hazard ratio; CI, confidence interval; alloHSCT, allogeneic haematopoietic stem cell 
transplantation; CT, chemotherapy; auto, autologous HSCT; and WBC, white blood cell count
* Indicating a test of equality of the HRs in period 1 and period 2 for each variable
Comments to Supplementary Table 1
The validity of the assumption of proportional hazards had been tested in two ways:
1.  Using scaled Schoenfeld residuals (SSR) with the method of Grambs & Therneau22 
2.  By splitting the follow up period in two periods: <= 12 months and >12 months and performing separate Cox 
regression analysis (with the same variables as shown in Table 3) for each period
Supplementary Table 1 shows the variables with non-proportionality by outcome. No indication for non-
proportionality was found in the other included variables in the multivariable analysis
The rho in the SSR section is the correlation coefficient between the scaled Schoenfeld residuals for each variable 
with the rank number of the event times. The P-values there are for a test whether that correlation coefficient is 0. 
The results indicate that non-proportionality was present for alloHSCT as compared with no further treatment, 
except for endpoint relapse. The endpoint non-relapse mortality showed a relatively high HR in the first year after 
alloHSCT, with almost no difference after the first year. That difference in non-relapse mortality impacted endpoints 
OS and RFS with  HR closer to 1 and not significant in the first year, and smaller HR’s around 0.5 in the period after 
1 year. The results for WBC suggest an effect of WBC only during early follow up.
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Supplementary Table 2  Outcome by non-alloHSCT PRT
estimates at 5 years (95% Ci)
no. of patients oS rFS Relapse nrM
CT 44 26 (19-33) 20 (15-27) 66 (57-74) 14   (8-25)
Auto 23 26 (10-45) 18   (6-36) 62 (43-82) 20   (8-45)
GO 110 24 (16-33) 19 (12-27) 72 (60-83) 10   (3-31)
Abreviations: CI, confidence interval; OS, overall survival; RFS, relapse-free survival; NRM, non-relapse mortality; 
CT, chemotherapy; Auto, autologous haematopoietic stem cell transplantation; and GO, gemtuzumab ozogamicin
Supplementary Table 3  Overall survival by PRT categorized by year of PRT
oS at 5 years (95% Ci)
no. of patients CT/Auto/Go no. of patients AlloriC
year of PrT - 2 categories
<2006 136 24 (17-32) 42 30 (17-44)
>2006 41 32 (18-47) 55 39 (26-52)
year of PrT - 3 categories
2001-2003 78 25 (16-36) 15 40 (16-63)
2004-2006 78 25 (16-35) 37 33 (19-48)
2007-2010 21 31 (12-52) 45 35 (21-49)
Abbreviations: CI, confidence interval; OS, overall survival; CT, chemotherapy; Auto, autologous haematopoietic 
stem cell transplantation; GO, gemtuzumab ozogamicin; alloRIC, allogeneic haematopoietic stem cell transplantation 
following reduced intensity conditioning; and PRT, post-remission treatment
Supplementary Table 4  Causes of Death by PRT 
Cause of death no PrT no allo PrT AlloriC Total
AML 175 59% 89 68% 36 56% 300
Pneumonia 18   6% 6   5% 2   3% 26
Other Infection 29 10% 10   8% 7 11% 46
Hemorrhage 8   3% 5   4% 0   0% 13
GvHD 0   0% 0   0% 3   5% 3
2nd Cancer 5   2% 1   1% 1   2% 7
Other 34 11% 10   8% 11 17% 52
Unknown 27   9% 9   7% 5   8% 40
Total 296 100% 130 100% 64 100% 490
Abbreviations: PRT, post-remission treatment; allo, allogeneic haematopoietic stem cell transplantation; alloRIC, 
allogeneic haematopoietic stem cell transplantation following reduced intensity conditioning; AML, acute myeloid 
leukaemia; and GVHD, graft-versus-host disease
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Supplementary Table 5  Results of the multivariable analysis stratified by center
oS
                    Hr* 95% Ci p-value
Post-remission treatment
AlloHSCT (n=97) vs. no PRT (n=366)   0.58 0.41-0.80 <.001
non-allo PrT
CT/auto (n=67) vs. no PRT (n=366)    1.02 0.65-1.36 .74
GO (n=110) vs. no PRT (n=366)     0.81 0.62-1.07 .14
Sex (female (n=294) vs. male (n=346))              0.85 0.70-1.03 .097
Age†  1.17 0.92-1.49 .21
risk AML‡  
Intermediate (n=444) vs. Favourable (n=65) 2.44 1.63-3.67 <.001
Adverse (n=131) vs. Favourable (n=65) 4.90 3.11-7.71 <.001
wbC at diagnosis (>20 (n=187) vs. ≤20 (n=453)) 1.39 1.11-1.75 .005
Cr (late (n=182) vs. early (n=458)) 1.00 0.80-1.25 .99
year of treatment
≥2006 (n=407) vs. <2006 (n=233)             0.95 0.76-1.18 .63
Abbreviations: OS indicates overall survival (with event death whatever the cause); HR, hazard ratio; CI, confidence 
interval; Allo, allogeneic haematopoietic stem cell transplantation; vs., versus; PRT, post-remission treatment; CT, 
chemotherapy; auto, autologous HSCT; GO, gemtuzumab ozogamicin; AML, acute myeloid leukaemia; and WBC, 
white blood cell count
* The HRs are the estimates of the effect of covariates for each outcome parameter, stratified by centre and 
adjusted for sex, age, AML risk, CR (late vs. early), WBC at diagnosis below or above 20, year of post-remission 
treatment before or after 2006, and type of post-remission treatment. The group after the team “vs.” is regarded 
as the reference group; † Linear with estimates of ten years difference; ‡ According to the European LeukemiaNET 
AML risk classification19
Supplementary Table 6  Outcome by PRT in AML risk groups
outcome at 5 years (95% Ci)
non-allogeneic HSCT Allogeneic HSCT
Overall survival
Favourable risk 59 (45-71) 36 (  8-66)
Intermediate risk 21 (17-26) 34 (23-46)
Adverse risk   8 (  4-15) 34 (16-53)
Relapse-free survival
Favourable risk 50 (36-62) 23 (  3-53)
Intermediate risk 15 (11-18) 34 (23-46)
Adverse risk   6 (  3-13) 28 (12-46)
Relapse
Favourable risk 30 (19-44) 66 (35-93)
Intermediate risk 76 (71-80) 42 (31-56)
Adverse risk 89 (81-94) 64 (45-82)
Abbreviations: CI, confidence interval; and HSCT, haematopoietic stem cell transplantation
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AbSTrACT
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid 
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients 
with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, 
including the FLT3-ITD allelic ratio. PRT consisted of reduced intensity conditioning (RIC) 
allogeneic hematopoietic stem cell transplantation (n = 68), myeloablative conditioning 
(MAC) alloHSCT (n = 137), autologous hematopoietic stem cell transplantation (autoHSCT) 
(n = 168), or chemotherapy (n = 148). Favorable overall survival (OS) was found for patients 
with mutated NPM1 without FLT3-ITD (71 ± 4%). Outcome in patients with a high FLT3-ITD 
allelic ratio appeared to be very poor with OS and relapse-free survival (RFS) of 23 ± 8% and 
12 ± 6%, respectively. Patients with wild-type NPM1 without FLT3-ITD or with a low allelic 
burden of FLT3-ITD were considered as intermediate-risk group because of similar OS and 
RFS at 5 years, in which PRT by RIC alloHSCT resulted in better OS and RFS as compared with 
chemotherapy (hazard ratio (HR) 0.56, P = 0.022 and HR 0.50, P = 0.004, respectively) or 
autoHSCT (HR 0.60, P = 0.046 and HR 0.60, P = 0.043, respectively). The lowest cumulative 
incidence of relapse (23 ± 4%) was observed following MAC alloHSCT. These results suggest 
that alloHSCT may be preferred in patients with molecularly intermediate-risk CN-AML, 
while the choice of conditioning type may be personalized according to the risk for non-
relapse mortality.
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inTroduCTion
Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous disease. 
Cytogenetically normal AML (CN-AML) is the largest cytogenetic subgroup (40-50% of AML 
patients),1 which currently can be further refined based on molecular markers. Mutations 
in nucleophosmin 1 (NPM1) and fms-like tyrosine kinase 3 internal tandem duplications 
(FLT3-ITD) are found in respectively 50% and 30% of patients with CN-AML.2 Molecular 
diagnostic analyses provide additional prognostic information that may be used for a 
risk adapted treatment approach.3-6 FLT3-ITD, particularly FLT3-ITD with a high mutant to 
wild-type ratio, is associated with an unfavorable prognosis, whereas NPM1 mutations in 
the absence of FLT3-ITD are associated with a relatively favorable outcome.2,3,7-11 Patients 
who obtain a first complete remission (CR1) are subsequently treated with post-remission 
treatment (PRT), including an additional cycle of chemotherapy, high dose chemotherapy 
followed by autologous hematopoietic stem cell transplantation (autoHSCT) or allogeneic 
HSCT (alloHSCT) following either myeloablative conditioning (MAC) or reduced intensity 
conditioning (RIC). PRT in patients with CN-AML CR1 is a subject of continued debate, 
especially taking molecular markers into account.12-19 AlloHSCT is generally not associated 
with better survival in patients with NPM1 mutations without FLT3-ITD, whereas the role 
of autoHSCT and alloHSCT in patients with FLT3-ITD is not definitely settled.3,9,10,12,19-21 In 
addition, large comparative studies of PRT including autoHSCT are lacking in molecularly 
defined subgroups. In the present study, we addressed the impact of NPM1 and FLT3-ITD 
including the FLT3-ITD allelic ratio on the outcome in patients with CN-AML, treated upfront 
within four prospective, consecutive HOVON-SAKK and EORTC studies. Second, we compared 
outcome of PRT with alloHSCT and autoHSCT vs chemotherapy by time-dependent analysis 
in patients with AML in CR1, according to molecularly defined subgroups.
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PATienTS And MeTHodS
Patients
A total number of 521 patients with newly diagnosed CN-AML were included, treated between 
1995 and 2010 and who obtained CR1 after one or two induction cycles of chemotherapy. 
Patient data were derived from two cohorts including consecutive, prospective HOVON-
SAKK phase III trials (AML29, AML42/42A, and AML92; n = 399),22-24 and a prospective 
EORTC phase III trial (AML12; n = 122).25 Patients were excluded if molecular information 
was not available or if EVI1 overexpression was present. Figure 1 shows the total number of 
patients enrolled in different trials and reasons why patients were excluded in the present 
analysis. The ratio of FLT3-ITD mutant to wild-type, defined by FLT3-ITD divided by FLT3-ITD 
plus FLT3-wild-type, was available for 86% of the patients with FLT3-ITD AML. A predefined 
cutoff of >0.50 was applied to define subgroups with a low or high allelic ratio of FLT3-ITD. 
Patients were considered as having a low allelic ratio in case the ratio was not available 
in order to define a mere poor risk group. Details of the molecular analysis are provided 
in the Supplementary Appendix. All studies were approved by the ethics committees of 
participating institutions and were conducted in accordance with the Declaration of Helsinki. 
All participants had given written informed consent. A detailed description of the inclusion 
and exclusion criteria of the studies have been previously published22-25. 
Treatment protocols
Treatment in the HOVON-SAKK AML29, AML42/42A, and AML92 studies involved a 
maximum of two remission induction cycles consisting of an anthracycline with cytarabine 
chemotherapy, as previously described.22-24 Induction chemotherapy was followed by three 
types of PRT in patients in CR1 according to a predefined strategy as outlined in the study 
protocols, including either a third cycle of chemotherapy with mitoxantrone and etoposide, 
high-dose chemotherapy with busulfan and cyclophosphamide followed by autoHSCT, or 
alloHSCT following either MAC or RIC. These different therapeutic modalities were applied 
according a risk-adapted strategy as previously described.22-24,26,27 Induction treatment in the 
EORTC AML12 study consisted of a combination of anthracycline, etoposide, and cytarabine-
based chemotherapy.25 All patients in the EORTC AML12 study received PRT with at least 
one cycle of chemotherapy after obtaining CR1 followed by continued PRT with either 
autoHSCT or alloHSCT. The preferred type of PRT in patients below the age of 50 years with 
an available donor was alloHSCT, whereas in patients above the age of 50 years or patients 
lacking a donor autoHSCT was performed as the preferred PRT.25 Conditioning with either 
RIC or MAC was performed based on center’s choice.
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Assessed for eligibility: patients with AML, aged 
 16-65 who received induction chemotherapy 
(n=4607) 
• HOVON 29: n=1022
• HOVON 42/42A: n=1513
• HOVON 92: n=  130 
• EORTC 12: n=1942
Excluded because of no CR (N=1020) 
Chemotherapy (n-148)
CR after one or two 
induction cycles (n=3587) 
Eligible patients: cytogenetically normal AML 
with molecular analysis for NPM1 and FLT3-ITD 
who received PRT (n=521)    
Excluded because of (total n=3066)  
•
•
cytogenetic abnormalities 
no PRT
AlloMAB (n=137)AutoHSCT (n=168) AlloRIC (n=68)
Figure 1  Patient flow chart
Patients with AML, included in EORTC and HOVON-SAKK trials, who were eligible for the present analysis with CN-
AML in CR1 with available molecular analysis who received PRT
Transplantation protocols
Patients received either a MAC or a RIC regimen followed by the infusion of donor cells. RIC 
alloHSCT was introduced in patients below 60 years as from 2001, whereby the indication for 
RIC or MAC was selectively determined by age and consistently adhered to by the individual 
center throughout the HOVON AML42/42A and AML92 studies. While some centers 
maintained their policy of MAC alloHSCT for all patients up to the age of 60, a number of 
centers changed their policy by setting the age limit for MAC at <40 and RIC for patients of 
40 years and beyond. The MAC regimen contained high-dose cyclophosphamide with total 
body irradiation (TBI) in 61 out of 81 (84%) HOVON patients, whereas the remainder received 
busulfan with cyclophosphamide. RIC regimens varied, but the vast majority consisted of 2.0 
gray TBI preceded by fludarabine (n = 51, 93%). MAC alloHSCT in the EORTC study preferably 
consisted of high-dose cyclophosphamide with TBI and alternatively busulfan with high-
dose cyclophosphamide. The most frequently used RIC regimen in the EORTC study was 
busulfan combined with fludarabin. A calcineurin inhibitor (either ciclosporin or tacrolimus) 
plus mycophenolate mofetil or methotrexate was given as prophylaxis for graft vs host 
disease.
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end points
The primary end point of the study was overall survival (OS), according to the type of PRT 
received. OS and relapse-free survival (RFS) were measured from the date of starting the 
first PRT. OS was based on death from any cause, and patients were censored at the date 
of last contact if alive. The events for RFS were death in CR1, designated as non-relapse 
mortality (NRM) or hematological relapse. The cumulative risks of relapse and NRM over 
time were calculated as competing risks with actuarial methods, where patients alive in 
continuing CR1 were censored at the date of last contact. 
Statistical Methods
A time-dependent analysis of PRT was performed as described previously,27,28 by applying 
multivariable Cox regression with time-dependent covariates autoHSCT and alloHSCT 
following MAC or RIC. The multivariable analysis is conceptually similar to a Mantel-Byar 
analysis,29 but more general as it allows for the adjustment of other factors. A number of 
patients received PRT with chemotherapy (n = 28) first before they proceeded to alloHSCT. 
In both the multivariable analysis and the estimation of survival curves, these patients were 
counted as at risk in the chemotherapy group from start of PRT until alloHSCT and after 
that as at risk in the MAC or RIC alloHSCT group. Multivariable Cox regression analysis for 
OS, RFS, relapse, and NRM was applied stratified by study cohort with adjustment for age, 
sex, white blood cell count at diagnosis, and late CR (after cycle II instead of I). Outcome 
estimates are at 5 years unless explicitly stated otherwise. All P-values were based on log 
likelihood ratio tests, except when explicitly stated otherwise. Log likelihood ratio tests 
were also used to test for interactions. The proportional hazard assumption was tested on 
the basis of Schoenfeld residuals.29,30 P-values were not adjusted for multiple testing. All 
analyses were done with Stata Statistical Software: Release 13.1 (2013, Stata Corporation, 
College Station, TX, USA). 
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reSuLTS
Patients
A total of 521 patients with CN-AML proceeded to PRT with either chemotherapy (n = 148), 
autoHSCT (n = 168) or alloHSCT following MAC (n = 137) or RIC (n = 68). Patient characteristics 
are presented in Table 1. Recipients of MAC alloHSCT were younger as compared with the 
other types of PRT. Patients with wild-type NPM1 received RIC alloHSCT more frequently as 
compared with chemotherapy and autoHSCT. More allografted patients obtained a relatively 
late CR1 (achieved after two cycles of induction chemotherapy). In addition, time from 
remission to PRT was longer for recipients of autoHSCT, and RIC alloHSCT was performed 
more frequently in the recent years. The median follow-up of patients still alive was 77 
months and differed between patients receiving chemotherapy (100 months), autoHSCT (70 
months), MAC alloHSCT (79 months) and RIC alloHSCT (72 months). Patient’s characteristics 
by the different study cohorts are presented in Supplementary Table 1. Due to different 
study protocols, time from CR1 to PRT was significantly longer for patients treated by the 
EORTC. All patients treated by the EORTC received PRT with chemotherapy followed by final 
PRT with either autoHSCT or alloHSCT with RIC or MAC. 
Treatment outcome
OS and RFS of all patients were 53 ± 2% and 47 ± 2%, respectively, at 5 years from the 
start of PRT. Outcome by molecular subgroups demonstrated distinct favorable and poor 
risk subgroups (Figure 2). Outcome of patients with mutated NPM1 was clearly determined 
by the absence or presence of FLT3-ITD with OS of 71 ± 4% and 39 ± 4%, respectively. In 
contrast, OS of patients with FLT3-ITD appeared to be not influenced by NPM1 mutational 
status (NPM1mut 39 ± 4%, NPM1wt 39 ± 8%), but by the ratio of mutant to wild-type FLT3-
ITD (low ratio 42 ± 3%, high ratio 23 ± 8%). Patients with mutated NPM1 without FLT3-ITD 
had a favorable outcome with OS and RFS of 71 ± 4% and 65 ± 4%, respectively. In contrast, 
AML patients with a high FLT3-ITD mutant to wild-type ratio appeared to exhibit a very 
poor outcome with OS and RFS of 23 ± 8% and 12 ± 6%, respectively. A large group of AML 
patients, designated as molecular intermediate risk, with either a low FLT3-ITD ratio (mutant 
or wild-type NPM1) or wild-type NPM1 without FLT3-ITD showed fairly similar OS and RFS 
estimating about 45% and 40%, respectively, allowing us to consider these three subgroups 
as one intermediate risk group.
outcome by PrT in molecular subgroups
Favorable risk (NPM1 mutant without FLT3-ITD AML) 
Patients with mutated NPM1 without FLT3-ITD shared similar OS following chemotherapy, 
autoHSCT, MAC alloHSCT or RIC alloHSCT (68 ± 7% and 71 ± 6%, 74 ± 7% or 67 ± 14%, 
respectively, P = 0.94, Figure 3A, Table 2). Although autoHSCT or alloHSCT following either 
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MAC or RIC reduced relapse more strongly, RFS appeared not statistically significantly 
different as compared with chemotherapy (66 ± 6%, 71 ± 7% or 67 ± 14 vs 58 ± 7%, 
respectively, P = 0.78, Figure 3B, Table 2 and Supplementary Table 2). Limiting the analysis to 
strictly favorably risk patients with an early CR (after one cycle of induction chemotherapy) 
did not show any differences in OS or RFS.
Table 1  Patient characteristics
Post-remission treatment
Chemotherapy
(n=148)
AutoHSCT
(n=168)
AlloMAC
(n=137)
AlloriC
(n=68)
Sex 
Male 72 49% 87 52% 67 49% 36 53%
Female 76 51% 81 48% 70 51% 32 47%
Age (years)
Median                     50 48 44 54
Range                      18–60 16–61 16–59 37-60
wbC at diagnosis
Median 34 28 26 11
Range 0.8-400 0.8-278 0.6-291 0.9-182
NPM1 
Mutated 95 64% 96 57% 72 53% 30 44%
Wild-type 53 36% 72 43% 65 47% 38 56%
FLT3-iTd 
Not present 94 64% 116 69% 92 67% 44 65%
Low ratio 39 26% 48 29% 37 27% 20 29%
High ratio 15 10% 4 2% 8 6% 4 6%
Cr reached after
Cycle 1 (early CR) 126 85% 155 92% 97 71% 49 72%
Cycle 2 (late CR) 22 15% 13 8% 40 29% 19 28%
Time from Cr to PrT (months)
Median                     2.1 2.6 2.4 2.3
IQ range                      1.4-2.7 2.0-2.9 1.0-2.9 1.2-2.8
year of PrT
<2005 104 70% 86 51% 76 55% 20 29%
≥2005 44 30% 82 49% 61 45% 48 71%
Abbreviations: AutoHSCT indicates autologous hematopoietic stem cell transplantation; AlloMAC, allogeneic 
hematopoietic stem cell transplantation following myeloablative conditioning, AlloRIC, alloHSCT following reduced 
intensity conditioning; WBC, white blood cell count; NPM1, nucleophosmin 1; FLT3-ITD, fms-like tyrosine kinase 3 
internal tandem duplication; IQ, interquartile range; CR, complete remission; and PRT, post-remission treatment
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Figure 2  OS and RFS by molecular subcategory
Kaplan-Meier estimates of overall survival (OS, panel A) and relapse-free survival (RFS, panel B) by molecular 
subcategory of patients with CN-AML in first complete remission from start of post-remission treatment. 
Abbreviations: NPM1, nucleophosmin-1, FLT3neg, no fms-like tyrosine kinase 3 internal tandem duplications; 
FLT3low, low allelic ratio of FLT3-ITD; FLT3high, high allelic ratio of FLT3-ITD. F, number of failures (ie, death 
whatever the cause); and N, number of patients
Intermediate risk (NPM1 wild-type without FLT3-ITD or low FLT3-ITD allelic ratio)
Recipients of RIC alloHSCT showed significantly better OS as compared with chemotherapy 
(63 ± 7% vs 39 ± 6%, respectively, P = 0.046). AutoHSCT and MAC alloHSCT had similar 
OS, which was not significantly different as compared with chemotherapy or RIC alloHSCT. 
RFS was improved by RIC alloHSCT as compared with chemotherapy (59 ± 7% vs 30 ± 5%, 
respectively, P = 0.008, Figure 3D). AutoHSCT and MAC alloHSCT reduced relapse more 
strongly as compared with chemotherapy, but RFS was not significantly different (40 ± 5%, 
44 ± 5% vs 30 ± 5, respectively, P = 0.20, Figure 3D, Table 2 and Supplementary Table 2). 
These results remained similar in patients with an early CR with improved OS and RFS by RIC 
alloHSCT as compared with chemotherapy. 
Poor risk (FLT3-ITD high mutant to wild-type ratio)
OS and RFS in patients with a FLT3-ITD mutant to wild-type ratio of >0.50 are very poor 
(Supplementary Figures 1A and 1B). Numbers of patients were low hampering a reliable 
comparison of the different types of PRT.
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Figure 3  OS and RFS in molecular subcategories by post-remission treatment
Overall survival (OS) and relapse-free survival (RFS) in molecularly favorable risk (panels A and B) and molecularly 
intermediate risk (panels C and D) patients with CN-AML in first complete remission from start of post-remission 
treatment. Molecularly favorable includes patients with mutated NPM1 without FLT3-ITD, and molecularly 
intermediate includes patients with wild-type NPM1 without FLT3-ITD or patients with a low allelic ratio of FLT3-
ITD. Of note, numbers of patients at risk (indicated below the x-axis) differ from the patient numbers (indicated 
in Table 1 and within the figure) because of the time-dependent nature of this analysis, which allows for time to 
transplantation by switching patients at the time of allograft in CR1 to the transplantation curve. Abbreviations: CT, 
chemotherapy; Auto, autologous hematopoietic stem cell transplantation (HSCT); MAC, myeloablative conditioned 
allogeneic HSCT (alloHSCT). RIC, reduced intensity conditioning alloHSCT, MAC; F, number of failures (ie, death 
whatever the cause); N, number of patients; and Cox LR, cox likelihood ratio 
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Multivariable analysis in molecularly intermediate risk patients
Table 3 shows the results of the multivariable analysis with adjustment for type of PRT, sex, 
age, white blood cell count below or above 100, and late CR. OS and RFS were better by RIC 
alloHSCT as compared with chemotherapy (hazard ratio (HR) 0.56, P = 0.022 and HR 0.50, P = 
0.004, respectively) and autoHSCT (HR 0.60, P = 0.046 and HR 0.60, P = 0.043, respectively), 
whereas NRM was not significantly different comparing RIC alloHSCT with chemotherapy 
or autoHSCT (HR 2.54, P = 0.16 and HR 1.58, P = 0.42, respectively). Although no significant 
differences were found comparing autoHSCT and chemotherapy, the risk of relapse after 
autoHSCT was reduced with a HR of 0.71, P = 0.087. RFS was improved comparing MAC 
alloHSCT with chemotherapy (HR 0.67, P = 0.048), with a strongly decreased risk of relapse 
(HR 0.20, P<0.001) and counterbalancing increased risk of NRM following MAC alloHSCT 
(HR 9.14, P<0.001). OS and RFS following autoHSCT or MAC alloHSCT yielded similar results 
with a reduced risk of relapse following MAC alloHSCT as compared with autoHSCT (HR 
0.29, P<0.001), but increased risk of NRM (HR 5.70, P<0.001). Furthermore, increasing age 
exhibited a significant HR for worse OS. In addition, late CR was associated with a significantly 
increased HR for OS, RFS and relapse as compared with CR after one cycle of induction 
chemotherapy. Of note, time from CR1 to start of PRT and year of treatment (before and 
after 2005) were added as factors to the model but showed no significant effects on OS, RFS, 
relapse or NRM. In addition, a sensitivity analysis of only patients receiving PRT after 2005 
showed similar results for PRT on all outcome parameters. 
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diSCuSSion
The preferred type of PRT in patients with CN-AML in CR1 continues to be debated. 
Molecular diagnostics provide additional prognostic information to further stratify patients 
with CN-AML in CR1. Here, we demonstrate that type of PRT does not differentially affect 
outcome in the favorable group of patients with mutated NPM1 without FLT3-ITD. Outcome 
in patients with a high allelic ratio of FLT3-ITD appeared very poor, with low patient numbers 
hampering a comparison by type of PRT. In contrast, outcome by type of PRT appeared to 
differ in a larger intermediate group, characterized by FLT3-ITD with a low allelic ratio and 
wild-type NPM1 without FLT3-ITD AML. RIC alloHSCT appeared associated with significantly 
better OS and RFS as compared with chemotherapeutic PRT, whereas MAC alloHSCT and 
autoHSCT yielded similar OS, which did not significantly differ from PRT by chemotherapy. 
The FLT3-ITD is an important molecular determinant of AML risk classification and 
outcome.4,5,31 Here, not only FLT3-ITD itself, but especially the mutant to wild-type ratio 
strongly affected outcome with poor outcome for patients with a high allelic ratio. Based 
on these and previous results, the FLT3-ITD allelic ratio should be included in AML risk 
classifications and PRT decision making.7-10,19,32 PRT has not extensively been studied in 
patients with AML, with a high allelic burden of FLT3-ITD, but improved outcome following 
alloHSCT has been suggested in patients with a FLT3-ITD allelic ratio of >0.50.10,19,32 In our 
study, the few surviving patients with a high allelic burden of FLT3-ITD were recipients of 
an alloHSCT in either CR1 or CR2, which compares well with recent results by Ho et al,19 
suggesting improved outcome by alloHSCT. 
Studies evaluating PRT by alloHSCT in patients with FLT3-ITD irrespective of the allelic 
ratio reported different results. While a study from the French GOELAMS study group 
reported improved outcome by alloHSCT,33 a recent prospective matched pair study failed to 
show such a survival benefit.34 The evaluation of all FLT3-ITD patients, including an unknown 
number of patients with a high allelic ratio, may have impacted on those results, questioning 
the comparability of those and other studies, focusing on FLT3-ITD. We combined patients 
with a low FLT3-ITD allelic ratio (irrespective of NPM1 mutations) and patients with wild-type 
NPM1 without FLT3-ITD into an intermediate risk group because of similar OS and RFS in 
these subgroups. In that molecularly intermediate risk group, OS and RFS were significantly 
better following RIC alloHSCT as compared with chemotherapy, which was confirmed by 
multivariable analysis stratified by study cohort and following adjustment for covariates. Of 
note, with a median follow-up of 72 months, NRM was low and a graft-vs-leukemia effect 
was preserved as evidenced by a HR of 0.35 for relapse as compared with chemotherapy. 
Although MAC alloHSCT showed an even stronger HR of 0.20, the anti-leukemic activity was 
counterbalanced by a significantly higher NRM (HR 9.14). Although a number of studies have 
shown a higher relapse rate following RIC alloHSCT as compared with MAC alloHSCT,35-41 the 
net effect in terms of OS and RFS in well-defined and sufficiently sized subcategories of 
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AML CR1 patients is still underreported. Here, we show that the balance of a preserved 
graft-vs-leukemia and a low NRM eventually resulted in favorable outcome in molecularly 
intermediate risk AML CR1 recipients, who proceeded to RIC alloHSCT. MAC alloHSCT and 
autoHSCT yielded similar outcomes in that intermediate risk category of patients. Most 
comparative PRT studies in molecular subgroups compare alloHSCT with chemotherapy, but 
lack a group of autoHSCT recipients. Here, a large subgroup of recipients of an autograft was 
also included. Although autoHSCT was not significantly associated with improved outcome 
as compared with chemotherapy or MAC alloHSCT, autoHSCT may provide a valuable 
alternative PRT in these subgroups, especially in patients lacking a well matched donor or in 
patients at higher risk for NRM determined by risk scores.42-44 In addition, the incorporation 
of minimal residual disease status assessed by flow cytometry45,46 or molecular analysis47 
may add to that decision making, by the preferred application of autoHSCT in minimal 
residual disease negative, molecularly intermediate risk patients in CR1. Of note, while RFS 
following autografting estimated 40% in the intermediate risk group, OS was 47%, indicating 
that a considerable number of relapsing patients may be rescued by an allograft in CR2, as 
previously reported in AML patients.48-50 
Combining results from two cooperative groups may implicate limitations. Although the 
induction chemotherapeutic regimens varied among the different study groups, all patients 
received cytarabine/anthracycline-based chemotherapy, obtained a hematological CR1 
within two cycles of induction chemotherapy, and outcome was not significantly different 
among the different study groups. In addition, differences in PRT approach among the 
study groups may have resulted in selection bias, although that bias is presumably similar 
among the three molecularly defined groups in the analysis, which were not differentially 
approached by the study groups. The analysis presented did not prospectively compare RIC 
and MAC regimens prior alloHSCT, which withholds us from conclusions in that regard. Given 
the significant lower NRM associated with RIC, as shown in many studies, the presentation of 
RIC alloHSCT and MAC alloHSCT as two distinct categories is, however, warranted. The latter 
notion is supported by results of the prospective randomized US study, showing different 
outcomes following either conditioning type.51 Although MAC alloHSCT is associated with 
a significantly stronger anti-leukemic effect, its counterbalancing effect on NRM need to be 
taken into account, especially in older patients with comorbidities. Therefore, as advocated 
before,5 we prefer to apply either treatment modality in a personalized fashion, tailored by 
risk factors, predicting NRM.52
Collectively, these results suggest that RIC alloHSCT may provide better survival than 
chemotherapeutic PRT in patients with CN-AML with wild-type NPM1 without FLT3-ITD or 
FLT3-ITD with a low allelic burden. AutoHSCT may be applied if not eligible, if no well-matched 
donor is available in CR1, or in case of absence of minimal residual disease. Although MAC 
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alloHSCT is associated with the strongest anti-leukemic effect, our results suggest that it 
might preferentially be applied in patients with an acceptable risk for complications and NRM. 
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SuPPLeMenTAry APPendix
Supplementary methods - Molecular analysis
FLT3 ITD detection and FLT3 ITD/wild type ratio
Total RNA was extracted with phenol chloroform and reverse transcribed using Superscript 
II RT (Invitrogen, Breda, the Netherlands). The presence of FLT3 ITD and NPM1 mutations 
in the AML samples were determined as described previously.1,2 AML samples harboring 
a FLT3 ITD were subsequently analyzed by Roche 454 next generation sequencing (NGS). 
Amplicon fusion primers for bi-directional sequencing were designed according to the 
manufacturers protocols (Roche, Amplicon Library Preparation Method Manual-Lib-A, GS-
Junior Titanium Series, May 2010 (Rev June 2010)) and consisted of an adapter sequence 
for the GS-Junior 454 system, a sample specific barcode sequence (MID – multiplex 
identifier) for both forward and reverse primers, and the template-specific sequence: 
FLT3 exon 12: FLT3ex12: 5’-TAAACTCTCCAGGCCCCTTC-3 and FLT3 exon 16: FLT3ex16: 
5’-TGAGTGCCTCTCTTTCAGAGC-3. PCR and cycling conditions: 0.25mM dNTP, 0.4 µM primer, 
2mM MgCl2, Taq polymerase and 1x buffer (Invitrogen, Breda, the Netherlands), cycling: 1 
cycle 4’ 94˚C, 35 cycles 1’ 94˚C, 1’ 60˚C, 1’ 72˚C, and 1 cycle 10’ 72˚C. Pooled PCR products 
were purified, diluted, clonally amplified by emulsion PCR and sequenced on the Roche 454 
GS junior system and analyzed according to the manufacturer’s protocols (Roche, Amplicon 
Library Preparation Method Manual-Lib-A, GS-Junior Titanium Series, May 2010, Rev June 
2010). Samples with > 60% FLT3 ITD as defined by (FLT3 ITD reads/ (FLT3 ITD reads + FLT3 
wild type reads) were indicated as homozygous FLT3 ITD. The threshold of 60% was chosen 
to ascertain that true FLT3 ITD homozygous were included in the study. Samples lacking 
FLT3-ITDs were used as control.
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Supplementary Table 1  Patient characteristics by cohort
eorTC
(n=122)
Hovon
(n=399)
p-value
Sex 
Male 54 44% 208 52%
.13
Female 68 56% 191 48%
Age (years)
Median                     47 49
.038
Range                      16-61 18-60
NPM1 
Mutated 64 52% 229 57%
.34
Wild-type 58 48% 170 43%
FLT3-iTd 
Not present 87 71% 259 65%
.062Low ratio 33 27% 111 28%
High ratio 3   2% 29   7%
Cr reached after
Cycle 1 (early CR) 114 93% 313 78%
<.001
Cycle 2 (late CR) 8   7% 86 22%
Time from Cr to start PrT (months)
Median                     3.0 2.3
<.001
IQ range                      2-4 1-3
PrT
 Chemotherapy 0   0% 148 37%
<.001
 AutoHSCT 71 58% 97 24%
 MAB 47 39% 90 23%
 RIC 4   3% 64 16%
year of PrT
<2005 71 58% 215 54%
.40
≥2005 51 42% 184 46%
Abbreviations: AutoHSCT indicates autologous hematopoietic stem cell transplantation; AlloMAB, allogeneic 
hematopoietic stem cell transplantation following myeloablative conditioning, AlloRIC, alloHSCT following reduced 
intensity conditioning; WBC, white blood cell count; NPM1, nucleophosmin 1; FLT3-ITD, fms-like tyrosine kinase 3 
internal tandem duplication; IQ, interquartile range; CR, complete remission; and PRT, post-remission treatment
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AbSTrACT
Purpose 
The detection of minimal residual disease (MRD) in patients with acute myeloid leukemia 
(AML) may improve future risk-adapted treatment strategies. We assessed whether MRD 
positive and MRD negative AML patients benefit differently from the graft-versus-leukemia 
effect of allogeneic hematopoietic stem cell transplantation (alloHSCT).
Patients and Methods 
A total of 1.511 patients were treated in subsequent HOVON-SAKK AML trials of whom 
547 patients obtained a first complete remission, received post-remission treatment (PRT) 
and had available flowcytometric MRD prior to PRT. MRD-positivity was defined by more 
than 0.1% cells with a leukemia associated immunophenotype within the white blood cell 
compartment. PRT consisted of alloHSCT (n=282), or conventional PRT with a third cycle of 
chemotherapy (n=160) or autologous HSCT (autoHSCT, n=105).
Results 
MRD was positive in 129 (24%) patients after induction chemotherapy before proceeding to 
PRT. OS and RFS were significantly better in patients without MRD prior to PRT compared 
with MRD-positive patients (65 ± 2% versus 50 ± 5% at 4 years, p=0.002, and 58 ± 3% versus 
38 ± 4%, p<0.001, respectively), which was mainly because of a lower cumulative incidence 
of relapse (32 ± 2% compared to 54 ± 4 %, p<0.001, respectively). Multivariable analysis with 
adjustment for covariates showed that the incidence of relapse was significantly reduced 
following alloHSCT compared with chemotherapy or autoHSCT (HR 0.36, p<0.001), which 
was similarly exerted in both MRD-negative and MRD-positive patients (HR 0.38, p<0.001 
and HR 0.35, p<0.001).
Conclusion 
The graft-versus-leukemia effect of alloHSCT is equally present in MRD-positive and MRD-
negative patients, which advocates a personalized application of alloHSCT taking the risk of 
relapse determined by AML risk group and MRD status as well as the counterbalancing risk 
of non-relapse mortality into account.
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inTroduCTion
Acute myeloid leukemia (AML) is a heterogeneous malignancy, characterized by a variety 
of underlying cytogenetic and molecular aberrations, which are associated with distinct 
prognostic features.1 Although current treatment approaches induce high percentages of 
hematological remission, relapse rates are high and vary according to the underlying risk 
profile.2 Recently, the European LeukemiaNet (ELN) has developed an updated classification 
based on cytogenetic and molecular aberrancies distinguishing patients with a favorable, 
intermediate or adverse treatment response.3 Post-remission treatment (PRT) decisions are 
currently tailored according to AML-risk groups, whereby allogeneic hematopoietic stem cell 
transplantation (alloHSCT) is generally not used in patients with favorable-risk AML, and on 
the other hand generally highly recommended in adverse-risk AML.3-6 AML-risk classification 
may be further improved by introducing the assessment of minimal residual disease (MRD) 
early after induction chemotherapy, but also after PRT.7-24 MRD after induction treatment 
being assessed by either multiparametric flow cytometry or quantitative PCR for specific 
markers, has firmly been shown to predict for relapse and overall outcome, irrespective 
of type of PRT.10-24 Consequently, MRD negativity was introduced as clinical endpoint in 
patients with a hematological complete remission (CR).3 Despite PRT with alloHSCT, a 2-5 
fold increased incidence of relapse in MRD-positive recipients was observed compared 
with MRD-negative patients,17-24 which observation questions whether and to what extent 
MRD-positive patients may benefit from the graft-versus-leukemia (GVL)-effect of alloHSCT. 
Conversely, the low relapse rate in MRD-negative alloHSCT recipients also evokes the 
question whether GVL is operational in that subgroup and to what extent it may be blunted 
by non-relapse mortality (NRM). Therefore, we set out to address whether and to what 
extent alloHSCT quantitatively reduces relapse compared with conventional PRT in upfront 
treated patients with MRD-positive or MRD-negative AML in first CR (CR1).
GVL-effect of alloHSCT and MRD in patients with AML
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MeTHodS
Patients
Patients participated in three prospective, consecutive HOVON-SAKK collaborative group 
trials (AML42, AML92 and AML102), for whom assessment of MRD after induction therapy 
and prior to PRT by either alloHSCT, chemotherapy or autologous HSCT (autoHSCT) was 
performed.25,26 The results of the AML92 trial have not been published, but trial information 
is available in the Netherlands Trial Register (NTR1446). A total number of 1511 newly 
diagnosed AML patients were included for whom treatment was started between 2006 and 
2014. Patients were excluded because of no CR1 after two induction cycles of chemotherapy 
(n=255, 17%), no application of PRT after obtaining CR1 (n=234, 15%). In addition, a total 
of 475 (31%) patients received a PRT in CR1 but had no available MRD status within a time 
window of four months before PRT. A total of 547 patients with available MRD status who 
received PRT in CR1 was available for analysis (Consort Diagram). Patients were classified by 
AML prognostic risk, based on the cytogenetic and molecular profile of the underlying AML, 
according to the ELN2017-risk classification.3 Molecular analysis was available for the majority 
of patients, specifically for NPM1 (93%), FLT3-ITD (91%), including the FLT3-ITD mutant to 
wild type ratio (86%), EVI1 (79%), ASXL1 (83%), RUNX1 (47%), and TP53 (47%). Patients for 
whom molecular analyses were not available were considered as not having the mutation in 
calculating the ELN2017-risk classification. All studies were approved by the ethics committees 
of participating institutions and were conducted in accordance with the Declaration of 
Helsinki. All participants had given written informed consent. A detailed description of 
the inclusion and exclusion criteria of the studies have been previously published.25,26 
Treatment protocols
Treatment in the HOVON-SAKK AML42A, AML92, and AML102 trials involved a maximum of 
two remission induction cycles consisting of a first course of idarubicin with cytarabine and 
a second cycle of high dose cytarabine with amsacrine, as previously described.25,26 Patients 
were randomized to G-CSF (AML42A), laromustine (AML92), and clofarabine (AML102). 
After obtaining CR1, patients subsequently received PRT to a predefined strategy as outlined 
in the study protocols, but without knowledge of the MRD status of the patients. PRT 
included either a third cycle of chemotherapy with mitoxantrone and etoposide, high-dose 
chemotherapy with busulfan and cyclophosphamide followed by autoHSCT, or alloHSCT 
following either myeloablative conditioning (MAC) or reduced intensity conditioning 
(RIC). The MAC regimen contained high-dose cyclophosphamide with at least 8 Gy total 
body irradiation (TBI) in 83 (76%) patients, whereas the remainder received busulfan with 
cyclophosphamide. Although RIC regimens varied, the majority contained low dose (2 or 
4 Gy) TBI preceded by fludarabine (n=126, 77%), whereas 23% of the patients received 
fludarabine with busulfan. These different PRT modalities were applied according a risk-
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Consort diagram  
Assessed for eligibility (n=1,511) 
• AML 42A  (n=511)  
• AML 92  (n=142)  
• AML 102  (n=858)  
Excluded (n=964) 
• Obtained no CR (n=255)  
• Received no PRT  (n=234)  
• No available MRD  (n=475)  
Patients eligible for analysis 
(n=547) 
MRD negative (n=418) 
• CT  (n=118) 
• Auto  (n=89) 
• Allo   (n=211) 
MRD positive (n=129) 
• CT  (n=42) 
• Auto  (n=16) 
• Allo   (n=71) 
adapted strategy: (1) patients with AML classified as favorable-risk, according to cytogenetic 
and molecular analysis, were planned for a third cycle of chemotherapy; (2) intermediate-
risk patients were preferentially treated by alloHSCT using a human leukocyte antigen (HLA) 
matched sibling donor or a fully HLA-matched unrelated donor if available; (3) patients with 
adverse-risk AML proceeded to alloHSCT using either a sibling donor, unrelated donor, or 
cord blood grafts; (4) patients alternatively received an autoHSCT or a third cycle of 
chemotherapy if no suitable donor was available.25-28
Mrd detection and sample selection
MRD flow cytometric analysis was performed in a two-step procedure, as previously 
described.18 In summary, the immunophenotype was determined on blasts defined by 
CD45 expression with a low sideward scatter. The leukemia associated immune phenotype 
(LAIP) at diagnosis was identified by detecting aberrantly expressed markers/marker 
combinations to distinguish leukemic blasts from normal hematopoietic progenitor cells. 
Bone marrow samples were collected at diagnosis to determine LAIP and follow-up after 
each chemotherapy cycle. The sensitivity of flow cytometry could lead to detection of one 
leukemic cell in 1,000 up to 100,000 white blood cells (WBC). MRD percentage was defined 
GVL-effect of alloHSCT and MRD in patients with AML
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as the percentage of LAIP cells within the WBC compartment multiplied by the correction 
factor (100% divided by the percentage of LAIP positive blasts at diagnosis). A percentage 
above 0.1% was considered as MRD-positive as validated in previous studies.18 MRD samples 
obtained after cycle 2 in patients with AML in CR1 were used with a maximum time from the 
MRD sample to subsequent PRT of four months. The sample with the shortest time interval 
between PRT and the date of collection was selected for analysis.
endpoints
The primary endpoint of the study was the cumulative incidence of relapse. Outcome 
estimates were measured from the date of starting the first PRT. Overall survival (OS) was 
based on death from any cause, and patients were censored at the date of last contact if 
alive. The events for relapse free survival (RFS) were death in CR1, designated as NRM, or 
hematological relapse. The cumulative risks of relapse and NRM over time were calculated 
as competing risks with actuarial methods, where patients alive in continuing CR1 were 
censored at the date of last contact. 
Statistical methods
A time-dependent analysis of PRT was performed as described previously,28,29 by applying 
multivariable Cox regression with alloHSCT as time-dependent covariate. The multivariable 
analysis is conceptually similar to a Mantel-Byar analysis,30 but more general as it allows for 
adjustment of other factors. A number of patients received PRT with chemotherapy (n=44) 
first before they proceeded to alloHSCT in continuing CR1. In both the multivariable analysis 
and the estimation of the survival curves, these patients were counted as at risk in the 
chemotherapy group from start of PRT until alloHSCT and after that as at risk in the alloHSCT 
group. Forward selection with the variables significantly associated with relapse following 
univariable analysis was used for developing the multivariable model. Multivariable Cox 
regression analysis for relapse, OS, RFS, and NRM was applied stratified by the total number 
of induction courses. Stratification by the total number of induction courses (ie, I or II) was 
done in order to allow the baseline hazard to differ between these two patient groups. All 
p-values were based on log likelihood ratio tests, except when explicitly stated otherwise. 
The proportional hazard assumption was tested on the basis of Schoenfeld residuals.30,31 
P-values were not adjusted for multiple testing. All analyses were done with Stata Statistical 
Software: Release 13.1 (Stata Corporation 2013, College Station, TX, USA). 
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reSuLTS
Patient characteristics
A total of 547 patients with AML in CR1 and available MRD-status proceeded to PRT with 
either alloHSCT (n=282), chemotherapy (n=160), or autoHSCT (n=105). A total of 129 (24%) 
patients were MRD-positive after induction chemotherapy before proceeding to first PRT. 
Patient characteristics are presented in Table 1. Patients with mutated NPM1 were more 
frequently MRD-negative, whereas MRD-positive patients more frequently tended to 
obtain a late CR1 (ie, after induction cycle 2). The ELN2017-risk classification was similarly 
distributed among the MRD-negative and positive patients. Interestingly, the time-interval 
from CR1 to PRT for patients with a MRD-positive AML was shorter compared with their 
negative counterparts, which was mainly apparent in favorable-risk AML patients. The 
median follow-up of patients still alive was 50 months. Details of the characteristics of 
alloHSCT are shown in Table 2. No other differences as regards donor source, conditioning, 
CMV-serostatus, and EBMT-score were apparent between MRD-negative and MRD-positive 
patients. AlloHSCT recipients received a sibling donor in 50% of the transplants, whereas 
42% patients were transplanted with a matched unrelated donor. AlloHSCT with RIC was 
predominantly performed, and conditioning mostly included total body irradiation. Patients 
with a high-risk for NRM according to the EBMT-score32 (>3 points) represented 45% of the 
transplanted patients. 
Treatment outcome
OS and RFS were significantly better in patients without MRD before PRT compared with 
MRD-positive patients (65 ± 2% versus 50 ± 5% at 4 years, p=0.002, and 58 ± 3% versus 38 
± 4%, p<0.001, respectively, Figure 1A and 1B). Improved outcome was mainly caused by 
a lower cumulative incidence of relapse in MRD-negative patients compared with MRD-
positive patients (32 ± 2% compared to 54 ± 4% at 4 years, p<0.001, respectively, Figure 1C), 
whereas NRM was not significantly different and estimated at 10 ± 1% (Figure 1D). More 
detailed outcome estimates according to MRD-status, type of PRT, and risk for NRM based 
on the EBMT-score are presented in Supplementary Table 1.
The cumulative incidence of relapse was significantly lower in patients without MRD 
receiving alloHSCT compared with chemotherapy or autoHSCT (26 ± 3% versus 38 ± 3% 
at 4 years, p=0.027, respectively, Figure 2A). The cumulative incidence of relapse in MRD-
positive patients estimated 45 ± 6% compared to 66 ± 6% at 4 years (p=0.058), for recipients 
of alloHSCT compared with recipients of chemotherapy or autoHSCT, respectively (Figure 
2B). RFS following alloHSCT proved similar compared with PRT with chemotherapy or 
autoHSCT in patients without MRD before PRT (58 ± 4% versus 58 ± 4% at 4 years, p=0.99, 
respectively, Figure 2C). RFS after alloHSCT in patients with positive MRD before PRT was 44 
± 6% compared to 31 ± 6% at 4 years (p=0.20) after chemotherapy or autoHSCT, respectively 
(Figure 2D).
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Table 1  Patient characteristics
Mrd negative
(n=418)
Mrd positive
(n=129)
P-value
Sex .129
Male 207 50% 70 54%
Female 211 50% 59 46%
Age (years) .099
Median 51 49
Range 18-65 18-65
wbC at diagnosis .049
<100 389 93% 113 88%
>100 29 7% 16 12%
Cytogenetics of AML .008
t(8;21) 25 6% 7 5%
inv(16) 15 4% 15 12%
CN-X-Y 220 53% 56 43%
Cytogenetic abnormalities 110 26% 36 28%
Monosomal karyotype 30 7% 12 9%
Missing 18 4% 3 2%
NPM1 mutation .001
No 238 57% 91 71%
Yes 151 36% 27 21%
Missing 29 7% 11 9%
FLT3-iTd* .87
Absent 289 69% 86 67%
Low ratio 75 18% 24 19%
High ratio 16 4% 6 5%
Missing 38 9% 13 10%
eLn2017 risk classification .20
Favorable 163 39% 39 30%
Intermediate 144 34% 51 40%
Adverse 111 27% 39 30%
Cr reached after .003
Cycle 1 (early CR) 373 89% 102 79%
Cycle 2 (late CR) 45 11% 27 21%
Post-remission treatment .079
Chemotherapy 118 28% 42 33%
Autologous HSCT 89 21% 16 12%
Allogeneic HSCT 211 50% 71 55%
Time from diagnosis to Cr (days) .084
Median 34 35
IQ range 29-40 31-46
Time from Cr to PrT (days) .009
Median 74 65
IQ range 56-96 48-90
year of PrT .11
Median 2011 2010
Range 2006-2014 2006-2014
Abbreviations: MRD, minimal residual disease; WBC, white blood cell count; AML, acute myeloid leukemia; NPM1, 
nucleophosmin-1; FLT3-ITD, fms-like tyrosine kinase 3 internal tandem duplication; ELN, European LeukemiaNET; 
CR, complete remission; IQ, interquartile range; and PRT, post-remission treatment. *The cuf-off of the FLT3-ITD 
ratio is defined as 0.50 
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Table 2  Transplant characteristics
Mrd negative Mrd positive P-value
(n=211) (n=71)
donor source .29
HLA-identical sibling 107 51% 35 49%
Matched unrelated donor 90 43% 29 41%
Umbilical cord blood 7 3% 6 8%
Other 7 3% 1 1%
Conditioning .85
Myeloablative          Cyclophosphamide + TBI 63 30% 20 28%
                   Cyclophospahmide + busulfan 20 9% 6 8%
Reduced intensity     Fludarabine + TBI 89 42% 31 44%
                 Fludarabine + busulfan 24 11% 11 15%
Unknown 15 7% 3 4%
Stem cell source .13
Bone Marrow 10 5% 4 6%
Peripheral Blood 186 88% 59 83%
Cordblood 6 3% 6 8%
Missing 9 4% 2 3%
CMv serostatus patient/donor .059
Neg/Neg 25 12% 3 4%
Other 108 51% 41 58%
Missing 78 37% 27 38%
Female donor to male recipient .89
No 168 80% 56 79%
Yes 43 20% 15 21%
ebMT-score .40
0 0 1 1%
1 26 12% 9 13%
2 93 44% 26 37%
3 81 38% 31 44%
4 11 5% 4 6%
Abbreviations: MRD, minimal residual disease; HLA, human leukocyte antigen; TBI, total body irradiation; CMV, 
cytomegalovirus; and EBMT, European Group of Blood and Marrow Transplantation
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Figure 1  Outcome by minimal residual disease status 
Kaplan-Meier estimates of overall survival (OS, panel A), relapse-free survival (RFS, panel B), cumulative incidence 
of relapse (panel C) and cumulative incidence of non-relapse mortality (NRM, panel d) by minimal residual 
disease (MRD) status in patients with AML in first complete remission from start of post-remission treatment. 
Abbreviations: F, number of failures (ie, death whatever the cause); and N, number of patients
The type of conditioning did not significantly impact on the incidence of relapse or RFS 
(Supplementary Figure 1). The cumulative incidence of NRM after alloHSCT was 15 ± 2% and 
was significantly affected by the EBMT-score (Supplementary Figure 2). NRM split by the 
EBMT-score showed less NRM in patients with a low EBMT-score compared with patients 
with a high EBMT-score (<2 compared to >2, 10 ± 2% compared to 22 ± 4%, p=0.005, 
respectively).
A total of 208 patients developed a relapse after having received PRT, of whom 120 
(57%) patients proceeded to salvage chemotherapy and 70 (59%) entered a second CR. Only 
46 (22%) of relapsing patients proceeded to alloHSCT after obtaining second CR.
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Figure 2  Outcome by post-remission therapy 
Kaplan-Meier estimates of the cumulative incidence of relapse in minimal residual disease (MRD) negative patients 
(A), cumulative incidence of relapse in MRD positive patients (B), relapse-free survival (RFS) in MRD negative 
patients (C), and RFS in MRD positive patients (d) by type of post-remission treatment in patients with AML 
in first complete remission from start of PRT. Of note, numbers of patients at risk (indicated below the x-axis) 
differ from the patient numbers (indicated in Table 1 and within the figure) because of the time-dependent 
nature of this analysis, which allows for time to transplantation by switching patients at the time of allograft in 
CR1 to the transplantation curve. Abbreviations: CT/auto, chemotherapy or autologous hematopoietic stem cell 
transplantation; allo, allogeneic hematopoietic stem cell transplantation; F, number of failures (ie, death whatever 
the cause); and N, number of patients
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Multivariable analysis
The following variables significantly predicted for relapse in the univariable analysis: 
MRD status, type of PRT, age, WBC category, FLT3-ITD category, year of PRT, time from 
diagnosis to CR, time from CR to PRT, cytogenetics, number of cycles to CR, ELN2017-risk 
classification, NPM1 mutation, EVI1 overexpression, and CEBPA double mutation. Following 
forward selection the multivariable analysis was performed, stratified by the total number 
of induction courses with adjustment for MRD status, type of PRT, age, WBC at diagnosis, 
FLT3-ITD, ELN2017-risk classification, number of cycles to CR, and year of PRT (Table 3). 
Relapse of AML was significantly reduced following alloHSCT compared with chemotherapy 
or autoHSCT (HR 0.36, p<0.001). That GVL-effect was similarly exerted in MRD-negative 
and MRD-positive patients (HR 0.38, p<0.001 and HR 0.35, p<0.001, Figure 3A), which was 
also similar comparing alloHSCT with either chemotherapy or alloHSCT with autoHSCT 
(Supplementary Figure 3). Despite significantly increased NRM (HR 2.94, p=0.003), RFS was 
better following alloHSCT compared with chemotherapy or autoHSCT (HR 0.53, p<0.001, 
Figure 3B, Supplementary Figure 4), whereas OS was not significantly different (Table 3). 
Different variables in the multivariable model were significantly associated, with relapse 
with the ELN2017-risk classification, FLT3-ITD mutant to wild-type ratio, number of cycles to 
reach CR, and type of PRT being the most important variables.
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 MRD status (cut-off 0.1)
 Negative  83 / 207  55 / 211
 Positive  38 / 58  32 / 71
 121 / 265  87 / 282
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 2P<0.001 0  0.5  1.0  1.5  2
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Figure 3  Forest plots of relapse comparing alloHSCT versus chemotherapy or autoHSCT 
Forest plot of pooled estimates of the relative reduction (hazard ratio (HR) and 95% confidence interval (CI)) of 
relapse (A) and relapse-free survival (B) by MRD status comparing allogeneic hematopoietic stem cell transplantation 
(HSCT) and chemotherapy or autologous HSCT
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diSCuSSion
The development of treatment approaches in AML patients is increasingly personalized 
by using genetic and molecular leukemia characteristics at diagnosis and individual 
treatment response.3-6 Response and especially MRD, detected by either multiparametric 
flow cytometry or quantitative PCR, has become an important parameter in a more precise 
treatment approach of AML patients.10-24 Currently it is unknown whether and how the 
presence or absence of MRD should guide the application of alloHSCT as PRT. Recently, 
the quantitative detection of mutated NPM1 has been shown of high predictive value and 
recommendations to tailor the application of alloHSCT by MRD were done.10-12 Balsat et 
al.10 suggested to refrain from alloHSCT in NPM1 MRD-negative patients and to selectively 
proceed to alloHSCT as PRT in CR1 in MRD-positive patients or adverse-risk patients based 
on karyotype or the presence of FLT3-ITD. In addition, Buccisano et al.33 concluded in a 
recent analysis that MRD-positive patients as determined by flow cytometry could also 
benefit from alloHSCT. Although overall outcome was suggested to be improved by alloHSCT 
in MRD-positive patients, the question to what quantitative extent alloHSCT reduces relapse 
in MRD-positive patients and how that compares to MRD-negative patients is still open. 
Here, we show that the allogeneic GVL-effect as estimated by the relative reduction of 
relapse is similar in MRD-positive and MRD-negative patients with a reduction of 63% by 
alloHSCT compared with chemotherapy or autoHSCT. These results compare well to earlier 
findings in cytogenetic subgroups, in which the GVL-effect appeared to be similar among 
patients with a monosomal karyotype, core binding factor AML, or patients with a normal 
karyotype.34 These observations are most readily explained by the abundant expression 
of class I and II HLA-antigens on malignant myeloid precursor cells and their susceptibility 
to alloreactive T-cells, including T-cells recognizing minor or major HLA-antigens.35-37 It 
suggests that T-cell alloreactivity might exert anti-leukemic effects irrespective of underlying 
subcategory of AML, although absolute estimates of relapse incidences do differ and may 
rather reflect differences in disease biology such as intrinsic resistance. 
Although alloHSCT provides a strong GVL-effect, counterbalancing NRM may be of 
concern. As NRM critically depends from a number of different risk factors, it has become 
imperative to assess the NRM-risk profile in addition to leukemia characteristics and response 
to induction chemotherapy.4 In the present study, the subset of patients with low EBMT-risk 
scores showed excellent outcome, whereas the GVL-effect of alloHSCT may be blunted by 
NRM in patients with a high-risk for NRM. Therefore, refined genetic leukemia-risk scores 
supplemented with MRD status may improve the latest risk score systems for NRM.32,38-44 
Transplant-risk scores have been developed and validated based on patient and transplant 
characteristics, including the EBMT-risk score32 and the Hematopoietic Cell Transplantation-
Comorbidity Index (HCT-CI)40, which is continuously being refined including age, disease 
status, or bio-markers.39,41,42 The EBMT-acute leukemia working party (ALWP) has developed 
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an integrated score based on the EBMT-risk score and the HCT-CI with increased predictive 
power in the setting of RIC alloHSCT.43 Alternatively, a more sophisticated, machine based 
learning model was developed by the EBMT-ALWP, which resulted in an alternating decision 
tree model with high predictive power for mortality at 100-days extending to 2-years.44 
As advocated before, by weighing both the risk for NRM and the risk for relapse, a more 
personalized treatment approach can be applied.5 Although that approach suits the 
precision needed for individual patients, it might also impair the prospective, randomized 
evaluation of AML treatment approaches, because patient selection may occur at various 
time points during treatment. Nevertheless, the advantages of personalized treatment for 
the individual patient are obvious and continuously being refined by updated and better risk 
scores. Also new technologies to better define MRD, like quantification of leukemic stem cell 
content, standardized protocols and antibody panels, and novel software possibilities, are 
emerging.45-47 
A personalized approach including MRD identifies patients with an high-risk of relapse, 
who qualify for alloHSCT, but who might benefit from attempts to induce MRD-negativity 
prior transplantation. Previously, a number of investigators reported that patients in CR1 
with persistence of MRD before alloHSCT have worse survival compared with recipients 
of alloHSCT with a MRD-negative CR1.17,19-24 Although alloHSCT is clearly indicated in MRD-
positive patients, it is important to study the value of approaches intended to induce MRD-
negativity before alloHSCT. A prospective inclusion of all MRD-positive patients subsequently 
analyzing such a strategy in a randomized fashion might answer this important question. 
It has been suggested that continued chemotherapy with one or two consolidation cycles 
may not be the preferred strategy to obtain a MRD-negative CR before alloHSCT,48 but 
several new drugs are currently being developed and evaluated in AML.49 Possible other 
strategies may include efforts to improve allogeneic immunotherapy by early tapering of 
immunosuppression and/or pre-emptive donor lymphocyte infusions, which also could be 
guided by MRD. In addition, the continued application of novel post-transplant strategies 
including epigenetic therapy to enhance the GVL-effect (ie, demethylating agents and 
histone deacetylase inhibitors50,51), new agents such as tyrosine kinase inhibitors for specific 
molecular mutations (ie, FLT3-ITD52, IDH1/253,54) or targeted immunotherapy with chimeric 
antigen receptor T-cells in MRD-positive patients may offer further therapeutic options 
minimizing relapse after alloHSCT.
Collectively, our study shows that the GVL-effect was strikingly similar in MRD-positive 
and MRD-negative patients. The personalized application of alloHSCT should take MRD-
response into account and also risk scores for NRM as GVL is not invariably blunted by 
NRM. Further prospective studies are needed to evaluate whether the conversion of MRD-
positivity into a MRD-negative remission prior alloHSCT further optimizes outcome and how 
the GVL-effect after alloHSCT can be optimized. Precision medicine for patients with AML 
is urgently needed, thus the decision to transplant or not in an individual patient might 
depend on weighing the risk of relapse versus the personalized risk of NRM. 
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SuPPLeMenTAry APPendix
Supplementary Table 1  Treatment outcome at 4 years
Mrd negative Mrd positive
(n=418) (n=129)
All patients
OS 65 ±2% 50 ±5%
RFS 58 ±3% 38 ±4%
Relapse 32 ±2% 54 ±4%
NRM 10 ±2% 8 ±2%
CT/auto
OS 71 ±3% 53 ±7%
RFS 58 ±4% 31 ±6%
Relapse 38 ±3% 66 ±6%
NRM 4 ±1% 3 ±2%
Allo
OS 60 ±4% 47 ±6%
RFS 58 ±4% 44 ±6%
Relapse 26 ±3% 45 ±6%
NRM 16 ±3% 12 ±4%
Abbreviations: MRD, minimal residual disease; OS, overall survival; RFS, relapse-free survival; NRM, non-
relapse mortality; CT, chemotherapy; Auto, autologous hematopoietic stem cell transplantation; Allo, allogeneic 
hematopoietic stem cell transplantation; EBMT,Eeuropean group for Blood and Marrow Transplantation
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Supplementary Figure 1  Outcome by conditioning type 
Kaplan-Meier estimates of the cumulative incidence of relapse in minimal residual disease (MRD) negative patients 
(A), cumulative incidence of relapse in MRD positive patients (B), relapse-free survival (RFS) in MRD negative 
patients (C), and RFS in MRD positive patients (d) by conditioning type in patients with AML in first complete 
remission from start of PRT. Abbreviations: MAC, myeloablative conditioning; RIC, reduced intensity conditioning; 
F, number of failures (ie, death whatever the cause); and N, number of patients
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Supplementary Figure 2  NRM by EBMT-score 
Kaplan-Meier estimates of non-relapse mortality (A) by EBMT-score, split into a low and a high risk group, from 
start of alloHSCT. Abbreviations: F, number of failures (ie, death whatever the cause); and N, number of patients
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Supplementary Figure 3  Forest plots of relapse comparing alloHSCT to CT and autoHSCT 
Forest plot of pooled estimates of the relative reduction (hazard ratio (HR) and 95% confidence interval (CI)) of 
relapse by MRD status comparing alloHSCT and chemotherapy (A) or alloHSCT and autoHSCT (B)
GVL-effect of alloHSCT and MRD in patients with AML
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 RFS: AlloHSCT vs Chemotherapy
 Study
 Events/Patients
 Chemotherapy  AlloHSCT
 HR & 95% CI 
 ( Chemotherapy :  AlloHSCT)
 Reduction
 (SD)
 MRD status (cut-off 0.1)
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Supplementary Figure 4  Forest plots of RFS comparing alloHSCT to CT and autoHSCT 
Forest plot of pooled estimates of the relative reduction (hazard ratio (HR) and 95% confidence interval (CI)) of RFS 
by MRD status comparing alloHSCT and chemotherapy (A) or alloHSCT and autoHSCT (B)
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AbSTrACT
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of 
choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML). 
With increasing alternative donors available, the preferred donor or stem cell source is 
debated. We set out to study outcome in recipients of alloHSCT with poor-risk AML in first 
complete remission (CR1) by donor type. A total of 6545 adult patients with poor-risk AML 
in CR1 receiving an alloHSCT using matched related donor (MRD, n = 3511) or alternative 
donors, including 10/10 (n = 1959) or 9/10 matched unrelated donors (MUDs, n = 549), 
umbilical cord blood (UCB) grafts (n = 333), or haplo-identical (haplo) donors (n = 193) were 
compared. Overall survival (OS) at 2 years following MRD alloHSCT was an estimated 59 
± 1%, which did not differ from 10/10 MUD (57 ± 1%) and haplo alloHSCT (57 ± 4%). OS, 
however, was significantly lower for 9/10 MUD alloHSCT (49 ± 2%) and UCB grafts (44 ± 
3%), respectively (P < .001). Non-relapse mortality (NRM) depended on donor type and was 
estimated at 26 ± 3% and 29 ± 3% after haplo alloHSCT and UCB grafts at 2 years vs 15 ± 1% 
following MRD alloHSCT. Multivariable analysis confirmed the impact of donor type with OS 
following MRD, 10/10 MUD, and haplo alloHSCT not being statistically significantly different. 
NRM was significantly higher for alternative donors as compared with MRD alloHSCT. 
Collectively, these results suggest that alloHSCT with MRDs and 10/10 MUDs may still be 
preferred in patients with poor-risk AML in CR1. If an MRD or 10/10 MUD is not available, 
then the repertoire of alternative donors includes 9/10 MUD, UCB grafts, and haplo-identical 
donors. The latter type of donor is increasingly applied and now approximates results with 
matched donors.
Key PoinTS
•  The preferred donor for patients with poor-risk AML in CR1 proceeding to alloHSCT include 
MRD or 10/10 MUD.
•  Alternative donors are 9/10 MUD, UCB grafts, and especially haplo, but sufficient numbers 
and follow-up to define a hierarchy are lacking.
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inTroduCTion
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the most effective post-
remission treatment for prevention of relapse in poor-risk acute myeloid leukemia (AML) in 
first complete remission (CR1).1,2 Although most patients lack an human leukocyte antigen 
(HLA) matched related donor (MRD), an alternative donor is available for almost every 
patient in need of an alloHSCT.3 Although the probability of identifying an adult matched 
unrelated donor (MUD) can be as high as 60% to 80% for Caucasian patients, finding a 
suitable MUD for patients from ethnic minorities is less successful.4-6 One allele mismatched 
unrelated donor (MMUD) may serve as a good alternative, but outcome has been 
associated with approximately 10% loss in overall survival (OS), which has predominantly 
been ascribed to increased non-relapse mortality (NRM).7 Following the favorable results 
in pediatric patients, alloHSCT with umbilical cord blood (UCB) grafts was also developed 
in adult patients. Results of UCB alloHSCT in retrospective registry studies approximated 
those of MUD alloHSCT, although hematopoietic recovery is delayed compared with MUD 
alloHSCT and graft failure was more frequently observed.8-10 More recently, a revived interest 
in the use of haplo-identical (haplo) donors has become apparent, because of improved 
transplantation techniques and pharmacological manipulation of host-versus-graft and 
graft-versus-host reactions.11 Although each type of donor and/or stem cell source has its 
own advantages and drawbacks, comparative studies evaluating survival estimates in well-
defined groups of patients are scarce. Here, we set out to compare outcome in patients with 
poor-risk AML in CR1 receiving alloHSCT between 2000 and 2014, using either MRD, 10/10 
or 9/10 MUDs, haplo or UCB grafts.
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MeTHodS
Patients
A total of 6545 adult patients with poor-risk AML in CR1 receiving an alloHSCT between 
2000 and 2014 and reported to the European Society for Blood and Marrow Transplantation 
(EBMT) Acute Leukemia Working Party and Eurocord were eligible for the analysis. Patients 
were transplanted with an MRD (n = 3511) or alternative donors, including 10/10 (n = 
1959) or 9/10 MUDs (n = 549), UCB grafts (n = 333), or haplo (n = 193). Poor-risk AML 
was defined as described previously,12 with either white blood cell count (WBC) >100 x 
109/L at diagnosis, secondary AML, cytogenetic abnormalities associated with adverse risk 
according to European LeukemiaNET classification,13 presence of an fms-like tyrosine kinase 
3 internal tandem duplication (FLT3-ITD), or no CR after 1 cycle of induction chemotherapy. 
Patients received conditioning therapy followed by infusion of donor cells with either MRD 
or alternative donors. In vivo T-cell depletion was defined as the use of either antithymocyte 
globulin (ATG) or alemtuzumab. No ex vivo T-cell depletion was performed on any of the 
patient grafts. The degree of HLA-matching was 9 or 10 of a 10 allele match for the MUDs, 
with mismatches allowed at HLA-A, HLA -B, HLA -C, HLA -DR, or HLA-DQ levels for the 9/10 
MUDs (Supplementary Table 1). AlloHSCT with UCB grafts was performed with either single 
or double cords. HLA matching for UCB was done according to the standard criteria on 
antigen level for A and B and allele level for DRB1. Haplo was defined as ≥4/8 HLA match. 
This study was a retrospective multicenter analysis and was performed in accordance with 
the principles of the Declaration of Helsinki and approved by the Acute Leukemia Working 
Party of the EBMT group. The EBMT is a nonprofit, scientific society representing more than 
600 transplant centers, mainly in Europe. The EBMT promotes all activity aiming to improve 
stem cell transplantation or cellular therapy, which includes registering all the activity 
relating to stem cell transplants. Data are entered, managed, and maintained in a central 
database with Internet access; each EBMT center is represented in this database. There are 
no restrictions on centers for reporting data, except for those required by the law on patient 
consent, data confidentiality, and accuracy. Quality control measures included several 
independent systems: confirmation of validity of the entered data by the reporting team, 
selective comparison of the survey data with minimum essential data A data sets in the 
EBMT registry database, cross-checking with the national registries, and regular in-house 
and external data audits. Since 1990, patients have provided informed consent authorizing 
the use of their personal information for research purposes.
end points
The primary end point of the study was OS at 2 years. Secondary end points included relapse-
free survival (RFS), relapse, NRM, and acute and chronic graft-versus-host disease (GVHD) 
at 2 years. All outcome parameters were measured from the date of transplantation. The 
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event for OS was death, whatever the cause, and patients were censored at the date of last 
contact if alive. The events for RFS were death in CR1, designated as NRM, or hematological 
relapse of the leukemia. Cumulative incidences of chronic GVHD were estimated in patients 
without graft failure with death without chronic GVHD as competing risk.
Statistical methods
Patient, disease, and transplant characteristics were compared by using the χ2 test for 
categorical variables and the Kruskal-Wallis test for continuous variables. Probabilities 
of OS and RFS were calculated using the Kaplan-Meier estimate.14 Cumulative incidence 
curves were used to estimate NRM and relapse because NRM and relapse were competing 
events.15 Outcome estimates are at 2 years unless explicitly stated otherwise. Multivariable 
Cox regression analysis for OS, RFS, relapse, and NRM was applied with adjustment for 
covariates, which were selected based on a P value < .05 by univariate analysis. All analyses 
were done with Stata Statistical Software: release 13.1 (Stata Corporation; 2013, College 
Station, TX, USA).
reSuLTS
Patient characteristics
A total of 6545 patients with poor-risk AML in CR1 were included. Patients received an 
alloHSCT from either an MRD (n = 3511), 10/10 MUD (n = 1959), 9/10 MUD (n = 549), UCB 
graft (n = 333), or haplo (n = 193). Patient characteristics are shown in Table 1, including 
the different poor-risk features of the AML, which were differentially distributed among 
the donor types. Recipients of UCB grafts were significantly younger compared with the 
other donor types (median 48 vs 52 years, P < .001). Poor-risk cytogenetics and a FLT3-
ITD were more frequently present in recipients of UCB grafts and haplo alloHSCT (P = .016 
and P < .001). The median time from diagnosis to alloHSCT was 4.7 months, which was 
significantly shorter for recipients of an MRD compared with the alternative donors (median 
5.8 months, P < .001). In addition, alternative donor transplantation has been performed 
more frequently in recent years as compared with MRD alloHSCT (P < .001). The median 
follow-up of patients still alive differed between the patient groups with a follow-up time 
of 43 months (range, 1-188) for recipients of MRD alloHSCT, whereas follow-up was shorter 
for 10/10 MUD (24 months; range, 1-159), 9/10 MUD (26 months; range, 1-139), UCB (24 
months; range, 2-124), and haplo (22 months; range, 1-120).
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Table 1  Patient characteristics
donor source p-value
Mrd Mud 10/10 Mud 9/10 Cb Haplo
(n=3511) (n=1959) (n=549) (n=333) (n=193)
Sex .019
Male 1809 52% 1034 53% 275 50% 146 44% 110 57%
Female 1701 48% 925 47% 273 50% 187 56% 83 43%
Age (years) <.001
Median                     50 54 52 48 51
Range                      18-74 18-80 18-74 18-72 18-75
wbC at diagnosis .009
>100 1716 49% 897 46% 264 48% 177 53% 69 36%
<=100 435 12% 176 9% 47 9% 36 11% 8 4%
Missing 1360 39% 886 45% 238 43% 120 36% 116 60%
Secondary AML <.001
No 2207 63% 1068 55% 318 58% 208 62% 116 60%
Yes 1304 37% 891 45% 231 42% 125 38% 77 40%
Poor risk cytogenetics (-7/-5/complex/11q23) .016
No 2028 58% 1109 57% 300 55% 163 49% 101 52%
Yes 1483 42% 850 43% 249 45% 170 51% 92 48%
FLT3-iTd <.001
No 366 10% 271 14% 83 15% 53 16% 50 26%
Yes 605 17% 353 18% 101 18% 72 22% 42 22%
Missing 2540 72% 1335 68% 365 66% 208 62% 101 52%
Cr reached after <.001
Cycle 1 (early CR) 2536 72% 1529 78% 404 74% 253 76% 144 75%
Cycle 2 (late CR) 975 28% 430 22% 145 26% 80 24% 49 25%
Time from diagnosis to PrT (months) <.001
Median                     4.7 5.6 6.1 5.9 6.2
IQ range                      3.7-6.1 4.3-7.2 4.7-8.1 4.8-7.8 4.5-8.7
year of PrT <.001
Median                     2008 2011 2011 2010 2012
Range                      2000-2014 2000-2014 2000-2014 2000-2014 2000-2014
Abbreviations: MRD, matched related donor; MUD, matched unrelated donor; CB, cord blood; haplo, haplo-
identical; WBC, white blood cell count; AML, acute myeloid leukemia; FLT3-ITD, fms-like tyrosine kinase 3 internal 
tandem duplication; IQ, interquartile range; CR, complete remission; and PRT, post-remission treatment
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Table 2  Transplant characteristics
donor source p-value
Mrd Mud 10/10 Mud 9/10 Cb Haplo
(n=3511) (n=1959) (n=549) (n=333) (n=193)
Conditioning <.001
MAC 1951 56% 888 45% 256 47% 145 44% 104 54%
RIC 1518 43% 1056 54% 291 53% 183 55% 89 46%
Missing 42 1% 15 1% 2 0% 5 2% 0
Peripheral stem cells <.001
No 712 20% 315 16% 76 14% 333 100% 100 52%
Yes 2799 80% 1644 84% 473 86% 0 93 48%
CMv patient/donor <.001
neg/neg 717 20% 585 30% 129 23% 64 19% 32 17%
pos/neg 522 15% 582 30% 166 30% 93 28% 35 18%
neg/pos 324 9% 166 8% 74 13% 42 13% 12 6%
pos/pos 1587 45% 582 30% 166 30% 78 23% 111 58%
Missing 361 10% 44 2% 14 3% 56 17% 3 2%
Tbi given <.001
No 2480 71% 1422 73% 424 77% 130 39% 141 73%
Yes 1028 29% 535 27% 124 23% 203 69% 52 27%
Female donor to male recipient <.001
No 2710 77% 1739 89% 472 86% 273 82% 147 76%
Yes 801 23% 220 11% 77 14% 60 18% 46 24%
in vivo T cell depletion <.001
No 2354 67% 535 27% 73 13% 198 59% 111 58%
ATG 707 20% 1201 61% 393 72% 123 37% 78 40%
Alemtuzumab 237 7% 216 11% 80 15% 0 3 2%
Missing 213 6% 7 0% 3 1% 12 4% 1 1%
Abbreviations: MRD, matched related donor; MUD, matched unrelated donor; CB, cord blood; haplo, haplo-
identical; MAC, myeloablative condioning; RIC, reduced intensity condtioning; CMV, cytomegalovirus; TBI, total 
body irradiation
Transplant characteristics
Myeloablative conditioning (MAC) was applied in a higher proportion in recipients of 
haplo (54%) and MRD (56%) compared with patients receiving MUD (46%) or UCB grafts 
(45%) (Table 2). The vast majority of MRD and MUD received peripheral blood stem cells, 
whereas 52% of the haplo recipients received bone marrow cells. Both family donors had a 
cytomegalovirus (CMV) donor match in more than two-thirds of the transplants, whereas 
a CMV mismatch was present in MUDs and UCB grafts in about 40% of the transplants. 
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Conditioning with total body irradiation was performed mostly in recipients of UCB grafts 
(69%), particularly in patients who received a UCB graft following reduced intensity 
conditioning (RIC) (80%). In vivo T-cell depletion with either ATG or alemtuzumab was used 
in the majority of MUDs (75%). In the haplo group, 90 (47%) haplo recipients received post-
transplant cyclophosphamide without ATG, whereas 62 (32%) patients received an ATG-
based regimen as GVHD-prophylaxis. Fourteen (7%) patients received both ATG and post-
transplant cyclophosphamide following a haplo donor. 
Table 3  Transplant outcome
donor source p-value
Mrd Mud 10/10 Mud 9/10 Cb Haplo
(n=3511) (n=1959) (n=549) (n=333) (n=193)
         <.001
Graft failure 53 2% 29 1% 20 4% 30 9% 11 6%
Time to engraftment (days) <.001
Median                     16 17 17 23 18
IQ range                      13-20 14-20 14-20 17-30 15-23
Acute Graft-versus-Host disease (maximum grade) <.001
Grade 0-1 2623 75% 1369 70% 374 68% 220 66% 140 73%
Grade 2-4 769 22% 518 26% 156 28% 99 30% 49 25%
Unknown 119 3% 72 4% 19 3% 14 4% 4 2%
Time transplant to acute GvHd (days) .11
Median                     28 27 25 28 29
IQ range                      18-47 17-43 16-42 19-38 18-48
Chronic Graft-versus-Host disease <.001
Mild 533 15% 283 14% 81 15% 28 8% 39 20%
Extensive 712 20% 310 16% 73 13% 37 11% 18 9%
Time transplant to chronic GvHd (months) <.001
Median                     6.0 5.4 5.6 4.9 6.4
IQ range                      4.0-9.6 3.7-8.3 3.7-8.3 4.1-6.9 4.1-9.6
outcome at 2 years
OS 59±1% 57±1% 49±2% 44±3% 57±4%
RFS 53±1% 53±1% 44±2% 41±3% 52±4%
Relapse 32±1% 27±1% 31±2% 30±3% 22±3%
NRM 15±1% 20±1% 24±2% 29±3% 26±3%
Abbreviations: MRD, matched related donor; MUD, matched unrelated donor; CB, cord blood; haplo, haplo-
identical; GvHD, graft versus host disease; IQ, interquartile; OS, overall survival; RFS, relapse-free survival; NRM, 
non-relapse mortality.
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Transplant outcome
The rate of graft failure at 100 days after transplant was significantly higher in recipients of 
UCB grafts and haplo compared with MRD and 10/10 MUD alloHSCT (9% and 6% vs 2% and 
1%, P < .001, respectively; Table 3). Maximum grade of acute GVHD was slightly increased 
in recipients of 9/10 MUDs and UCB grafts (P < .001; Table 3; Supplemental Table 2). Lim-
ited chronic GVHD was less frequently present in recipients of UCB grafts, and the highest 
incidence of chronic extensive GVHD was observed in MRD recipients (Table 3). The cumula-
tive incidence of chronic GVHD by MRD, 10/10 MUD, 9/10 MUD, UCB and haplo at 2 years 
is an estimated 38 ± 1%, 36 ± 1%, 33 ± 2%, 24 ± 2%, 37 ± 4%, respectively. With a median 
follow-up of 32 months, OS at 2 years was not significantly different between MRD alloHSCT, 
10/10 MUD alloHSCT, and haplo alloHSCT (59 ± 1%, 57 ± 1%, and 57 ± 4%, respectively, 
P = .19; Figure 1A). 
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Figure 1  Outcome by different donor types 
Kaplan-Meier estimates of OS (A), RFS (B), relapse (C), and NRM (d) by donor type of patients with poor-risk 
AML in CR1. Abbreviations: MRD, matched related donor; MUD, matched unrelated donor; CB, cord blood; haplo, 
haplo-identical donor; F, number of failures (ie, death whatever the cause); N, number of patients; and Cox LR, cox 
likelihood ratio 
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However, OS was significantly lower in recipients of 9/10 MUD alloHSCT and UCB grafts 
compared with MRD alloHSCT (49 ± 2%, 44 ± 3%, and 59 ± 1%, respectively, P < .001; Figure 
1A). These results were similar in subgroups of poor-risk cytogenetics and secondary AML 
(Supplementary Figure 1). RFS was 53 ± 1%, 53 ± 1% and 52 ± 4% at 2 years following MRD, 
10/10 MUD, and haplo alloHSCT, respectively, which was significantly (P < .001) better than 
following UCB grafts (41 ± 3%) or 9/10 MUD alloHSCT (44 ± 2%) (Figure 1B). The cumulative 
incidence of relapse at 2 years is an estimated 22 ± 3% for haplo alloHSCT, whereas other 
types of donor transplantation were associated with a relapse incidence of about 30% 
(Figure 1C). NRM depended on donor type and is an estimated 26 ± 3% and 29 ± 3% after 
haplo and UCB alloHSCT at 2 years, respectively, vs 15 ± 1% following MRD alloHSCT (Figure 
1D). Causes of death by donor type are shown in Supplementary Table 3. Infections and 
GVHD were the most common causes of non-relapse death, which were increased in the 
alternative donor transplants.
Multivariable analysis
The multivariable analysis is shown in Table 4 and was performed with adjustment for donor 
type, age, cytogenetics, secondary AML, time interval from diagnosis to transplant, year of 
transplant, in vivo T-cell depletion, and conditioning type. OS was not significantly different 
comparing alloHSCT following MRD with 10/10 MUD, and haplo alloHSCT (hazard ratio [HR], 
0.99 and 1.12, respectively). OS following both 9/10 MUD and UCB grafts was significantly 
worse compared with MRD (HR, 1.23; P = .001; and HR, 1.54; P < .001, respectively). A 
similar pattern was found for RFS with non-significant differences for MRD, 10/10 MUD, 
and haplo alloHSCT, whereas both 9/10 MUD alloHSCT and UCB grafts were associated with 
worse RFS. Relapse was decreased for 10/10 MUD (HR, 0.74; P < .001), and haplo (HR, 0.60; 
P = .001) compared with MRD alloHSCT. NRM was significantly higher for all alternative 
donors compared with MRD alloHSCT. Older age was associated with increased risk for all 
outcome parameters. Both poor-risk cytogenetics and secondary AML had an increased 
HR for OS, RFS and relapse, whereas a shorter time from diagnosis to transplant predicted 
for better OS, RFS, and relapse. A higher HR for relapse was found for RIC compared with 
MAC (HR, 1.23; P < .001), which was counterbalanced by a lower HR for NRM (0.78; P < 
.001), resulting in similar OS and RFS comparing RIC and MAC. A detailed analysis of the 
different alternative donors following either a RIC or MAC preparative regimen is presented 
in Supplementary Table 4. Higher NRM associated with 9/10 MUD, UCB, and following haplo 
donors was observed after both RIC and MAC, but appeared most pronounced after MAC. 
OS again showed similar survival following MRD and 10/10 MUD.
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diSCuSSion
Post-remission therapy by alloHSCT remains the treatment of choice in poor-risk AML 
patients upon achieving CR1 and qualifying for intensive therapy.1,2 Possible donor sources 
currently include MRDs or alternative donors such as MUDs with either a 10/10 or 9/10 
HLA match, UCB grafts, or haplo. The present retrospective study from the EBMT Acute 
Leukemia Working Party demonstrates similar OS for patients with poor-risk AML in CR1 
following alloHSCT with either MRD or 10/10 MUD. In contrast, recipients of 9/10 MUD 
and UCB grafts experienced worse outcome compared with MRD or 10/10 MUD, which 
was mainly the result of increased NRM. Recipients of T-cell replete haplo alloHSCT showed 
encouraging outcomes, which appeared not statistically different from MRD and 10/10 
MUD, although a larger cohort and longer follow-up may be needed. 
Historically, alloHSCT with an MRD has been the preferred type of donor for patients 
with hematological diseases. However, 70% of the patients lack a suitable MRD and the use 
of older MRD in elderly AML patients has recently been questioned.16,17 The present study 
confirms that an MRD should still be considered the preferred donor. AlloHSCT with a 10/10 
MUD yielded similar survival in the present study, confirming 10/10 MUD as the preferred 
alternative if an MRD is not available. Several study groups have compared outcome 
of transplantation using either MRD or MUD in patients with AML and reported similar 
survival rates.18-22 Some studies reported slightly higher NRM following MUD, whereas 
counterbalancing lower relapse resulted in similar outcome compared with MRD, which 
was also found in the present study.
Inferior survival was found for recipients of MMUDs (9/10 HLA-match) compared with 
MRD, which was primarily caused by increased incidence of (severe) GVHD and subsequent 
NRM. A recent meta-analysis of 7 retrospective studies comparing 10/10 MUD and 9/10 
MUD alloHSCT showed a 27% increased risk of mortality for recipients of a 9/10 MUD.23 
Here, a similarly increased risk (25%) was found when comparing 9/10 MUDs with 10/10 
MUDs in patients with poor-risk AML in CR1. These results suggest that transplants using 
9/10 MUD may be followed by more stringent prevention of GVHD to limit NRM. Studies 
addressing the value of intensified GVHD-prophylaxis, such as being applied in a haplo 
alloHSCT setting, may possibly direct  how to improve transplants with MMUDs.11,24
Following the initial favorable results in pediatric patients, alloHSCT with UCB grafts was 
also developed in adults with acute leukemia. Although a higher incidence of graft failure 
and delayed hematopoietic recovery are associated with UCB grafts, largely similar outcomes 
compared with MRD, MUD, or MMUD alloHSCT were reported.9,10,25,26 However, these 
studies included different groups of patients, which hampered a precise comparison. The 
present study in a homogenous group of patients shows that alloHSCT with UCB grafts is still 
associated with higher NRM compared with MRD, which resulted in significantly lower OS. 
The incidence of graft failure following alloHSCT with UCB grafts in our study is an estimated 
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9% and the majority of causes of death were infections, to which graft failure and delayed 
recovery contributed. No significant differences in outcome were found between single vs 
double UCB grafts, and no difference between UCB with low vs high total nucleated cells at 
infusion of the UCB grafts were found, although information was not available for all UCB 
grafts (data not shown). These results suggest that improving hematopoietic engraftment 
and hematopoietic recovery remains a major challenge in UCB graft alloHSCT in adult 
patients, which is currently addressed and studied by several groups exploring expansion of 
UCB hematopoietic stem cells.27,28
Allogeneic transplantation with a haplo-identical family donor was extensively studied 
by the Perugia group.29 Although that approach consisting of transplantation with high 
numbers of CD34+ cells, intensified conditioning and stringent GVHD-prophylaxis appeared 
to result in favorable engraftment in the majority of patients, a relatively high NRM precluded 
application on a broader scale. More recently, both the approach by the Baltimore group 
based on post-transplant cyclophosphamide and the Chinese approach based on in vivo 
T-cell depletion, were demonstrated to result in favorable engraftment, limited GVHD, 
and limited NRM.30,31 A recent biologically randomized study from China suggested similar 
outcomes using matched related or haplo-identical family donors.30 Updated results from 
the Baltimore group also suggested similar survival following haplo alloHSCT and matched 
donor alloHSCT.31 A recent retrospective study from the Acute Leukemia Working Party of 
the EBMT showed a similar relapse incidence in patients receiving T-cell replete and T-cell 
depleted haplo alloHSCT as compared with MRD, which suggested a similar graft-versus-
leukemia effect.32 The present study included T-cell replete haplo alloHSCT which appeared 
associated with a stronger graft-versus-leukemia effect compared with MRD (HR 0.60), 
whereas severe grades of acute and chronic GVHD were relatively low as compared with 
the other donor types. A large retrospective study of the Center for International Blood 
an Marrow Transplant Research comparing MRD with haplo alloHSCT using post-transplant 
cyclophosphamide also found less GVHD following haplo alloHSCT and an overall similar 
outcome.33 Our study showed a relatively low incidence of relapse following haplo alloHSCT, 
but a higher incidence of NRM, resulting in similar outcome as compared with MRD alloHSCT. 
Both the relatively short follow-up and unknown patient selection preclude more definite 
conclusions as regards the comparison with sibling donors. However, haplo alloHSCT was 
also suggested to result in better outcome as compared with UCB alloHSCT. In a less 
homogenous group of AML patients, UCB and haplo alloHSCT were previously suggested 
to result in similar overall outcome.34 The latter results are in line with the 2 parallel 
phase 2 trials of Brunstein et al,35 which addressed UCB grafts and unmanipulated haplo 
alloHSCT including post-transplant cyclophospamide. Although haplo was associated with 
less NRM, a higher relapse rate counterbalanced that favorable effect, resulting in similar 
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RFS.35 Currently, a prospective randomized phase 3 trial is being conducted comparing UCB 
and haplo alloHSCT (BMT CTN 1101), which will address the question how UCB and haplo 
alloHSCT compare in patients with hematological malignancies. 
Our study may have several limitations. First, a center’s preference regarding preferred 
alternative donors may result in selection bias.36 Reasons for the choice of an alternative 
donor transplant are not registered in the EBMT database and therefore not known. We 
focused on a homogenous group of poor-risk AML patients with no important differences 
in baseline characteristics, but time intervals from diagnosis to transplant did differ, which 
may be associated with selection resulting from exclusion of early relapses in the group 
of alloHSCT recipients with the longest timeframe. Second, an increasingly important 
parameter is the presence or absence of minimal residual disease, which was unknown in 
the present study, but has recently been shown to strongly predict for subsequent relapse 
and overall outcome.37-40 Although not recorded, residual disease is not routinely assessed 
in most centers and also not uniformly used for risk-adapted treatment; as a result, it is 
unlikely to have resulted in a strong selection bias. Last, the retrospective multicenter 
nature of our study implies that the physician/centers intention and/or preference is 
not taken into account, which can only be addressed in a prospective randomized study. 
However, prospective studies with more than 2 or 3 donor types will be extremely difficult, 
necessitating larger registry studies. To our knowledge, our study is the largest comparative 
study of MRD and alternative donors in the homogenous subgroup of patients with poor-risk 
ALM in CR1 in urgent need of an alloHSCT. Our results compare well with a recent study by 
Raiola et al, who performed a single-center retrospective study of 459 patients that received 
alloHSCT using different donors, including unmanipulated haplo, MRD, MUD or UCB grafts. 
Although the recipients suffered from various hematological malignancies and haplo has 
been performed more frequently in recent years, their results also suggested higher NRM in 
MMUD alloHSCT and following alloHSCT with UCB grafts.41 
In conclusion, our study suggests that well-matched donors including MRD and 10/10 
MUD are to be preferred over UCB and MMUD patients with poor-risk AML in CR1. Nine of 
10 MUD, UCB grafts, and haplo-identical donors could be used as alternatives in case a fully 
matched donor is not available or an urgent transplant is required. Haplo-identical donors 
are increasingly used and results are encouraging. However, comparative prospective 
studies of haplo alloHSCT with other donor types are warranted and longer follow-up after 
haplo alloHSCT may be needed to definitely establish its place in the hierarchy of alternative 
donors.
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Supplementary Figure 1  OS by donor type in AML poor risk subcategories
Kaplan-Meier estimates of OS by donor type in patients with AML with poor risk cytogenetics (A) or secondary 
AML (B). Abbreviations: MRD, matched related donor; MUD, matched unrelated donor; CB, cord blood; haplo, 
haplo-identical donor; F, number of failures (ie, death whatever the cause); N, number of patients; and Cox LR, cox 
likelihood ratio
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Supplementary Table 1  Mismatch loci of 9/10 matched unrelated donors
Mud 9/10
(n=549)
Loci
A 150 27%
B 80 15%
C 167 30%
DR 49 9%
DQ 103 19%
Supplementary Table 2  Grades of acute graft-versus-host disease by donor
donor source
Mrd Mud 10/10 Mud 9/10 Cb Haplo
(n=3511) (n=1959) (n=549) (n=333) (n=193)
Acute Graft-versus-Host disease (maximum grade) p<0.001
Grade 0 2049 58% 966 49% 255 46% 160 48% 108 56%
Grade 1 574 16% 403 21% 119 22% 60 18% 32 17%
Grade 2 478 14% 351 18% 96 17% 62 19% 35 18%
Grade 3 196 6% 113 6% 37 7% 23 7% 8 4%
Grade 4 95 3% 54 3% 23 4% 14 4% 6 3%
Unknown 119 3% 72 4% 19 3% 14 4% 4 2%
Abbreviations: MRD, matched related donor; MUD, matched unrelated donor; CB, cord blood; and haplo, haplo-
identical
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Supplementary Table 3  Causes of Death
donor source
Mrd Mud 10/10 Mud 9/10 Cb Haplo
(n=3511) (n=1959) (n=549) (n=333) (n=193)
Cause of death
Relapse of AML 912 56% 384 47% 118 44% 80 44% 28 33%
GvHD 247 15% 134 17% 59 22% 30 17% 10 12%
Infection 198 12% 144 18% 49 18% 43 24% 26 31%
Second malignancy 30 2% 15 2% 4 1% 4 2% 2 2%
Interstitial pneumonitis 24 1% 19 2% 4 1% 3 2% 3 4%
Veno occlusive disease 23 1% 10 1% 5 2% 6 3% 3 4%
Haemorrhage 21 1% 5 1% 2 1% 2 1% 1 1%
Cardiac toxicity 8 0% 8 1% 1 0% 0 0
Failure/Rejection 2 0% 5 1% 0 0 1 1%
Other transplant related 74 5% 35 4% 16 6% 9 5% 7 8%
Missing 87 5% 51 6% 9 3% 4 2% 3 4%
Abbreviations: MRD, matched related donor; MUD, matched unrelated donor; CB, cord blood; haplo, haplo-
identical; AML, acute myeloid leukemia; and GvHD, graft versus host disease
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AbSTrACT
Non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation 
(alloHSCT) can be predicted by the hematopoietic cell transplantation comorbidity index 
(HCT-CI) and the European Group for Blood and Marrow Transplantation (EBMT) score, which 
are composed of different parameters. We set out to integrate the parameters of both scores 
in patients with acute myeloid leukemia (AML) in first complete remission (CR1) receiving 
reduced intensity conditioning (RIC) alloHSCT. All parameters from the HCT-CI and the EBMT-
score with the addition of patient and donor cytomegalovirus serology were evaluated in 
812 patients by multivariable analysis with end-point NRM at 2 years. Subsequently, 16 
parameters were selected based on hazard ratio >1.2 and were incorporated into a novel 
score, which was further internally validated by bootstrapping. Both the HCT-CI and the 
EBMT-score showed relatively weak predictive value, whereas the integrated score allowed 
to identify three clearly distinct risk groups with 2-year NRM estimates of 8 ± 2% (low-risk), 
17 ± 2% (intermediate-risk) and 38 ± 4% (high-risk), which also translated in prediction of 
overall survival. Collectively, integration of the most dominant parameters from the HCT-CI 
and the EBMT-score allowed to develop a simple and robust, integrated score with improved 
prediction of NRM for AML patients proceeding to RIC alloHSCT in CR1.
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inTroduCTion
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the most effective post-
remission treatment for prevention of relapse in patients with acute myeloid leukemia 
(AML) in first complete remission (CR1) as compared with non-alloHSCT approaches.1-3 
However, non-relapse mortality (NRM) may compromise the favorable effects of alloHSCT 
on overall survival (OS). Currently, an increasing number of patients receive their allograft 
after reduced intensity conditioning (RIC), because of age and/or comorbidities. AML 
has become the predominant indication for RIC alloHSCT and with a median age of 67-
71 years in newly diagnosed AML patients,4,5 the application of RIC alloHSCT is steadily 
increasing.6 Apart from age, other important risk factors for NRM include pre-existing co-
morbidities and transplantation-related risk factors such as donor source and patient/donor 
histocompatibility.7-9 
In order to quantify the risk of NRM, composite risk scores have been established, which 
allowed to predict NRM and survival before transplantation. The most widely accepted and 
clinically applied predictive models are the hematopoietic cell transplantation comorbidity 
index (HCT-CI)10 and the European Group for Blood and Marrow Transplantation (EBMT) 
score.9 The HCT-CI originated from the Charlson Comorbidity Index7 and was further 
developed by the Seattle group consisting of 17 comorbidities which contribute to a 
cumulative score based on each parameters’ own hazard ratio (HR) as regards NRM.10 
Subsequently, three risk groups were defined with 2-year cumulative incidences of NRM of 
14%, 21% and 41% in the low-, intermediate- and high-risk groups, respectively. The HCT-CI 
was developed and validated in a cohort of alloHSCT patients with different diseases (that 
is, leukemia, lymphoma, myeloma and non-malignant diseases), but has been confirmed 
in other disease categories, including AML.11,12 The EBMT-score was originally developed 
to predict overall outcome in 3142 chronic myeloid leukemia patients by Gratwohl et al.,9 
with two patient parameters (that is, age and disease stage) and three transplantation-
related parameters (that is,  donor source, gender mismatch and time from diagnosis to 
transplantation). The score predicted for overall outcome and NRM and the score was 
externally validated in another chronic myeloid leukemia cohort,13 and also in other patient 
categories, including AML patients.14
The ability of both scores to predict NRM was also confirmed in patients receiving RIC 
alloHSCT.15-17 However, some reports did not confirm the predictive ability of the HCT-CI 
in RIC recipients with much higher baseline NRM risk (that is, older patients with a higher 
prevalence of comorbidities).18-20 The EBMT-score also performed less well in older patients 
receiving RIC alloHSCT.14,20-22 Considering that RIC alloHSCT is currently applied more 
frequently in older, medically less fit AML patients and that the EBMT-score and HCT-CI take 
different parameters into account, we set out to integrate the predominant parameters of 
each score into a novel scoring system in AML CR1 patients receiving RIC alloHSCT. 
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PATienTS And MeTHodS
Patients
A total of 812 adults with de novo or secondary AML in CR1 who received consolidation 
therapy with RIC alloHSCT between 2000 and 2011 were included in this study. All patients 
were documented in the EBMT database. RIC regimens consisted of either fludarabine with 
total body irradiation (n = 191, 23%) or chemotherapy (that is, fludarabine with busulfan or 
melphalan; n = 621, 77%). The dose ranges of melphalan, busulfan and fludarabine were 
110-150 mg/m2, 3.2-8.6 mg/kg and 90-300 mg/m2 respectively. Anti-thymocyte globulin 
supplemented the conditioning regimen in 340 (42%) patients. Post-transplantation 
graft versus host disease (GVHD) prophylaxis consisted of a calcineurin inhibitor with 
mycopenolate mofetil or methotrexate. Patients received standard infection prophylaxis 
with acyclovir and trimethoprim-sulfamethoxazole post-transplant. Cytomegalovirus (CMV) 
DNA was monitored regularly and early treatment with ganciclovir was started in case of 
reactivation. In addition to baseline characteristics, pre-transplantation data were available 
for all patients in order to assess both the HCT-CI and the EBMT-score. This study was 
performed in accordance with the principles of the Declaration of Helsinki and approved by 
the Acute Leukemia Working Party of the EBMT group.
end points
The primary end point of the study was 2-year NRM. Secondary end points included 2-year 
OS, relapse-free survival, relapse, 5-year NRM and acute and chronic GVHD. All outcome 
parameters were measured from the date of transplantation. The event for OS was death 
whatever the cause and patients were censored at the date of last contact if alive. The 
events for relapse-free survival were death in CR1, designated as NRM, or hematological 
relapse of the leukemia.
Statistical methods
Cumulative incidence curves were used to estimate NRM and relapse, as NRM and relapse 
were competing events, as well as probability of acute and chronic GVHD, with NRM without 
GVHD being treated as a competing event.23 Probabilities of OS and relapse-free survival 
were calculated using the Kaplan-Meier estimate.
Variable selection and model development
Multivariable analysis of all parameters of both the HCT-CI and the EBMT-score was 
performed. We also added patient and donor CMV serology status before transplantation 
to the analysis, in accordance with previous observations that positive patient and/or donor 
CMV serology is associated with an increased risk of NRM.14,24-26 The 17 comorbidities of the 
HCT-CI were assessed as previously defined.7,10,27 In addition, donor type, donor/recipient 
Chapter 7
155
gender combination, time from diagnosis to transplant and age were included, as applied 
in the EBMT-score.9 Of note, different cutoff points for the time interval from diagnosis 
to transplantation and patient age were applied, as the median time to transplant was 
close to 6 months and the median patient age was close to 60 years in these RIC alloHSCT 
recipients. The EBMT-score parameter disease stage was omitted, because all patients were 
transplanted in CR1. All covariates were included in both the Cox proportional hazards 
model and the Fine-Gray model28,29 as follows: patient age (< versus ≥ 60 years), interval from 
diagnosis to transplant (< versus ≥ 6 months), type of donor (unrelated versus HLA identical 
sibling), female donor to male recipient (versus other gender combinations), patient CMV 
serology (positive versus negative), donor CMV serology (positive versus negative) and all 
comorbidities (present versus not present). The Cox and the Fine-Gray models were stratified 
on the type of RIC regimens (with or without total body irradiation) in order to allow the 
underlying hazard function to vary across these two conditioning modalities. Integer weights 
were derived from HRs estimated by the Cox model. The integrated score was the sum of 
integer weights obtained by rounding HRs of all covariates associated with HR > 1.2, similar 
to variable selection as was applied in the original development of the HCT-CI.10 
Model validation
The model’s ability to discriminate between patients with or without NRM at 2 years post-
transplant was quantified by using c statistics.30 For a binary outcome (survival without 
relapse larger or smaller than 2-years post-transplant), c statistics reflect the area under 
a receiver operating characteristic  curve. A model with a c statistic of 1.0 indicates no 
false-positives, which means that no patients who did not die of NRM were missed by the 
model. The internal validity of the regression model was assessed using the bootstrapping 
technique (‘rms’ R package), which includes taking out random samples with replacement 
300 times. For the analysis including all variables, a predictive model was developed at each 
step including variable selection using a P-value of 0.15.31 The same procedure, without 
variable selection, was used for the Cox model including the score in three classes. The 
bootstrapping procedure leads to estimates of the optimism-corrected performance, 
which is calculated as apparent performance minus optimism. Time-dependent receiver 
operating characteristic  curves and the area under curves (AUCs) were also estimated 
non-parametrically using the inverse probability of a censored weighting approach32 with 
competing risks.33 The ‘timerROC’ R package was used to derive confidence intervals and 
for comparison of the AUC obtained with the different scores. All statistical tests were 
performed with R package (R 3.0.1 by R development Core Team).
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Table 1  Patient characteristics: transplantation related parameters
Parameter no. (%)
no. of patients 812  
Age (years)
Median 58
Range 20-76
Time from diagnosis to alloHSCT (days)
Median 167
Range 50-959
year of transplantation
Median 2008
Range 2000-2011
Female donor to male recipient
No 658 (81)
Yes 154 (19)
donor type
Sib 432 (53)
MUD 380 (47)
Cytogenetic risk of the AML34
Good 22 (3)
Intermediate 446 (55)
Poor 86 (11)
Unknown 258 (32)
Patient CMv serology
Negative 250 (31)
Positive 562 (69)
donor CMv serology 
Negative 362 (45)
Positive 450 (55)
Conditioning regimen
Fludarabine + busulfan 372 (45)
Fludarabine + melphalan 162 (20)
Fludarabine + 2 Gy TBI 173 (21)
Fludarabine + 4 Gy TBI 18 (2)
Other 87 (11)
Abbreviations: alloHSCT, allogeneic hematopoietic stem cell transplantation; Sib, sibling; MUD, matched unrelated 
donor; AML, acute myeloid leukemia; CMV, cytomegalovirus; Gy, Gray; TBI, total body irradiation
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reSuLTS
Patient characteristics
Characteristics of the 812 patients are shown in Table 1. The median age at transplantation 
was 58 (range: 20-76) years. Fifty percent of patients were transplanted within 167 days 
after diagnosis of AML. Grafts from female donors for male recipients were used in 19% and 
patients received an unrelated graft in 47% of the transplants. The majority of underlying 
leukemia’s exhibited an intermediate-risk karyotype.34 CMV serology was positive in 55% of 
the donors and 69% of the patients before transplantation. The median follow up time in 
patients alive was 34 (range: 3-138) months. The comorbidities of all patients are listed in 
Table 2, with active infection, cardiac disease and moderate pulmonary disease being the 
most frequently observed comorbidities with a prevalence of more than 15%.
Table 2  Patient characteristics: comorbidities
Parameter no. (%) 
no. of patients 812
Comorbidity*
Arrhythmia 38 (5)
Cardiac 128 (16)
Cerebrovascular disease 20 (2)
Diabetes 69 (8)
Heart valve disease 45 (6)
Hepatic (mild) 80 (10)
Hepatic (severe) 21 (3)
Inflammatory bowel disease 17 (2)
Infection 192 (24)
Obesity 40 (5)
Peptic ulcer 18 (2)
Psychiatric disturbance 49 (6)
Pulmonary (moderate) 170 (21)
Pulmonary (severe) 73 (9)
Renal (moderate/severe) 27 (3)
Rheumatologic disease 21 (3)
Solid tumor 83 (10)
* Comorbidities are defined as described previously7,10,27
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Predictive value of the ebMT-score and the HCT-Ci
All patients scored at least one point on the EBMT-score but the vast majority (90%) were 
captured with scores of two (n = 331, 41%) or three points (n = 401, 49%). Figure 1A depicts 
the cumulative incidence of NRM of the 812 patients, according to the EBMT-score. The 
2-year cumulative incidence of NRM by the EBMT-score estimated 14 ± 2%, 20 ± 2% and 24 
± 5% for patients with scores 1-2, 3 and ≥ 4, respectively. The c statistic was 0.546, indicating 
a weak predictive value. Non parametric estimation of the AUC was 0.575 (95% confidence 
interval: 0.523-0.627).
With respect to comorbidities, almost 80% of the patients scored at least one point on 
the HCT-CI. The 2-year cumulative incidence of NRM by the subgroups as defined by the 
HCT-CI estimated 11 ± 2%, 21 ± 2% and 18 ± 2%, for patients with scores 0, 1-2 and ≥ 3, 
respectively (Figure 1B). Also, the HCT-CI showed relatively weak predictive power with a 
c statistic of 0.580. Non parametric estimation of AUC was 0.584 (95% confidence interval: 
0.527-0.640).
Model development, validation and predictive value
The HRs of all individual parameters for 2-year NRM as predicted by the integrated, 
multivariable Cox regression analysis including all covariates are shown in Table 3. Based on 
this analysis, variable selection and model development was performed. As a result, seven 
parameters were dismissed from the integrated model because of HRs < 1.2 (Table 3), including 
six comorbidities and one transplantation-related parameter: cerebrovascular disease, 
moderate pulmonary disease, prior solid tumors, mild hepatic disease, cardiac disease, 
diabetes mellitus and female donor to male recipient. Subsequently, 11 comorbidities, 
age, donor type, time interval from diagnosis to transplantation and patient and donor 
CMV serology were selected for the integrated model based on HRs of > 1.2 (Table3). 
Years after transplantation
C
um
ul
at
iv
e 
In
ci
de
nc
e 
of
 N
R
M
0 1 2
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1−2  (n=341): 14±2%
3      (n=327): 20±2%
4−5  (n=70):   24±5%
EBMT
Years after transplantation
C
um
ul
at
iv
e 
In
ci
de
nc
e 
of
 N
R
M
0 1 2
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0     (n=171): 11±2%
1−2 (n=327): 21±2%
3+   (n=314): 18±2%
HCT−CI
A B
Figure 1  Non-relapse mortality by EBMT-score and the HCT-CI 
Cumulative incidences of non-relapse mortality by (A) the EBMT-score and (B) the HCT-CI. Performance of the 
EBMT-score and the HCT-CI in predicting non-relapse mortality in these patients was tested using c statistics (0.546 
versus 0.580, respectively), likelihood ratios (4.88 versus 3.68) and non-parametric area under the curve (0.575 
versus 0.584). The event for NRM was death in CR1 with relapse as a competing event. 
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The selected parameters were then attributed points, as determined by their quantified, 
rounded HR (Table 4). As a result, six parameters were given one point, including active 
infection, severe pulmonary disease, unrelated donor, positive donor CMV serology, severe 
hepatic disease and interval from diagnosis to transplantation ≥ 6 months. Furthermore, 10 
parameters were attributed two points including peptic ulcer, inflammatory bowel disease, 
heart valve disease, psychiatric disturbance, age at transplantation ≥ 60 years, arrhythmia, 
positive patient CMV serology, obesity, rheumatologic disease and moderate/severe renal 
disease (Table 4). As a result, the integrated score was completed to 16 parameters and c 
statistic using this model was estimated at 0.691. After bootstrapping including variable 
selection, the corrected c statistic was 0.641. Subsequently, the score was collapsed into 
three groups according to the number of patients and 2-year NRM in each category: 0-3 
points for low-risk patients, 4-6 points for intermediate-risk patients and 7 or more for high-
risk patients.
Table 3  Hazard ratios for 2-year NRM by Cox regression
variable HR
Cerebrovascular disease 0.76
Female donor to male recipient 0.80
Pulmonary (moderate) 0.83
Solid tumor 0.93
Hepatic (mild) 1.01
Cardiac 1.07
Diabetes 1.08
Infection 1.22
Pulmonary (severe) 1.22
Unrelated donor 1.31
Donor CMV serology positive 1.31
Hepatic (severe) 1.34
Interval diagnosis to alloHSCT 1.35
Peptic ulcer 1.51
Inflammatory bowel disease 1.52
Heart valve disease 1.53
Psychiatric disturbance 1.68
Age at alloHSCT 1.79
Arrhythmia 1.84
Patient CMV serology positive 1.87
Obesity 2.20
Rheumatologic disease 2.40
Renal (moderate/severe) 2.42
Abbreviations: alloHSCT, allogeneic hematopoietic stem cell transplantation; and CMV, cytomegalovirus
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Table 4  Definitions and weights of parameters included in the integrated score
Parameter definition* Attributed score
Infection Requiring continuation of antimicrobial treatment after alloHSCT 1
Pulmonary disease DLco and/or FEV
1
 ≤ 65% or dyspnea at rest or requiring oxygen 1
Unrelated donor Matched unrelated donor 1
Donor CMV Donor CMV IgG serology positive 1
Hepatic disease Liver cirrhosis, bilirubin > 1.5 ULN, or AST/ALT > 2.5 x ULN 1
Time interval to alloHSCT Time interval from diagnosis to alloHSCT ≥ 6 months 1
Peptic ulcer Requiring treatment 2
Inflammatory bowel disease Crohn disease or ulcerative colitis 2
Heart valve disease Any valve disorders, except prolapsed mitral valve 2
Psychiatric disturbance Depression or anxiety requiring psychiatric consultation or treatment 2
Age at alloHSCT ≥ 60 years 2
Arrhythmia Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias 2
Patient CMV Patient CMV IgG serology positive 2
Obesity Patients with a body mass index > 35 kg/m2 2
Rheumatologic disease SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica 2
Renal disease
Serum creatinine > 2mg/dL or > 177 micromol/L, on dialysis, or prior 
renal transplantation
2
Abbreviations: alloHSCT, allogeneic hematopoietic stem cell transplantation; DLco, diffusing capacity of carbon 
dioxide; FEV
1
, forced expiratory volume in 1 second; CMV, cytomegalovirus; IgG, immunoglobuline G, ULN, upper 
limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SLE, systemic lupus erythmatosis; 
RA, rheumatoid arthritis; and CTD, connective tissue disease 
* Parameters are defined as described previously7,9,10,27
The cumulative incidence of 2-year NRM in the integrated score estimated 8 ± 2%, 17 
± 2% and 38 ± 4% for low-, intermediate- and high-risk patients, respectively (Table 5 and 
Figure 2A). The non-parametric estimation of AUC 0.680 (95% confidence interval: 0.630-
0.730) for the integrated score with three groups indicated relatively strong predictive power 
for NRM at 2-years as compared with the EBMT-score and the HCT-CI (P = 0.0009 and P = 
0.0018, respectively). In addition, higher scores in the integrated score were more strongly 
associated with increased NRM as compared with the HCT-CI and the EBMT-score based 
on the likelihood ratio (50.5 versus 3.7 and 4.9, respectively). The integrated model with 
3 groups was internally validated after bootstrapping with a corrected c statistic of 0.66. 
Moreover, cumulative incidences of NRM at 5 years from transplant increased to 12 ± 2%, 
21 ± 2% and 44 ± 5% in the low-, intermediate- and high-risk subgroups, respectively. The 
cumulative incidences of 2-year NRM were similar among the different RIC regimens (data 
not shown). The integrated score was also significantly associated with OS, as depicted in 
Figure 2B and shown in Table 5. A non-significant trend was observed for the association of 
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the integrated score with cumulative incidence of acute GVHD grade 2 to 4 with estimates at 
2 years of 18 ± 2%, 20 ± 2%, 26 ± 4% (P = 0.10) for low-, intermediate- and high-risk patients, 
respectively. Cumulative incidences for chronic GVHD were not different among the three 
risk groups, estimating 50 ± 3%, 53 ± 3%, 50 ± 5% (P = 0.49) at 2 years for low-, intermediate- 
and high-risk patients, respectively. Furthermore, the integrated score did not predict for 
relapse, with similar relapse rates among all three groups (data not shown). 
Table 5  Integrated score: cumulative incidence of NRM and OS
Probability at 2 years
Score (%) nrM oS
0 – 3 points 272 (33) 8 ± 2 69 ± 3
4 – 6 points 392 (48) 17 ± 2 60 ± 3
≥ 7 points 148 (18) 38 ± 4 43 ± 4
corrected c statistics 0.665 0.578
non-parametric AUC 0.680 0.598
likelihood ratio 50.5 20.7
Abbreviations: NRM, non-relapse mortality; OS, overall survival; and AUC area under the curve
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Figure 2. Overall survival and non-relapse mortality by the integrated score. (A) Cumulative incidence of non-relapse 
mortality (NRM) and (B) Kaplan-Meier estimates of overall survival (OS) by the integrated score. Performance of 
the integrated score in predicting NRM and OS in these patients is described in Table 5. The event for NRM was 
death in CR1 with relapse as a competing event. The event for OS was death whatever the cause and patients were 
censored at the date of last contact if alive. 
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diSCuSSion
Currently, RIC alloHSCT is increasingly applied as post-remission treatment in patients with 
AML in CR1,6 who do not qualify for myeloablative alloHSCT because of age or pre-existing 
comorbidities. Transplant decisions in older or medically less fit patients increasingly 
depend on risk assessment of both the underlying leukemia and the risk of NRM.21 In the 
past, composite risk scores were developed in order to optimize NRM risk assessment. 
The most widely applied and validated risk scores include the HCT-CI and the EMBT-score, 
which each use different parameters.9,10 Of these, the EBMT-score appeared to discriminate 
risk groups less clear in older recipients of RIC alloHSCT.14,21 Here, we set out to integrate 
these scores by reassessing the individual parameters in recipients of RIC alloHSCT with 
AML in CR1. Multivariable analysis of all parameters from both scores plus patient and 
donor CMV serology status resulted in the identification of 16 predominant parameters, 
including 11 comorbidities, 3 EBMT-score parameters and patient and donor CMV serology 
status. Subsequently, three risk groups were defined in an integrated score based on these 
parameters and their respective weights. The integrated score yielded a strong NRM risk 
categorization, particularly for low- and high-risk patients and was significantly associated 
with NRM and OS at 2 years after RIC alloHSCT. Moreover, NRM was found to increase at 
5 years post-transplantation with continued discriminative power of the integrated score. 
Thus, the integrated score may contribute to NRM risk assessment in patients with AML in 
CR1, for whom RIC alloHSCT is considered as post-remission treatment for prevention of 
AML relapse.
The EBMT-score, which was initially developed to assess OS after myeloablative 
conditioning alloHSCT in chronic myeloid leukemia patients, demonstrated relatively weak 
predictive power in the present study. Several explanations may be considered. First, 
the EBMT-score was originally not selectively developed for predicting NRM. The score 
was designed to predict overall outcome by incorporating both disease parameters and 
transplant parameters.9 Here, we selectively focused on NRM after RIC alloHSCT. In addition, 
only AML CR1 patients were studied, which patient group exhibits different characteristics 
as compared with the original and confirmatory reports of the EBMT-score.9,14 Reassessment 
of the individual parameters of the EMBT-score in an integrated model resulted in different 
HRs as compared with the original report.9 The HRs of the parameters age and time from 
diagnosis to transplantation were largely similar in the present study, although these 
parameters were defined differently as compared with the original report of the EBMT-
score.9 Strikingly, male patients receiving grafts from female donors were not associated 
with an increased risk for NRM at 2 years. The dismissal of the latter parameter may be 
explained by differences in patient characteristics; especially type of conditioning regimen, 
which itself is a risk factor for GVHD and NRM. Of note, in the original reports of the EBMT-
score female donor to male recipient was also the parameter with the lowest relative risk 
and non-significant in several disease subgroups (for example, acute lymphoblastic leukemia 
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and myelodysplastic syndrome).9,14 In the present study, the parameter donor type was 
associated with an increased HR for 2-year NRM, similar to the EBMT-score.9,14 Furthermore, 
positive patient and donor CMV serology affected outcome in a confirmatory analysis of 
the EBMT-score, but CMV serostatus did not alter the EBMT-score and was therefore not 
included in the score.14 However, in the present study, patient and donor CMV serology 
status independently predicted for 2-year NRM and were therefore both included in the 
model. Last, differences in HRs may be partly explained by the statistical method used in the 
original EBMT-score,9 because NRM and relapse were evaluated separately by cause-specific 
hazards at that time, while ignoring NRM and relapse as competing risks. In contrast, the 
present score was based on a competing risk regression model (that is, Fine-Gray model29) 
which allows for a more accurate estimation of these end points.
The HCT-CI appeared to be associated with a relatively low predictive value in the 
present study, which may be partly explained by strong differences in patient characteristics 
as compared with the original report.10 The present study included a homogeneous cohort 
of AML patients with an increased frequency of comorbidities as compared with the original 
description of the HCT-CI.10 In particular, cardiovascular-related comorbidities were found 
more frequently (that is, cardiac disease, heart valve disease and diabetes), which would be 
expected given the relative advanced median age of this cohort as compared with the Seattle 
cohort (median 58 years versus 44 years, respectively).10 Furthermore, we found a relative 
high prevalence of infections (24%, versus 4% in the Seattle cohort), which may be explained 
by the intensive pre-transplant chemotherapy of AML, rendering patients susceptible for 
invasive infections requiring antimicrobial treatment at the time of transplant. Following 
integrated reassessment of all individual parameters, mild and moderate comorbidities (that 
is, pulmonary disease and hepatic disease) showed weak associations with 2-year NRM, 
which may be explained by decreased toxicity of RIC. It resulted in the omission of mild 
hepatic disease and moderate pulmonary disease from the integrated score. Previously, 
the Seattle group reported similar findings that recipients of RIC alloHSCT experienced less 
pulmonary toxicity, despite having worse lung function pre-transplantation.35 The parameter 
prior solid tumor was also dismissed despite a considerable prevalence (10%) in our cohort. 
Collectively, our integrated reassessment in AML CR1 patients receiving RIC alloHSCT 
yielded HRs that differed from the original report by Sorror et al.10 Overall, it suggests that 
prediction of NRM may merit from a more tailored model, here as developed for older 
patients with AML in CR1 proceeding to RIC alloHSCT, which is currently the predominant 
indication for allografting. 
Apart from the established EBMT-score and HCT-CI, other groups developed predictive 
models for NRM.18,22,36-38 Some groups modified the weights of the EBMT-score and 
the HCT-CI,18,37,38 whereas others combined transplant-related parameters and patient 
characteristics.22,36 Recently, Barba et al.22 showed the combined ability of the EMBT-score 
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and the HCT-CI to predict NRM, whereas leaving each individual score unchanged. Improved 
discrimination of patients at high risk for NRM was demonstrated. Of note, parameters of 
both scores were not reassessed individually while the original scores showed relatively weak 
predictive value. Most alternative models performed reasonably well in the original reports, 
but external validation in other cohorts of patients and/or diseases is often lacking. 18,22,36-38 In 
general, the performance of a predictive model within a population the model was derived 
from may be too optimistic, which may also apply to our integrated score. In the present 
study, the internal validity of the regression model was assessed using a bootstrapping 
technique in order to avoid a possible increase in false positive and false negative error 
rates that would occur if we would have split the data into a training and test set. However, 
despite bootstrapping, external validation of a predictive score remains mandatory and 
should be performed in an independent cohort of RIC alloHSCT recipients with AML, but 
also in other disease groups. Besides validity, the consistency of parameter analysis and 
coding is another important concern in constructing scores, as recently stressed by Sorror.27 
He proposed a brief training program in order to have consistent guidelines in assessing 
comorbidities and he found marked improvement in interevaluator agreement after using 
those guidelines. The data used in the present study have been gathered by the EBMT 
Acute Leukemia Working Party among more than 100 centers from 23 countries. Although 
30 centers included more than two-thirds of the patients, the accuracy in the assessment 
of comorbidities may be of concern, which could lead to an over- or underestimation of 
the prevalence of comorbidities and may compromise the performance of the score, as 
well as the individual HRs upon reassessment. Therefore, the integrated score proposed in 
the present study would need external validation preferable in centers with standardized 
scoring systems and guidelines.
In conclusion, we present an integrated score for the assessment of NRM in patients with 
AML in CR1 eligible for RIC alloHSCT, based on a selection of parameters of the original EBMT-
score and HCT-CI. The integrated score yielded relatively strong prediction of 2-year NRM 
that allowed for a clear discrimination of both low-risk and high-risk patients. Optimizing 
composite risk scores is of importance in order to support individual risk assessment in 
transplant decisions, as recently stressed by the European LeukemiaNET AML Working 
Party.21 The working party advocated that individual transplant decisions should be made 
on both leukemia-related and NRM-related parameters, necessitating the use of scores 
with a high predictive value. Although the integrated score in the present study showed 
improved predictive power, future research is needed, in order to validate this score in an 
independent cohort of RIC alloHSCT recipients. 
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AbSTrACT
Hepatitis E virus (HEV) is increasingly acknowledged as a cause of hepatitis in healthy 
individuals as well as immunocompromised patients. Little is known of HEV infection in 
recipients of allogeneic hematopoietic stem cell transplantation (alloHSCT). Therefore, we 
set out to study the incidence and sequelae of HEV as a cause of hepatitis in a recent cohort 
of 328 alloHSCT recipients. HEV-RNA was tested in episodes of liver enzyme abnormalities. In 
addition, HEV-RNA and HEV serology were assessed pre- and post-alloHSCT. We found 8 cases 
(2.4%) of HEV infection, of which 5 had developed chronic HEV infection. Seroprevalence 
pre-alloHSCT was 13%. Four patients died with HEV viremia, with signs of ongoing hepatitis, 
having a median time of infection of 4.1 months. The 4 surviving patients cleared HEV after 
a median period of 6.3 months. One patient was diagnosed with HEV reactivation after 
a preceding infection prior to alloHSCT. Although the incidence of developing acute HEV 
post-alloHSCT is relatively low, the probability of developing chronic hepatitis in severely 
immunocompromised patients is high. Therefore, alloHSCT recipients should be screened 
pre-transplantation by HEV serology and RNA. Furthermore, a differential diagnosis including 
hepatitis E is mandatory in all alloHSCT patients with severe liver enzyme abnormalities.
Key PoinTS
•  The incidence of acute HEV infection after alloHSCT is relatively low, in contrast to a high 
probability of developing chronic hepatitis. 
•  HEV infection or reactivation should be included in the differential diagnosis of liver 
enzyme abnormalities in alloHSCT recipients.
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inTroduCTion
In 1983, a new waterborne hepatitis agent was found after an outbreak of unexplained 
hepatitis at a military camp, later identified as hepatitis E virus (HEV). HEV is endemic in 
resource-limited countries and an emerging health issue in industrialized countries.1,2 It 
is a causative agent of acute and chronic hepatitis, transmitted via fecal-oral route, with 
a mostly self-limiting course in healthy individuals. In human HEV infection, there are 4 
known genotypes prevalent, with genotypes 1 and 2 responsible for large waterborne HEV 
outbreaks in developing countries (Africa and Asia), and genotypes 3 and 4 generally seen in 
sporadic cases as a zoönotic infection in industrialized countries.1,3 Since the first evidence of 
chronic hepatitis due to HEV in recipients of solid organ transplants, an increasing awareness 
for HEV has become apparent.4,5
Persistent chronic infection and cirrhosis have been reported in immunocompromised 
patients, with most cases in solid organ transplant recipients.5 However, HEV was recently 
also reported in recipients of allogeneic hematopoietic stem cell transplantation (alloHSCT).6-9 
A prevalence of 1% to 3% of hepatitis E viremia in recipients of solid organ transplants has 
been reported, with 47% to 83% of the patients developing chronic hepatitis.10-13 So far, the 
incidence and sequelae of hepatitis due to HEV in recipients of alloHSCT is largely unknown.
After 2 recent cases of HEV infection in our clinic, we set out to retrospectively evaluate 
the point prevalence and clinical sequelae of HEV infection in a cohort of alloHSCT recipients 
in our clinic, and we studied the role of HEV in transplant recipients presenting with liver 
enzyme abnormalities.
Hepatitis E virus in alloHSCT recipients
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MeTHodS
Sample collection
We conducted a retrospective cross-sectional analysis of all adult alloHSCT recipients 
transplanted in the period January 2006 to July 2011, whose serum or EDTA-plasma 
samples were available in the biobank of Erasmus Medical Center (ErasmusMC; Rotterdam, 
The Netherlands). These samples, stored at -20°C or -80°C, had been collected during 
routine visits to our outpatient clinic for clinical assessment of cytomegalovirus (CMV) 
and EpsteinBarr virus (EBV) reactivation. To select samples, we performed a Laboratory 
Information Management System database search for last pre-transplantation and most 
recent post-transplantation sample availability. In addition to the cross-sectional analysis, 
samples were selected from patients experiencing episodes with alanine transaminase (ALT) 
abnormalities grade 2 to 4, according to Common Terminology Criteria for Adverse Events 
version 3.0. Common Terminology Criteria for Adverse Events grades 2 to 4 ALT abnormalities 
are defined as at least 2.5 times the upper limit of normal. This study was approved by the 
medical ethical committee (MEC) of ErasmusMC (MEC approval: 2012-522). This study was 
conducted in accordance with the Declaration of Helsinki.
Virological parameters 
For detection of both HEV-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) in 
serum or plasma samples, the commercially available HEV enzyme-linked immunosorbent 
assays (Wantai, Beijing, People’s Republic of China) were used. Available peripheral blood, 
feces and cerebrospinal fluid (CSF) samples of HEV RNA positive patients were retrospectively 
analyzed during the course of infection to study the kinetics of serum antibody responses 
(IgM and IgG) and viremia in different body compartments.  
All samples were screened for HEV RNA by an internally controlled quantitative real-
time reverse transcription-polymerase chain reaction (RT-PCR), described  previously.13 The 
RT-PCR had a lower limit of detection (95% hit rate) of 143 (2.16 log) IU/mL as determined 
by the first World Health Organization standard for HEV RNA nucleic amplification testing- 
based assays (6329/10; Paul Ehrlich Institute, Langen, Germany). Phylogenetic analysis 
was performed to determine genotype, to exclude a common source of infection, and to 
examine potential HEV reactivation. Statistical analysis and data collection were performed 
using Microsoft Office Excel 2007 and SPSS (version 20).
Case definition
A case of HEV infection was defined as a patient with an HEV RNA positive serum or plasma 
sample and was confirmed either by showing HEV-specific serum IgM or IgG antibody 
response, or by showing the presence of HEV RNA in sequential samples. Chronic infection 
was diagnosed by retrospective testing of stored samples of identified cases and was defined 
as having HEV viremia of more than 6 months.
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reSuLTS
Patient characteristics 
A total of 207 episodes of acute ALT abnormalities, occurring in 138 out of 328 alloHSCT 
recipients, were evaluated, in addition to a cross-sectional RT-PCR analysis of all 328 patients 
(Figure 1). As delineated in Table 1, the cohort included 178 (54%) male and 150 (46%) female 
patients with a median age at transplantation of 50 (range: 17-66) years. Stem cell sources 
included sibling donors (n = 145, 44%), adult matched unrelated donors (MUD) (n = 137, 
42%), and umbilical cord blood (UCB) grafts (n = 46, 14%). Acute myeloid leukemia was the 
most frequent diagnosis for transplantation (n = 142, 43%), followed by acute lymphoblastic 
leukemia (n = 49, 15%), and non-Hodgkin’s lymphoma (n = 31, 9%). All patients received 
graft versus host disease (GVHD) prophylaxis with a combination of a calcineurin inhibitor 
(cyclosporine A) and mycophenolate according to local policy. Acute GVHD grades II to 
IV occurred in 130 (40%) patients, and chronic extensive GVHD was present in 122 (37%) 
patients. At the time of analysis (December 2012), 180 (55%) patients were still alive, with a 
median follow-up of 40.9 (range, 10-77) months from alloHSCT. 
serologic screening prior
to allHSCT
n=328 samples
screening HEV RNA of
samples during ALT
abnormality episodes
n=207 samples
n=138 patients
HEV RNA
screening last
available sample
n=328 samples
IgG positive n=41 (12,9%)
IgM positive n=2 (0,6%)
HEV RNA positive
n=1
HEV RNA positive
n=7
8 patients with
confirmed HEV
infection (2.4%)
328 patients included
Figure 1  Overview of sample selection and study results
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Table 1  Patient characteristics of the cohort (n = 328)  
Characteristic number
Age of Transplantation, years   
 median (range) 50.4 (17-66)
Sexe, number (%)   
 Male 178 (54%)
 Female 150 (46%)
diagnosis, number (%)   
 AML 142 (43%)
 ALL 49 (15%)
 NHL 31 (9%)
 CLL 24 (7%)
 MM 18 (5%)
 MDS 16 (5%)
 Other 48 (15%)
Type of allogeneic transplantation, number (%)  
 UCB 46 (14%)
 MUD 137 (42%)
 SIB 145 (44%)
GvHd, number (%)   
 Acute grade I 42 (13%)
 Acute grade II - IV 130 (40%)
 Chronic limited 32 (10%)
 Chronic extensive 122 (37%)
Patients alive   
 number (%) 180 (55%)
Time to follow-up (months)   
 median (range) 40.9 (10-77)
Abbreviations: AML indicaties acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin’s 
lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; MDS, myelodysplastic syndrome; UCB, 
umbilical cord blood; MUD, matched unrelated donor; SIB, sibling; and GVHD, graft versus host disease
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Virological parameters
In total, 8 (2.4%) cases of confirmed HEV infection were found in 328 patients, of which seven 
(88%) were identified by cross-sectional analysis, and 1 (13%) by screening the episodes of 
acute ALT abnormalities. 
HEV-specific IgG prior to alloHSCT was detected in 41 (13%) patients. Two (0.6%) patients 
were IgM positive, though HEV viremia could not be confirmed by RT-PCR. Presence or 
absence of HEV specific antibodies (both IgM and IgG) prior to alloHSCT was not predictive for 
HEV infection after alloHSCT, tested by Pearson’s chi square- test of independency (P = .313). 
The courses of HEV infection of all 8 cases are presented in Figure 2. Clinical and virological 
features are delineated in Table 2. Patients will be annotated according to their assigned 
letter: ‘patients A–H’. Within the 8 cases, complete HEV-IgM and -IgG seroconversion 
occurred in 5 patients, of whom 4 eventually cleared the virus and 1 deceased with a HEV 
viremia (patient A–C, F, H). Median time from first HEV RNA detection to HEV-IgM and HEV-
IgG conversion of these patients was 65 (range, 0-245) days, and 126 (range, -594-351) days, 
respectively. Three patients, who all died with HEV viremia, had aberrant serodynamics: 1 
patient did not have detectable HEV-IgG, with only 1 serum sample testing HEV-IgM positive 
(patient G). Two patients did not have detectable HEV-IgM levels (patients D, E). One of 
them had detectable HEV-IgG in only 1 sample (patient D), and 1 had detectable HEV-IgG 
levels at time of alloHSCT, though declining to undetectable at the time of death 7 months 
later (patient E). 
HEV-open reading frame 1b (ORF1b) sequences were generated for all 8 cases and 
deposited in Genbank under the accession numbers JQ015439, JQ015407, KC171439-
KC1714444, KC171447, KC171450 and KC171451. Phylogenetic analysis did not identify a 
common or nosocomial source of HEV transmission. All HEV isolates were classified within 
genotype 3, as shown in the phylogenetic tree (Figure 3). Interestingly, confirmed HEV 
reactivation occurred in 1 patient, as described below (patient H).
Hepatitis E virus in alloHSCT recipients
8
176
Characteristics of Hev rnA positive patients
The median age of 8 HEV infected patients was 56 (range 39-66) years at transplantation, 
including 5 (63%) males and 3 (37%) females (Table 2). All patients were screened for 
hepatitis B virus, hepatitis C virus, EBV, adenovirus, varicella zoster virus, herpes simplex 
virus type 1 and 2, and CMV by PCR to exclude the role of other potential hepatrophic 
viruses. All tested samples were undetectable by PCR, except for 1 patient experiencing CMV 
reactivation at the time of HEV infection (patient E). In this patient, HEV viremia persisted 
after successful treatment with ganciclovir, excluding the role of CMV in hepatitis in this 
patient. All 8 patients received a graft from an alternative donor, including peripheral blood 
grafts from an adult MUD in 5 patients (63%) and UCB grafts in 3 (37%) patients. Plasma of 
the adult MUD grafts was HEV RNA negative. No samples of the UCB grafts were available 
for HEV RNA screening, yet 2 of 3 UCB recipients were HEV viremic at the time of alloHSCT 
(patients G,H). Six patients received multiple blood transfusions within 3 months prior to 
HEV infection, including platelet and red blood cell transfusions. None of the blood products 
were available for testing for HEV serology or RNA at the time of submission.
The median time from alloHSCT to infection was 4.6 (range, -2 to 18) months. The median 
peak ALT during HEV infection was 289 (range, 138-1507) U/L. At the time of infection, 6 
(75%) patients were receiving intensive immunosuppressive therapy (>2 agents), prescribed 
for GVHD prevention (n = 2, 33%) or GVHD treatment (n = 4, 66%). In the HEV-infected 
patients, liver enzyme abnormalities were thought to be related to hepatic GVHD in 5 (63%) 
patients, and drug induced liver injury in 3 (38%) patients.
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Figure 2. Courses of Hepatitis E infection in all eight individual patients. 
(A) HEV RNA persisted, although HEV-IgM and HEV-IgG seroconversion occurred under immunosuppressive 
therapy. This patient deceased of therapy refractory progressive gastro-intestinal GVHD with concurrent chronic 
HEV infection; (B) Acute ALT abnormalities arised during HEV infection. This patient was mistakenly diagnosed 
as hepatic GVHD, and immunosuppression was intensified multiple times because of persisting liver enzyme 
abnormalities. This patient cleared HEV with stopping all immunosuppression, after the diagnosis of HEV infection 
in this study; (C) This patient developed primary graft failure of a 8/8 HLA-matched unrelated donor graft after 
reduced intensity condition with rabbit antithymocyte globulin, fludarabine, and a single donor fraction of 2 gray 
total body irradiation. HEV RNA was present after second alloHSCT. This patient cleared infection after HEV-IgM and 
HEV-IgG seroconversion, supported by reduction of immunosuppressive therapy; (d) This patient developed graft 
failure of a 7/8 HLA-matched unrelated donor graft after reduced intensity conditioning with rabbit antithymocyte 
globulin, fludarabine, and a single fraction of 2 gray total body irradiation. Patient’s disease relapsed three months 
after graft failure. Reinduction therapy was started with alemtuzumab (ALEM) and a second alloHSCT was prepared. 
However, due to recurrent infections, this patient was not able to complete treatment. Patient died shortly after 
his second cycle of alemtuzumab because of complications of a meningitis and secondary sepsis with Escherichia 
coli. Of note, patient’s CSF samples tested positive for HEV; (e) Secondary graft failure occurred three months 
after the first alloHSCT. The second alloHSCT was complicated by multiple respiratory viral and bacterial infections, 
which eventually led to respiratory failure and death; (F) This patient was diagnosed as hepatic GVHD and 
immunosuppression was introduced in August 2010. Patient cleared HEV after cessation of all immunosuppression, 
following the diagnosis of HEV infection; (G) HEV RNA was detectable at time of alloHSCT and viral load increased 
under immunosuppressive therapy until patient deceased due to a respiratory viral infection. This patient showed 
HEV-IgM in one sample (black bar) and no HEV-IgG seroconversion; (H) HEV reactivation occurred after initial 
undetectable HEV RNA without seroconversion. After reduction of immunosuppressive therapy and addition of 
ribavirin (RIBA) the patient seroconverted and cleared HEV. For explanation of symbols and abbreviations see 
legend attached to Figure 2. The ALT upper limit of normal is 33 U/L and 44 U/L for females and males, respectively. 
The HEV RNA lower limit of detection is 143 (2.16 log) IU/ml.
Four (50%) patients died with persistent HEV viremia and signs of ongoing hepatitis 
(patients A, D, E, G). Median duration of HEV infection in deceased patients was 4.1 (range, 
2-13) months, with acute HEV infection in 3 patients and chronic HEV infection in 1 patient. 
The cause of death was respiratory failure due to infection (fungal, bacterial, and viral) in 
3 patients (patients D, E, G), and 1 patient died of therapy refractory progressive gastro-
intestinal GVHD (patient A). Of note, one of the deceased patients appeared to have HEV 
RNA positive CSF with retrospective testing of CSF samples (patient D). These samples were 
obtained during an episode of meningitis and secondary sepsis with positive CSF and blood 
cultures for Escherichia coli. Radiological evaluation (computed tomography scan) revealed 
cerebral ischemia due to infection. This patient eventually died of respiratory failure due to 
fluid aspiration with a low level of consciousness since the meningitis.
The 4 (50%) living patients cleared HEV infection within a median period of 6.3 (range, 
2-42) months (patients B, C, F, H). One patient received ribavirin treatment twice daily with 
400 mg for 3 months after a starting dose of three times 600 mg daily for 10 days because of a 
concurrent respiratory syncytial virus infection (patient H). Three patients cleared HEV during 
cessation of immunosuppressive therapy (patients B, F, H). The cessation rate depended on 
the presence or occurrence of GVHD. Among living patients, chronic HEV occurred in 3 patients 
(patients B, C, F), whereas 1 patient was able to clear HEV infection within 6 months (patient H). 
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Figure 3  Phylogenetic tree of ORF1b HEV sequences in eight HEV infected alloHSCT recipients 
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Phylogenetic relation of 321 bp ORF1b region was 
calculated using Maximum likelihood, K2P analysis 
with bootstrapping (n = 1000). Branch lengths are 
proportional to the evolutionary relationship between 
the sequences and internodal confidence of >70% is 
depicted in the tree. Genbank accession numbers, 
country of origin (eg, NL), HEV study number (eg, 
HEV001) and date of drawal (yyyymmdd) and alloHSCT 
recipients are indicated in the taxa (red text). No 
indication for a common origin or for nosocomial HEV 
transmission was found.
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After HEV diagnosis was confirmed, a liver biopsy was taken from 2 patients (patients B, F), 
showing hepatitis, severe fibrosis, and portal inflammation (Figure 4). Liver histology was 
available in 1 patient by autopsy, showing no abnormalities (patient G).
Remarkably, 1 patient initially cleared the virus and showed reactivation after a period of 
53 days of undetectable HEV RNA (patient H). At the time of alloHSCT, HEV RNA was detectable, 
though viral load was low (<143 IU/mL). The second viremic period was characterized as viral 
reactivation after alloHSCT, based on identical HEV-ORF1b sequences (Figure 3). This patient 
finally cleared the reactivated HEV infection within 2 months after diagnosis, supported 
by ribavirin treatment (as described above) and reduction of immunosuppressive therapy.
* 
*
*
* 
Figure 4 Liver histology of a patient with chronic HEV
The histopathology of chronic HEV infection in this patient is characterized by a dense lympho-plasmocellular 
infiltrate (dashed arrow) in the portal tracts, combined with severe fibrosis (F3) and porto-portal septation (*). 
Multiple foci of apoptotic bodies are seen in the lobuli surrounded by few inflammatory cells, indicating individual 
hepatocyte necrosis (Councilman-bodies: arrow) and probably caused by viral replication.
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diSCuSSion
Recipients of allogeneic stem cell grafts, and especially those receiving alternative donor 
grafts, are at increased risk of opportunistic bacterial, fungal and viral infections. Here we 
describe the first retrospective cross-sectional study of HEV infection in a large cohort of 
alloHSCT patients. We report a relatively low incidence of 2.4%, in comparison with other 
opportunistic infections in alloHSCT recipients. Nevertheless, we found a high probability of 
63% of developing chronic HEV infection. 
Previously, 2 cohorts of 72 and 52 alloHSCT patients were screened for HEV by 
Abravanel et al.6 and Koenecke et al.8 respectively, without positive cases for HEV infection 
or reactivation, concluding that alloHSCT patients are at low risk for HEV infection and 
reactivation. However, these 2 cohorts of alloHSCT recipients comprised a more limited 
number of patients. In our study we identified 8 HEV cases in a larger cohort (n = 328), 
confirming the HEV prevalence of 2.4% in immunocompromised patients.4,5,11,13 Second, the 
study of Abravanel et al.6 included a restricted follow-up period of 6 months after alloHSCT, 
whereas our study had  a median follow-up time of 41 months. Additionally, misdiagnosing 
HEV as drug induced liver injury has been reported previously by Dalton et al,14 whereas 
this patient group was excluded in the study of Koenecke et al.8 To reduce the risk of 
missing HEV infections, we screened all patients for HEV RNA at episodes of liver enzyme 
abnormalities in addition to last available samples. Of the confirmed HEV cases, 5 were 
misdiagnosed as GVHD, and 3 cases were mistakenly diagnosed as drug induced liver injury. 
Diagnosis of HEV in these patients is hampered by relatively low peak aminotransferase 
levels in comparison with non-immunocompromised patients,15 which may be explained by 
intensive immunosuppressive therapy suppressing inflammation. 
In our cohort, chronic hepatitis occurred in 5 out of 8 acute HEV cases. However, only 
6 patients had sufficient follow-up for a potential diagnosis of chronic hepatitis, because 
2 patients died within 2 months after acquiring HEV infection. Progression to chronic HEV 
in alloHSCT patients may be explained by an impaired immune reconstitution, including 
insufficient lymphocyte recovery, which are well known risk factors for post-transplantation 
infections.16-18 In particular, impaired reconstitution of CD4+ and CD8+ T-cells predispose 
for infectious morbidity,19 which is confirmed in studies with CMV and EBV viremia, with 
patients having low specific CMV and EBV CD4+ and CD8+ T-cell counts predisposing for CMV 
and EBV reactivation, respectively.20,21 
Phylogenetic analysis of patient-derived HEV sequences before and after alloHSCT 
established HEV reactivation in 1 patient. This is the second case of HEV reactivation after 
alloHSCT described so far in the literature.7 We could not unequivocally demonstrate a 
reinfection or reactivation in 3 viremic patients having detectable IgG prior to alloHSCT, because 
no HEV RNA was detected in available samples prior to alloHSCT. Four other patients were 
seronegative prior to transplantation, suggesting that transmission had occurred after alloHSCT. 
In industrialized countries, HEV genotype 3 predominantly infects pigs, wild boars, and 
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deer but also humans and is recognized as a zoönotic agent. However the main modes of 
transmission of genotype 3 and 4 viruses remain to be determined.2,3 The source of HEV 
infection is unclear, but HEV transmission may be enterically (food borne: porcine livers, 
shellfish), via blood or blood products, mother-to-child, and although rare, human-to-
human.1,22 Donors and donated blood are not routinely tested for HEV RNA worldwide, 
although reports of several cohorts in different countries of healthy blood donors reported 
HEV RNA and HEV IgM reactivity, suggesting active infection.23-25 In our cohort, transmission 
of HEV by blood products cannot be excluded because 6 out of 8 viremic patients received 
multiple blood transfusions. Unfortunately none of these blood products were available for 
testing at the time of submission. 
The high probability of developing chronic HEV found in this study was consistent with 
other studies in recipients of solid organ transplants.4,5,11,13 HEV-infected patients are at 
risk of progression to fibrosis (67%) in 1 year from infection,11 and also cirrhosis (10%).10 
Therefore immunocompromised patients should be screened prior to transplantation, and 
during episodes of liver enzyme abnormalities, post-transplantation. In our study, patients 
showed aberrant serology, which may be explained because of their impaired immune 
reconstitution. Thus, HEV RT-PCR testing is the preferred diagnostic method in these 
immunocompromised patients. 
Treatment of HEV infection after transplantation includes reduction of immunosuppressive 
therapy, and there is no registered drug therapy. Anecdotal evidence supports the use of oral 
ribavirin in immunocompromised patients. In our study, 3 patients cleared HEV with a dose 
reduction of immunosuppressive agents (ie, cyclosporine A or prednisone) alone. Treatment 
with ribavirin should be considered in patients, for whom immunosuppression cannot be 
reduced, such as, for example, patients with active GVHD. The optimal daily dose of ribavirin 
is unknown; in case-reports sustained viral response has been described with daily dosages 
between 200 mg and 1200 mg.11,26 If HEV infection is confirmed prior to alloHSCT, it can be 
considered as a contraindication to transplantation. Clearance of HEV viremia is therefore of 
high importance. AlloHSCT candidates are usually pretreated with chemotherapy, resulting 
in impaired or delayed immune reconstitution. Therefore, early ribavirin treatment can be 
initiated to support rapid HEV clearance in these future alloHSCT recipients.
In conclusion, this study shows that recipients of alloHSCT are at risk for HEV infection, 
albeit with a relatively low risk. However, the probability of developing severe chronic 
hepatitis in immunocompromised patients is high. Therefore, patients should be screened 
for HEV antibodies and HEV RNA prior to alloHSCT, and patients with acute liver enzyme 
abnormalities after alloHSCT should be analyzed for HEV reactivation or infection. Moreover, 
HEV should be included in the differential diagnosis of liver GVHD and drug-induced liver 
injury, because of the largely overlapping picture with respect to liver enzyme abnormalities.
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inTroduCTion
The majority of patients with newly diagnosed acute myeloid leukemia (AML) obtain 
complete hematological remission (CR) after induction chemotherapy, but the incidence 
of relapse is considerable despite chemotherapeutic consolidation therapy. The risk of 
relapse is predominantly determined by the genetic characteristics of the leukemia, 
which can be assayed by cytogenetic or molecular analysis.1-6 In addition, assessment of 
minimal residual disease (MRD) upon achievement of hematological CR significantly adds 
to estimating the risk of disease recurrence.7-9 Currently, post-remission treatment (PRT) for 
the prevention of relapse may include continued chemotherapy, autologous hematopoietic 
stem cell transplantation (HSCT), or allogeneic HSCT (alloHSCT). Although alloHSCT is 
associated with the lowest incidence of relapse, counterbalancing non-relapse mortality 
(NRM) may compromise overall outcome. The decision to perform an alloHSCT for patients 
with AML in first CR depends on the assessment of risks and benefits (ie, mortality and 
relapse risk reduction), which is based on disease features, but also factors related to 
patient characteristics, transplantation procedures and type of donor. Such a risk versus 
benefit evaluation of alloHSCT has evolved into a personalized approach for patients with 
AML in first CR.10,11 The studies described in the first part of this thesis address the benefits 
of alloHSCT identifying different AML patient subgroups with improved outcome following 
alloHSCT. Secondly, the studies in this thesis also addressed morbidity and mortality 
following alloHSCT. In order to improve a risk-benefit evaluation, we developed a new NRM 
risk score. We have also described a new opportunistic infection in alloHSCT recipients. In 
the current chapter, we discuss the value of alloHSCT as PRT in specific AML subgroups, 
potential challenges with respect to alloHSCT-related NRM, and statistical considerations 
analyzing PRT for AML. Lastly, we present a personalized transplant decision approach for 
patients with AML in first CR, which may be applied in daily clinical practice. 
The indication of alloHSCT as PrT in patients with AML in first Cr
Risk classification
AML risk classifications define risk groups with distinct prognostic features that are 
continuously being refined. Recently, the European LeukemiaNet (ELN) described an updated 
classification based on cytogenetic and molecular features, classifying patients in three risk 
groups with a favorable, intermediate or adverse prognosis.1 Applying that classification 
retrospectively to a cohort of 2.899 AML patients for whom induction treatment was started 
within four prospective HOVON-SAKK trials, the three risk groups were clearly identified 
(overall survival [OS] at 5 years: favorable risk 64 ± 2%, intermediate risk 41 ± 1%, and 
adverse risk 23 ± 1%, p<0.001, Figure 1). 
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Figure 1. Overall survival from AML diagnosis by ELN risk classification.1 
Patient data derived from AML29, AML42, AML92 and AML102 HOVON-SAKK studies.142-144 
Risk classifications are used for optimizing induction and consolidation approaches, and for 
tailoring PRT decisions. AlloHSCT is generally not being indicated in patients with a favorable 
risk profile, but highly recommended for patients with adverse risk AML in first CR.1,10-14 We 
have addressed outcome of AML patients in first CR by PRT in different age groups including 
40-60 years, and beyond 60 years of age in Chapter 2 and Chapter 3, respectively. Similar 
to previous studies and their meta-analyses,15-20 outcome following alloHSCT as compared 
with chemotherapy or autologous HSCT was not significantly different in patients with a 
favorable risk profile. Patients with intermediate risk or adverse risk AML had improved OS 
and relapse-free survival (RFS) following alloHSCT as compared with chemotherapy, although 
the number of elderly alloHSCT recipients with intermediate risk AML was relatively small. 
Autologous HSCT was associated with improved RFS as compared with chemotherapy in 
patients aged 40-60 years with favorable, intermediate or adverse risk AML. However, OS 
appeared not significantly different because more recipients of chemotherapy could be 
rescued by an allograft in second CR. 
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Results of alloHSCT as compared with chemotherapy have previously yielded 
contradicting results in intermediate risk patients, especially taking molecular markers 
into account.6,15-24 In Chapter 4, we have addressed the comparative value of alloHSCT in a 
large cohort of intermediate risk patients, who had cytogenetically normal AML in first CR 
with available molecular status of NPM1 and FLT3-ITD including the allelic ratio. Similar to 
previous studies,24-30 we confirmed the prognostic impact of the FLT3-ITD mutant to wild-type 
ratio, which is currently included in the latest ELN risk classification.1 Importantly, the ELN 
classification has used a different calculation of the FLT3-ITD allelic ratio as compared with 
our analysis (Chapter 4) and previous studies.26,30 The ELN has classified AML patients with 
mutated NPM1 with a low ratio as favorable risk, whereas patients without NPM1 and a low 
ratio of FLT3-ITD are classified as having an intermediate risk profile. Patients with mutated 
NPM1 with a high allelic ratio of FLT3-ITD are currently also considered as intermediate risk, 
whereas a high ratio of FLT3-ITD without NPM1 is categorized as adverse risk. However, the 
additive value of NPM1 mutations in patients with FLT3-ITD remains questionable. Gale et 
al.26 were able to show better outcome in patients with mutated NPM1 with FLT3-ITD as 
compared with NPM1 wild-type patients, but did not address the FLT3-ITD allelic ratio in 
that comparison. Other studies showed poor outcome of patients with a high allelic ratio 
of FLT3-ITD, and no differential impact of mutated NPM1 on outcome,24,28-30 questioning 
whether these patients may be classified as intermediate risk. We were also not able to 
identify differences in outcome of the subgroup with a high allelic ratio of FLT3-ITD with or 
without mutated NPM1 (Chapter 4). In addition, similar outcome of patients with mutated 
NPM1 with a low ratio of FLT3-ITD or mutated NPM1 without FLT3-ITD was found in the 
study of Linch et al.,30 whereas others were not able to confirm these results.24,27,28 Our 
study showed inferior survival of patients with mutated NPM1 with a low ratio of FLT3-ITD 
as compared with patients having NPM1 without FLT3-ITD (Chapter 4), again questioning 
whether these patients may be classified as favorable risk. These observations urge further 
studies to delineate the impact of NPM1 mutations in the context of FLT3-ITD, irrespective 
of the allelic ratio. Nevertheless, the NPM1 mutational status and FLT3-ITD should both be 
included in PRT decision making. We found that alloHSCT improves OS as compared with PRT 
with chemotherapy and autologous HSCT in patients with wild-type NPM1 without FLT3-ITD 
or FLT3-ITD with a low allelic burden. Patients with favorable molecular characteristics in our 
cohort (ie, mutated NPM1 without FLT3-ITD) were associated with a favorable prognosis, 
which was not further improved by alloHSCT. A small subset of patients with a high FLT3-
ITD mutant to wildtype ratio was characterized by poor outcome, irrespective of type of 
PRT. Other research groups have suggested improved outcome following alloHSCT in AML 
patients with a high mutant to wild-type ratio of FLT3-ITD.24,28,29 Collectively, alloHSCT is not 
indicated in patients with cytogenetically normal AML with mutated NPM1 without FLT3-
ITD, but alloHSCT may be considered in patients with cytogenetically normal AML with wild-
type NPM1 without FLT3-ITD or FLT3-ITD with a low or with a high allelic ratio. 
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Minimal residual disease
AML risk classification may be further improved by the assessment of MRD, which can 
be measured by either multiparametric flow cytometry or quantitative PCR for specific 
molecular markers.7-9 MRD may be detected at time points early after induction treatment 
to assess the remission status of the AML, but also after PRT to detect imminent relapse. 
Consequently, MRD negativity was introduced as an endpoint in patients with a hematological 
CR.1 MRD has been shown to predict for relapse and overall outcome early after induction 
treatment, but also after PRT.31-45 Despite PRT with alloHSCT, a 2-5 fold increased incidence 
of relapse was observed in MRD positive AML patients as compared with MRD negative 
recipients of an allograft.38-45 In Chapter 5 we addressed whether and to what extent 
alloHSCT quantitatively reduces relapse as compared with conventional PRT in patients 
with or without MRD in first CR. We were able to demonstrate that the relative reduction 
of relapse by alloHSCT is similar in MRD positive and MRD negative patients as compared 
with chemotherapy or autologous HSCT. Of note, the relative reduction of relapse by 
alloHSCT as determined by a hazard ratio of 0.3-0.4 suggests a strong graft-versus-leukemia 
(GVL)-effect in our studies (Chapters 2, 3, 4 and 5). These results compare well to earlier 
findings in cytogenetic subgroups, in which the GVL-effect appeared to be similar among 
patients with a monosomal karyotype, core binding factor AML, or patients with a normal 
karyotype.46 These observations are most readily explained by the abundant expression 
of class I and II HLA-antigens on malignant myeloid precursor cells and their susceptibility 
to alloreactive T-cells, including T-cells recognizing minor or major HLA-antigens.47-49 Thus, 
T-cell alloreactivity may exert anti-leukemic effects irrespective of underlying subcategory of 
AML and MRD status. Collectively, the quantitative detection MRD should be used together 
with AML risk classifications to tailor the application of alloHSCT as PRT in patients with AML 
in first CR, which will be discussed in the last part of this chapter. 
Although alloHSCT provides a strong GVL-effect, counterbalancing NRM may be of 
concern. As NRM critically depends from a number of different risk factors, it has become 
imperative to assess the NRM risk profile in addition to leukemia characteristics and 
response to induction chemotherapy.10,11
Morbidity and mortality in alloHSCT
AlloHSCT is associated with substantial NRM, which may be attributed to graft-versus-host 
disease (GVHD), infectious complications, organ toxicity and other causes.50 A number of 
parameters may relate to alloHSCT-related NRM, including the procedure (eg, conditioning 
regimen, application of T-cell depletion), donor characteristics (eg, human leukocyte antigen 
[HLA]-matching) and recipient features (eg, age and comorbidity). 
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Conditioning
The infusion of allogeneic stem cells is preceded by a preparative regimen which permits 
engraftment. Myeloablative conditioning (MAC), containing high-dose chemotherapy and 
radiotherapy, has been developed to allow engraftment, to exert an anti-leukemic effect 
and to ensure a subsequent allogeneic GVL-effect.51 However, such intensive conditioning 
resulted in significant toxicity and mortality prohibiting the use of alloHSCT in elderly 
patients or patients with comorbidities.52 It prompted the development of reduced intensity 
conditioning (RIC) strategies limiting NRM and maintaining sufficient GVL-effect.53,54 Which 
type of conditioning is preferred in patients with AML in first CR? In the past, several studies 
have compared conventional consolidation with MAC alloHSCT with sibling donors and 
found improved survival in younger recipients of MAC alloHSCT.15-20 However, because of 
increased NRM in patients over the age of 40 years, the advantage appeared to be restricted 
to patients <40 years.15-20 In Chapter 2, improved survival was noted in AML patients aged 
40-60 years receiving RIC alloHSCT as compared with chemotherapeutic PRT. Although 
MAC alloHSCT also strongly reduced relapse, overall outcome was not significantly different 
comparing MAC alloHSCT with chemotherapy because of increased NRM following MAC 
alloHSCT. The prospective comparison of RIC vs MAC alloHSCT was done in a prematurely 
closed randomized study with no major differences in outcome, although the RIC regimen 
involved relatively intensive conditioning with 8 Gy of total body irradiation.55 Recently, 
Scott et al.56 reported a prospectively randomized study, including 272 patients with AML or 
myelodysplastic syndromes (MDS) receiving either RIC or MAC. The median age of included 
patients was 55 years with similar distribution of patient and disease characteristics. 
With a follow-up of only 18 months, RFS was significantly better following MAC alloHSCT, 
whereas OS was not significantly different as compared with RIC alloHSCT. As expected, RIC 
resulted in decreased NRM but higher relapse rates as compared with MAC. The cumulative 
incidence of NRM was remarkably low following MAC alloHSCT estimating 16% (95% CI 10–
23%) at 18 months,56 stressing the improvement of NRM as underlined by the longitudinal 
results of the Seattle group as reported by Gooley et al.50 The European Group of Blood and 
Marrow Transplantation (EBMT) also conducted a prospective randomized study comparing 
RIC and MAC alloHSCT in 129 patients with MDS or secondary AML.57 Similar OS and RFS 
at 2 years were reported, although a trend towards improved OS following RIC alloHSCT 
was observed (OS at 2 years: 76% (95% CI 66–87%) after RIC versus 63% (95% CI 51–75%) 
after MAC).57 Based on the results of these trials, both RIC and MAC alloHSCT continue to 
be used in patients with MDS or AML. Obviously, longer follow-up from these studies is 
needed. Somewhat disappointingly, these prospective randomized studies failed to provide 
a definite answer but rather emphasize the use of a more personalized approach taking 
into account the risk for NRM, instead of applying a strict age cut-off to decide for RIC 
of MAC. Meanwhile, the risk of NRM continues to decline, most recently because of the 
introduction of post-transplantation cyclophosphamide for GVHD prevention.58-63 Therefore, 
new prospective studies are needed re-evaluating established risk scores for NRM. 
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What is the optimal type of donor or graft source?
HLA-identical sibling donors and adult matched unrelated donors (MUD) have become the 
most common type of donor for alloHSCT.64 The probability of identifying an adult MUD for 
patients who lack a HLA-identical sibling can be as high as 60-80% for Caucasian patients, 
whereas finding a suitable MUD for patients from ethnic minorities is less successful.65-68 
Alternative stem cell sources include umbilical cord blood (UCB) and stem cells from haplo-
identical donors. UCB grafts are usually available within a few weeks and HLA-matching is 
less stringent for UCB as compared with adult donor grafts, HLA matching does impact on 
outcome following alloHSCT with UCB.69 The main issue has been the relatively low number 
of hematopoietic progenitor cells in UCB grafts, which is associated with a higher rate of graft 
failure and delayed hematopoietic recovery.70-74 Recently, the use of haplo-identical donors 
for alloHSCT has gained attention and application because of improved transplantation 
techniques and pharmacological manipulation of host-versus-graft and graft-versus-host 
reactions.75 
Each type of donor and/or stem cell source has its own advantages and drawbacks, 
but which donor type has to be preferred? Chapter 6 compared outcome of alloHSCT with 
HLA-identical siblings, MUD, mismatched unrelated donors (MMUD), UCB grafts and haplo-
identical donors. Similar to previous studies,76-80 we found slightly higher NRM following 
MUD, whereas counterbalancing lower relapse resulted in nearly equivalent outcomes as 
compared with HLA-identical siblings. 
One or two allele MMUD may serve as a good alternative in case a HLA-identical sibling 
or MUD is not available, but HLA-incompatibility results in increased incidence of GVHD 
and subsequent increased NRM.81 Although HLA-incompatibility may augment a GVL-effect 
resulting in slightly less relapse, MMUDs were associated with reduced OS because of 
higher NRM (Chapter 6). A recent meta-analysis compared outcomes of patients who were 
allografted with either 10/10 HLA-MUD or 9/10 HLA-MUD and found an estimated 27% 
increased risk of NRM for patients following 9/10 HLA-MUD.82 These data strongly suggest 
that alloHSCT with a MMUD may benefit from intensified GVHD prophylaxis, such as being 
applied in the setting of haplo-identical donors. 
Results of alloHSCT with UCB grafts approximated those of MUD alloHSCT in retrospective 
registry studies, although hematopoietic recovery is delayed as compared with MUD 
alloHSCT and graft failure was more frequently observed.83-85 In addition to a significant higher 
incidence of graft failure, we also observed that alloHSCT with UCB grafts is associated with 
higher NRM as compared with HLA-identical siblings and MUD, which resulted in significantly 
lower OS (Chapter 6). Thus, improving hematopoietic engraftment and hematopoietic 
recovery remains a major challenge in UCB graft transplantation. Currently, a number of 
groups are developing several techniques including ex-vivo expansion of hematopoietic 
cells,86-89 priming of UCB progenitors,90,91 or intra bone marrow injection.92,93
Chapter 9
197
The use of haplo-identical donors was previously associated with extensive NRM 
precluding a broad application.94 The development of a transplant strategy in which high-dose 
cyclophosphamide is infused after alloHSCT to selectively deplete proliferating alloreactive 
T-cells, resulted in favorable engraftment, limited GVHD, limited NRM and overall survival, 
approximating that following matched donor alloHSCT.58-63 A recent biologically randomized 
study from China suggested similar outcome using HLA-identical donors or haplo-identical 
family donors with ATG as part of the conditioning regimen.95 As shown in Chapter 6, we 
found encouraging outcome of haplo-identical donors, which approximated results of HLA-
identical siblings and MUDs. However, conditioning and post-transplant regimens varied 
and follow-up was relatively short in the cohort of haplo-identical donors. 
What is the optimal type of donor or graft source? As recently shown in a large cohort 
of patients from the EBMT, outcomes of alloHSCT were systematically improved with 
decreasing phenotypic and genotypic antigen disparity.96 Thus, if a HLA-identical donor or 
MUD is available, the best match should be the donor of choice. Alternative donors including 
MMUD, UCB grafts and haplo-identical donors could be used when a fully matched donor 
is not available and an urgent transplant is required. Results following haplo-identical 
donors are encouraging, which donor type may step up in the donor hierarchy. However, 
comparative prospective studies including haplo-identical donors are needed to definitely 
establish its new place in the donor hierarchy. 
Improving infectious complications
Apart from GVHD, infectious complications are a common cause of NRM following 
alloHSCT.50,97 Several risk factors for infectious complications have been identified including 
conditioning regimen, prolonged neutropenia after alloHSCT, prolonged T-cell and B-cell 
immune reconstitution, the use of immunosuppressive drugs, the presence GVHD, the use 
of a central venous catheter and previous exposure to infectious agents during pre-alloHSCT 
treatment.98-103 Recipients of an alloHSCT are at risk for different infectious complications, 
which occurrence is generally divided in three phases as summarized here.103,104 Firstly, the 
early pre-engraftment phase is characterized by neutropenia and mucosal damage. The most 
common infectious threats are bacterial (ie, gram-negative bacteria related to mucositis, 
gram-positive bacteria related to central venous catheters and Clostridium difficile) and 
fungal pathogens (ie, Candida species and molds). Herpes simplex virus (HSV) may reactivate 
during neutropenia in most HSV-seropositive patients, which can be prevented by aciclovir. 
The second time-interval starts after engraftment and early hematopoietic recovery including 
neutrophil and NK-cell mediated immunity. The development of GVHD in the early post-
engraftment phase poses an additional risk for bacterial infections, particularly in patients 
with intestinal GVHD whom are at risk for life-threatening bacteremia. Patients who require 
high-dose steroids may develop infections with Aspergillus species and other mold infections, 
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but also Pneumocystis pneumonia. The intensified immunosuppression for patients with 
GVHD further adds to the risk for opportunistic infections, including cytomegalovirus (CMV) 
viremia, which is still associated with transplant outcome (Chapter 7).105,106 CMV viremia 
may precede pneumonia or enterocolitis, which may result in substantial morbidity and 
mortality.105,106 In addition, adenovirus, and BK virus are encountered during that phase. The 
third phase usually starts as from three months after alloHSCT with gradual reconstitution 
of humoral and cellular immunity. Infectious complications may include similar pathogens 
as described in the second phase, as these are primarily related to GVHD and the prolonged 
use of immunosuppression. Late infections after alloHSCT may also include encapsulated 
bacteria (eg, Streptococcus pneumoniae) because of impaired opsonization, but also varicella 
zoster virus (VZV) infections. Of note, patients who have received a T-cell depleted graft or 
conditioning with ATG are at increased risk for Epstein-Barr virus reactivations and Epstein-
Barr virus lymphoproliferative disease.107-109 Other opportunistic infections may include 
parasites including Protozoa (eg, Toxoplasma gondii, Leishmania species, Giardia Lamblia) 
and Helminths (ie, Strongyloides stercoralis).110 The risk of community-acquired respiratory 
viruses is considerable during all three phases after transplant, but predominantly related 
to seasonal outbreaks.104,105 Recipients of alloHSCT are at increased risk of viral reactivations, 
but also de novo infections, with for example fulminant hepatitis following infection with 
hepatitis A virus, hepatitis B virus and hepatitis C virus.111 In Chapter 8, we identified hepatitis 
E virus (HEV) as a novel opportunistic pathogen in alloHSCT recipients. We discovered a 
relatively high probability of developing chronic HEV infection in patients who were 
mistakenly diagnosed with drug induced liver injury or hepatic GVHD. The incidence of HEV 
infection may be up to 2.4%, which should be included in the differential diagnosis of liver 
enzyme abnormalities post-alloHSCT.112 As serum immunoglobulins against HEV appeared 
not reliable for the diagnosis of HEV infection, we recommend the use of a HEV PCR in 
patients for whom impaired immune reconstitution is expected (eg, alloHSCT recipients). 
Supportive care post-alloHSCT is intended to prevent many of the above infectious 
pathogens and also depends on the phase after transplant. Generally, alloHSCT recipients are 
screened for viral reactivations and prophylactically treated for Pneumocystis pneumonia, 
HSV and VZV. In case complications may develop, intensive screening for viral infections 
or reactivations is recommended, preferably not only by serology, but also by PCR, as 
immunoglobulin responses fail to occur in most alloHSCT recipients. 
Predictive models
With GVHD and infections being the most common causes of alloHSCT-related mortality, 
the risk of mortality needs to be quantified. Composite risk scores have been established, 
which allowed to predict for NRM and overall outcome. Two generally approved transplant-
risk scores have been developed and validated, including the EBMT-risk score113 and the 
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Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI).114 The EBMT-risk score 
is based on patient and transplantation characteristics, which was developed in CML 
patients and subsequently validated in other patient groups including AML.115,116 The HCT-CI 
originated from the Charlson Comorbidity Index117 and consists of 17 comorbidities which 
contribute to a cumulative score.114 The HCT-CI was extensively validated and has been 
continuously being refined including age, disease status, or bio-markers.118-120 Other groups 
have also developed predictive models for NRM, with some groups modifying the weights 
of the EBMT-risk score and the HCT-CI,121-123 whereas others combined transplant-related 
parameters and patient characteristics.124-126 A very interesting model was developed by the 
EBMT acute leukemia working party which is based on a machine learning algorithm.127 The 
model was constructed and validated in acute leukemia patients and based on 10 variables 
which strongly predicted for NRM at 100 days and at 2 years.126,128 With the introduction 
of RIC, alloHSCT has become a treatment option for older and medically less fit patients. 
However, both the EBMT-risk score and the HCT-CI performed less well in older patients 
receiving RIC alloHSCT.115,121,124,129,130 In Chapter 8, we developed a dedicated score integrating 
the EBMT-risk score and HCT-CI by reassessing the individual parameters in recipients of RIC 
alloHSCT with AML in first CR. Three risk groups were identified with increased predictive 
power in this subgroup of elderly patients, although external validation is needed. The lack 
of predictive power of the established risk scores and the development of a refined and 
dedicated model emphasizes that prediction of NRM requires a continued reassessment of 
risk scores. Predictive scores may also merit from studying specific subgroups, such as older 
patients who receive RIC alloHSCT, which is currently the majority of alloHSCT recipients. In 
addition, recent results of post-transplantation cyclophosphamide suggest a further decline 
of NRM towards 10-15%.58-63 Therefore, new developments in post-transplant care urges the 
need to continuously re-evaluate established risk scores for NRM, preferably in prospective 
studies.
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How to deal with alloHSCT in statistical analysis of AML patients?
Analyzing alloHSCT as PRT may yield statistical challenges and a number of methods have 
been developed and used over the years. Table 1 summarizes the different statistical 
methods with each their own advantages and disadvantages, which will be discussed here. 
Randomized studies
Obviously, the golden standard to compare treatment approaches continues to be a 
prospective randomized study to minimize selection bias and to allow for an intention to 
treat analysis. However, these studies have been extremely difficult to perform in the field 
of PRT in AML patients because of the divergent intensity of the treatment arms. Recently, 
patient numbers to be included in the randomized study from the EBMT (NCT00766779) 
comparing alloHSCT with no alloHSCT in elderly patients with AML had to be adapted due to 
slow accrual. Alternative comparative methods were developed and applied as randomized 
studies are scarce, but the need for comparative data is high, with ongoing improvement of 
both conventional treatment and transplantation approaches in AML.
Donor vs no-donor analysis
First, alloHSCT has been evaluated by comparing patients with a donor vs those without, 
which analysis is based on a biological treatment assignment with the availability of a sibling 
donor.18-20,131 These studies allow for a prospective intention to treat analysis and thereby 
may approximate real randomized studies. However, concern has been raised that such 
a methodology may underestimate the donor group, because the percentage of patients 
actually receiving a transplant may be relatively low due to a number of reasons. First, the 
availability of a donor should not be mistaken for an intention to transplant, as indications 
and preferences may vary among countries, cooperative groups, centers, and individual 
physicians.132 Second, the availability of an HLA-identical sibling does not take critical 
eligibility criteria of both donor and recipient into account. Third, the actual percentage of 
patients receiving a transplant may also decline in patients with high risk disease, failing to 
achieve remission or encountering early relapse. These patients are less likely to receive 
an allograft in first CR, despite an identified donor and being accounted for in the donor 
group of the analysis.133,134 With the advent of MUDs and their increasing application in 
AML, sibling donor versus no-donor studies have become obsolete. Therefore, alternative 
statistical methods were applied to compare alloHSCT with other types of PRT, including 
retrospective analysis, landmark analysis, or a time-dependent analysis.133,135,136
Retrospective analysis
Retrospective registry studies have been performed on a broad scale since the establishment 
of large registries, including the EBMT and the International Blood and Marrow Transplant 
Research (IBMTR). Retrospective studies compare treatment groups that include only those 
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patients, who actually completed the originally allocated treatment. The analysis provides 
an estimate of the true efficacy of an intervention, although selection bias may result in 
an exaggerated treatment effect, because of more fit patients in the transplant group, and 
unfit patients ineligible for alloHSCT in the reference group. That selection bias can only be 
minimized by excluding those patients in a retrospective comparison, but still that bias may 
compromise the comparison. Another type of selection bias that occurs in retrospective 
analyses is a time-interval bias, also called the guarantee time, which is the time from CR 
to transplant.133,136 Time to transplant may depend on different factors including donor 
search, hematological recovery and clinical recovery from previous chemotherapy. During 
the time needed to prepare for an allograft, patients may receive an additional course of 
chemotherapy, but also may experience disease relapse or even NRM. However, that does 
not apply to transplanted patients, especially those with a long guarantee time during which 
time period no early relapse occurred. The bias of guarantee time may be reduced when 
including that time-interval as a covariate in the multivariable analysis of a retrospective 
analysis. However, including a variable in a multivariable comparison does not solve the 
problem of its inherent bias. 
Landmark analysis
The landmark analysis is a statistical method that may account for the time-interval bias 
by attributing predefined guarantee time to all patients. However, determining a clinically 
relevant landmark time is very difficult in transplant studies as time from first CR to 
transplant may vary from a few weeks to a year. In addition, the type of risk differs between 
treatment groups and evolves in time. Landmark analysis may be used when a clinically 
relevant fixed time-point is present before the start of PRT, such as the 30-day period after 
induction chemotherapy for recipients not receiving PRT, as described in Chapter 3. The 
same selection bias applies to a landmark approach as compared with retrospective studies. 
In addition, a number of patients are excluded from the analysis because of early events, 
which subsequently may favor the alloHSCT group as early transplant-related deaths are 
more frequently excluded than relapse-related deaths in the reference group. 
Time-dependent analysis
The time-dependent methodology is a statistical method, which completely excludes the 
bias introduced by the time to transplant. That method was developed by Mantel and 
Byar attributing the favorable time period of guarantee time to the reference group.137 In a 
time-dependent analysis, patients are initially counted as at risk in the control group (right-
censoring) until alloHSCT and thereafter as at risk in the alloHSCT group (left-censoring). 
The time-dependent methodology has a number of disadvantages similar to the landmark 
analysis, including the selection bias of patients who actually received a transplant. Both 
analyses might favor alloHSCT recipients as patients who are not transplanted because of 
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ineligibility are included in the control group.136 However, the weight of events for relapse or 
NRM is less in the reference group in the early time period as the denominator of that group 
is larger and it lacks the events of the (right-censored) patients waiting for their allograft. 
The time-dependent methodology may also correct for the most important characteristics 
affecting relapse and NRM by multivariable analysis, as previously described by Simon and 
Makuch.138 We have used such an analysis with time-dependent covariates autologous HSCT 
and alloHSCT in Chapters 2, 3, 4 and 5. 
Which type of statistical method has to be preferred for analyzing PRT in patients with 
AML? Previously, Hospital et al.133 performed both a donor versus no-donor analysis and a 
time-dependent analysis of PRT with alloHSCT in a cohort of patients with adverse karyotype 
AML. The effect of alloHSCT was found to be stronger as compared with no alloHSCT in a 
time-dependent analysis, which may largely be explained by the percentage of patients not 
being transplanted in the donor group of the donor versus no-donor analysis. Collectively, in 
view of the advantages and disadvantages of the different statistical methods and the lack 
of randomized studies, a time-dependent method may currently be the preferred method 
for the comparative analysis of alloHSCT in AML, as retrospective and landmark studies may 
overestimate the effect of alloHSCT. 
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Table 1  Types of comparative studies evaluating alloHSCT
Type of study Principle Advantages disadvantages
Prospective 
randomized
Randomized 
allocation of 
treatment
• Intention to treat
•  No selection bias, which  
creates comparable groups
•  Observer bias is minimized
•  Exclusion of non-eligible patients
•  Randomizing treatments with 
divergent intensity may not be 
ethical and feasible
•  Patient refusal
•  AlloHSCT not applied in all 
allocated patients
Donor vs  
no-donor
Treatment  
allocation based  
on the availability  
of a sibling donor
•  Biological randomization 
based on sibling donor 
availability approximating  
a randomized study
•  Intention to treat
•  Observer bias is minimized
•  Can be incorporated in  
well-designed prospective 
AML studies
•  Donor availability does not imply 
intention to transplant or actual 
receipt of alloHSCT 
•  The use of unrelated donors 
overestimates the no-donor group
Retrospective Comparison of 
patients who  
actually completed 
the treatment
•  True effect of alloHSCT
•  Easily applicable by most 
international transplant 
registries
•  Selection bias of patients who 
actually received transplant
•  Time-interval bias
•  Incomplete picture of preceding 
treatment and medical history
•  No or incomplete data monitoring
Landmark Analysis from a 
 fixed time point 
after the initiation  
of therapy
•  Less time-interval bias
•  To be incorporated in 
prospective studies
•  Clinical relevant landmark time may 
be difficult to determine
•  Selection bias of patients who 
actually received transplant
•  Loss of patients
•  Time interval bias caused by 
landmark (exclusion of more early 
events in the alloHSCT group than 
the reference group)
Time-
dependent
Analysis from the 
start of post-
remission treatment 
(or achievement 
of CR) allowing for 
patients to switch 
from treatment 
groups
•  No time-interval bias
•  True effect of alloHSCT
•  Allows for evaluating a 
number of time-varying 
covariates
•  Selection bias of patients who 
actually received transplant
•  Interpretation of non-
proportionality of time-dependent 
covariates may be difficult
9
204
Future perspectives: personalized PrT approach for AML patients
Given the many variables associated with outcome and their possible opposing effects, it 
seems no longer acceptable to propose a ‘one size fits all’ model in decision making for 
PRT. That approach would imply an application of alloHSCT only based on AML risk groups, 
although neglecting a number of important parameters impacting on overall outcome 
after alloHSCT, autologous HSCT or continued chemotherapy. The following characteristics 
would need to be incorporated in a personalized approach: leukemia risk, MRD status, and 
the risk for NRM. Integrating all these parameters, I would propose a personalized model 
for the application of alloHSCT in patients with AML in first CR as summarized in Figure 2. 
Leukemia risk is based on the ELN risk classification,1 and MRD status may be determined by 
multiparametric flow cytometry or quantitative PCR. NRM risk may be estimated by using 
risk scores which are preferably dedicated for a specific patient subgroup and validated in 
different studies. 
Favorable risk AML patients without MRD may not be transplanted in first CR, which 
procedure may be reserved for salvage therapy in second CR. However, the risk of relapse in 
favorable risk patients who harbor MRD after induction chemotherapy may still be significant, 
evoking the question which type of PRT should be preferred. For those patients with a very 
low risk for NRM and a well matched donor, one might consider alloHSCT as PRT, whereas 
autologous HSCT or chemotherapy can be used in patients without a well matched donor 
and/or higher risk for NRM. AlloHSCT in patients with intermediate risk AML increasingly 
depends on the presence or absence of MRD. The possibility to apply alloHSCT in second 
CR provides an additional argument to refrain from allografting in intermediate risk patients 
without MRD, similar to the policy in favorable risk patients without MRD. Intermediate 
risk patients however with MRD qualify for alloHSCT unless a predicted NRM risk of 30% is 
exceeded. Adverse risk AML patients with MRD harbor the highest risk of relapse and are 
preferably transplanted as early as possible after obtaining CR. Patients with an adverse risk 
AML without MRD are also preferably transplanted, although patients with a high risk for 
NRM (>30%) may alternatively receive autologous HSCT or a third cycle of chemotherapy. 
Donor availability should not affect the indication for an allograft primarily, although it 
may be important when considering alloHSCT in patients with favorable risk AML with MRD 
or intermediate risk AML without MRD, for whom a well-matched donor may be preferred. 
Chapter 9
205
NRM low risk 
NRM
AML in ﬁrst CR
Favorable risk
Intermediate 
risk
MRD-
MRD-
consider 
AlloHSCT*
consider 
AlloHSCT 
No alloHSCT
or high risk
intermediate
NRM low or
risk
intermediate
Adverse risk
MRD+
MRD-
MRD+
MRD+
NRM high risk
AlloHSCT
Figure 2  Personalized transplant decision model for patients with AML in first CR
-  Leukemia risk is based on the ELN risk classification.1
-   Minimal residual disease (MRD) may be measured by either multiparametric flow cytometry or quantitative PCR 
for specific molecular markers
-   Non-relapse mortality (NRM) could be assessed by preferably dedicated predictive models. NRM low risk is 
considered as <15%, intermediate risk as 15-30%, high risk as >30%.
* In case a well-matched donor is available (ie, HLA-identical sibling or MUD)
†  Consider an alloHSCT based on donor availability and alternatively proceed to PRT with autologous HSCT or a 
third cycle of chemotherapy.
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The optimal conditioning strategy for patients with AML in first CR is still not clear, as 
recent randomized studies show no significant differences in overall outcome between 
MAC and RIC irrespective of age and comorbidity.56,57 Some studies suggested that specific 
patient subgroups, especially with high risk disease, may benefit from a MAC alloHSCT. The 
open question of preferred conditioning type and the continued decline of NRM necessitate 
further prospective studies evaluating both conditioning type and the risk of NRM, including 
other variables associated with NRM.
Post-transplant strategies for alloHSCT are continuously evolving in order to improve 
outcome. GVHD prophylaxis with cyclophosphamide has been established as an excellent 
post-transplant platform with low toxicity with NRM rates of only 10-15%, but maintaining 
GVL-effect. These promising results may impact on the indication of alloHSCT, but also 
urge the need to validate predictive scores for NRM in the setting of post-transplant 
cyclophosphamide. In addition, allogeneic immunotherapy may be improved by early 
tapering of immunosuppression and/or pre-emptive DLI for optimal leukemic control. In 
addition, the continued application of novel post-transplant strategies including epigenetic 
therapy to enhance the GVL-effect (ie, demethylating agents and histone deacetylase 
inhibitors63), new agents such as tyrosine kinase inhibitors for specific molecular mutations 
(ie, FLT3-ITD139, IDH1/2140,141) or targeted immunotherapy with chimeric antigen receptor 
T-cells may offer further therapeutic options minimizing relapse after alloHSCT.
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Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow characterized 
by impaired maturation and increased proliferation of myeloid progenitor cells. Although 
still based on morphological examination, genetic assays have become indispensable for 
diagnosis, risk classification, and treatment decision making. This thesis deals with the place 
of allogeneic hematopoietic stem cell transplantation (alloHSCT) as post-remission treatment 
in patients with newly diagnosed AML. The choice for alloHSCT increasingly depends on 
genetic characteristics of the leukemia, treatment response, and risk factors associated with 
the transplant procedure. The majority of patients obtain a first hematological complete 
remission (CR) after chemotherapeutic induction treatment, but the risk of relapse without 
further treatment constitutes the major obstacle. Post-remission treatment reduces the 
risk of relapse and may consist of continued chemotherapy, autologous HSCT and alloHSCT. 
The beneficial effect of alloHSCT is mainly based on an immunological graft-versus-leukemia 
(GVL)-effect of alloreactive T-cells resulting from allogeneic antigen disparity. The GVL-effect 
of alloHSCT was shown to provide the most effective anti-leukemic therapy in AML, but 
counterbalancing non-relapse mortality may compromise that favorable effect, especially in 
older patients or patients with comorbidities. Non-relapse mortality has been reduced with 
the development of reduced intensity conditioning regimens, whereas the alloreactive GVL-
effect was still present. Reduced intensity conditioning regimens broadened the application 
of alloHSCT, particularly for elderly patients or for patients with concurrent morbidity. The 
clinical decision for post-remission treatment is primarily based on the genetic risk profile 
of the leukemia, but also on other factors, including the possibility to harvest autologous 
stem cells, the availability of an allogeneic donor, and patients’ performance status with 
concurrent comorbidity (Chapter 1). The integration of all these parameters has become 
complex and asks for a personalized approach of patients with AML. The studies described in 
this thesis have addressed a number of these parameters, finally resulting in a personalized 
approach as regards transplant decision making. 
Previous studies suggested that the favorable effect of alloHSCT was limited to 
patients below the age of 40 years as a result of increased non-relapse mortality following 
myeloablative conditioning alloHSCT. In Chapter 2, the comparative value of post-remission 
treatment with alloHSCT, autologous HSCT and chemotherapy was addressed in patients 
with AML aged 40 to 60 years. Improved overall survival was observed by alloHSCT compared 
with chemotherapeutic post-remission treatment in patients with intermediate risk and 
adverse risk AML. In addition, the intensity of the conditioning regimen did not significantly 
affect the rate of relapse after alloHSCT, thereby questioning the necessity of myeloablative 
conditioning in patients aged 40 to 60 years. Of note, alloHSCT and autologous HSCT did 
not significantly differ with respect to overall survival in intermediate risk patients, although 
relapse-free survival was better following alloHSCT, suggesting that autologous HSCT 
remains a treatment option to be considered in patients with intermediate risk AML. 
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Chapter 3 describes a comparative analysis of post-remission treatment in patients above 
the age of 60 years. Post-remission treatment in these elderly patients was performed with 
alloHSCT following reduced intensity conditioning, which was compared with other types of 
post-remission treatment including, chemotherapy, gemtuzumab ozogamicin or no further 
treatment. The analysis showed that alloHSCT was associated with better overall survival 
compared with other post-remission therapies or no post-remission therapy, especially in 
patients with intermediate risk or adverse risk AML. Non-relapse mortality in these elderly 
recipients of reduced intensity conditioning alloHSCT was relatively low.
Patients with a cytogenetically normal intermediate risk AML may be further 
subclassified based on molecular markers including NPM1 and FLT3-ITD with its mutant to 
wild-type ratio. In Chapter 4, post-remission treatment with alloHSCT, autologous HSCT and 
chemotherapy was compared in a cohort of cytogenetically normal intermediate risk AML 
patients with available NPM1 and FLT3-ITD mutational status. Post-remission treatment 
did not differentially affect outcome in a favorable group of patients with mutated NPM1 
without FLT3-ITD. Outcome in patients with a high allelic ratio of FLT3-ITD appeared 
very poor, with low patient numbers hampering a comparison by type of post-remission 
treatment. In contrast, overall survival by alloHSCT following reduced intensity conditioning 
compared with chemotherapy was improved in a larger intermediate group, characterized 
by FLT3-ITD with a low allelic ratio and wild-type NPM1 without FLT3-ITD AML. Recipients of 
myeloablative conditioning alloHSCT and autologous HSCT yielded similar overall survival in 
that intermediate risk group, which did not significantly differ from post-remission treatment 
with chemotherapy. Thus, alloHSCT may be the preferred type of post-remission treatment 
in these patients with molecularly intermediate risk AML.
Chapter 5 addresses the GVL-effect of alloHSCT in patients with AML in first CR with 
or without minimal residual disease (MRD) as determined by flow cytometry. The GVL-
effect was considered as the relative reduction of relapse of alloHSCT compared with post-
remission treatment with chemotherapy or autologous HSCT. The GVL-effect appeared to 
be similar in MRD positive and MRD negative patients, which suggests that the alloreactive 
effect of T-cells rather depends on immunological characteristics and differences than on 
characteristics of the underlying AML. It further suggests that alloHSCT may be applied 
in both MRD negative and positive patients and that decision making should take other 
characteristics into account as well, such as risk scores for non-relapse mortality. 
Although alloHSCT may be the preferred type of post-remission treatment for patients 
with adverse risk AML, the preferred type of donor may be debated. Alternative stem 
cell sources are increasingly being used for alloHSCT, including matched or mismatched 
unrelated donors, cord blood grafts or haplo-identical donors. In Chapter 6, these different 
type of donors were compared with HLA-identical siblings in patients with adverse risk AML 
in first CR. The comparative analysis suggests that well-matched donors including HLA-
identical siblings and MUDs are to be preferred over cord blood grafts and mismatched 
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unrelated donors. Results of alloHSCT with haplo-identical donors are encouraging and 
approximate those of matched related or matched unrelated donors. However, comparative 
prospective studies of haplo-identical alloHSCT with other donor types are warranted and 
longer follow-up after haplo-identical alloHSCT may be needed to definitely establish its 
place in the hierarchy of alternative donors.
Non-relapse mortality after alloHSCT can be predicted by the hematopoietic cell 
transplantation comorbidity index (HCT-CI) and the European Group for Blood and Marrow 
Transplantation (EBMT) score, which are composed of different parameters. In Chapter 7, 
these composite risk scores were reassessed in a cohort of patients with AML in first CR who 
received an alloHSCT as post-remission treatment following reduced intensity conditioning. 
Both established risk scores showed relative weak predictive power. Subsequently, all 
parameters were reevaluated in a multivariable model resulting in the selection of a total of 
16 parameters, which were subsequently integrated into a new score. That integrated score 
yielded increased predictive power for patients with AML in first CR. The lack of predictive 
power of the established risk scores and the development of a refined and dedicated model 
emphasizes that prediction of non-relapse mortality requires a continued reassessment of 
risk scores.
Infectious complications are a common cause of non-relapse mortality following alloHSCT. 
In Chapter 8, we have been the first to study the incidence and sequelae of hepatitis E virus 
infection in recipients of alloHSCT. The incidence of hepatitis E virus was 2.4% in our study, 
whereas a number of patients developed a chronic hepatitis E virus infection. In our cohort, 
patients with a hepatitis E virus infection were previously diagnosed with hepatic graft-
versus-host disease or drug induced liver injury as a cause of liver enzyme abnormalities. 
Thus, hepatitis E virus infection should be included in the differential diagnosis in all 
recipients of alloHSCT with severe liver enzyme abnormalities.
Finally, a ‘one size fits all’ model seems no longer acceptable in decision making for 
post-remission treatment with many variables associated with outcome and their possible 
opposing effects. Precision medicine for patients with AML is urgently needed. Thus, the 
decision to transplant or not in an individual patient might depend on weighing the risk of 
relapse versus the personalized risk of non-relapse mortality. A personalized approach of 
post-remission treatment for patients with AML in first CR is proposed in Chapter 9. Such 
a personalized approach should be based on the risk of AML, MRD status and the risk for 
non-relapse mortality. However, prospective studies continue to be important to evaluate 
new risk parameters and to study their individual and integrated impact on personalized 
decision making.
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Acute myeloïde leukemie (AML) is een kwaadaardige ziekte van het beenmerg waarbij er 
sprake is van een verminderde uitrijping en een toegenomen proliferatie van myeloïde 
voorlopercellen. Hoewel de diagnose van AML nog steeds gebaseerd is op morfologie wordt 
genetische analyse steeds belangrijker voor de diagnostiek, risico classificatie, en de keuze 
voor behandeling van AML patiënten. Dit proefschrift bespreekt de plaats van allogene 
(donor) hematopoïetische stamceltransplantatie (alloHSCT) als behandeling voor patiënten 
met een nieuw gediagnosticeerde AML, die een remissie bereikt hebben na 1 of 2 kuren 
chemotherapie. De keuze voor alloHSCT als post-remissie behandeling hangt steeds meer 
af van genetische kenmerken van de leukemie, de respons op de voorgaande behandeling, 
maar ook van risicofactoren die geassocieerd zijn met de transplantatie. De meerderheid 
van de patiënten behaalt weliswaar een eerste hematologische complete remissie (CR) na 
inductie behandeling met chemotherapie, maar het risico op een recidief van de leukemie 
zonder verdere behandeling blijft een groot struikelpunt. Post-remissie behandeling 
reduceert het risico op een recidief en kan uiteindelijk tot genezing leiden. Deze kan bestaan 
uit het continueren van chemotherapie, een autologe HSCT, of een alloHSCT. Het gunstige 
effect van alloHSCT is voornamelijk gebaseerd op een immunologisch anti-leukemie effect 
van alloreactieve T-cellen, die reageren op antigeen verschillen tussen donor en patiënt. Het 
is aangetoond dat dit anti-leukemie effect van alloHSCT de meest effectieve behandeling 
is, hoewel sterfte gerelateerd aan de transplantatieprocedure dat gunstige effect teniet 
kan doen. AlloHSCT behandelingssterfte speelt voornamelijk een rol bij oudere patiënten 
of patiënten met comorbiditeit. Deze sterfte is afgenomen sinds de ontwikkeling van een 
minder intensieve voorbehandeling of conditionering voorafgaande aan de transplantatie, 
terwijl het anti-leukemie effect nog steeds aanwezig bleek. De ontwikkeling van minder 
intensieve conditioneringsschema’s hebben de toepassing van alloHSCT doen toenemen, 
in het bijzonder bij oudere patiënten of patiënten met relevante comorbiditeit. De 
klinische besluitvorming voor post-remissie behandeling is hoofdzakelijk gebaseerd op 
het genetische risico profiel van de leukemie (gunstig, intermediair of ongunstig), maar 
ook andere factoren spelen een rol zoals de mogelijkheid tot het verzamelen van autologe 
stamcellen, de beschikbaarheid van een allogene donor en de conditie van de patiënt 
inclusief comorbiditeit (Hoofdstuk 1). Het samenvoegen van al deze parameters voor de 
benadering van patiënten met AML is complex en vraagt om een individuele aanpak. De 
studies die worden beschreven in dit proefschrift hebben een aantal van deze parameters 
als onderwerp. Dit heeft geresulteerd in een voorstel tot een sterk geïndividualiseerde 
benadering van de besluitvorming om een alloHSCT al dan niet toe te passen. 
Eerdere studies hebben laten zien dat het gunstige effect van alloHSCT zich beperkte 
tot patiënten met een leeftijd van 40 jaar of jonger als gevolg van een toegenomen 
behandelingssterfte na een myeloablatieve conditionering bij de oudere patiënten. 
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In Hoofdstuk 2 wordt post-remissie behandeling met alloHSCT, autologe HSCT en 
chemotherapie vergeleken bij patiënten met AML in de leeftijdscategorie van 40 tot 60 
jaar. De overleving van patiënten met een intermediair of ongunstig AML risicoprofiel bleek 
beter te zijn na een alloHSCT vergeleken met post-remissie chemotherapie. Tevens werd 
gevonden dat de intensiteit van de conditionering van alloHSCT geen significante invloed 
had op het optreden van een recidief, waardoor de noodzaak van een myeloablatieve 
conditionering voor patiënten in de leeftijdscategorie van 40 tot 60 jaar ter discussie gesteld 
kan worden. Overigens werd geen verschil gezien in overleving tussen alloHSCT en autologe 
HSCT in patiënten met een AML met een intermediair risicoprofiel, hoewel de ziektevrije 
overleving wel beter was na alloHSCT. Deze resultaten suggereren dat autologe HSCT een 
behandelingsoptie blijft voor patiënten met een intermediair risico AML. 
Hoofstuk 3 beschrijft een vergelijkende analyse van post-remissie behandeling 
voor patiënten boven de leeftijd van 60 jaar. Post-remissie behandeling in deze oudere 
patiëntengroep bestond uit alloHSCT na minder intensieve voorbehandeling en werd 
vergeleken met andere vormen van post-remissie behandeling inclusief chemotherapie, 
gemtuzumab ozogamicin of geen verdere behandeling. De analyse laat zien dat patiënten 
die behandeld werden met een alloHSCT een betere overleving hebben vergeleken met 
andere post-remissie behandelingen of geen verdere post-remissie behandeling. Dit 
overlevingsvoordeel was vooral zichtbaar bij patiënten met een intermediair of ongunstig 
risicoprofiel. In deze oudere groep patiënten bleek de behandelingssterfte relatief laag 
door de toepassing van de minder intensieve voorbehandeling voorafgaande aan de 
transplantatie. 
Patiënten met een intermediair risico AML met normale cytogenetica kunnen verder 
onderverdeeld worden op basis van moleculaire kenmerken zoals NPM1 en FLT3-ITD, waarbij 
ook de ratio van gemuteerd versus wild-type FLT3-ITD in acht wordt genomen. In Hoofdstuk 4 
wordt post-remissie behandeling met alloHSCT, autologe HSCT en chemotherapie vergeleken 
in een patiëntengroep met een intermediair risico AML met normale cytogenetica, waarvan 
de NPM1 en FLT3-ITD mutatie status beschikbaar was. Het type post-remissie behandeling 
bleek geen invloed te hebben op de reeds gunstige overleving van een groep AML patiënten 
met gemuteerd NPM1 zonder FLT3-ITD. Patiënten met een hoge ratio van FLT3-ITD bleken 
een zeer slechte overleving te hebben, terwijl de patiënten aantallen te klein waren voor 
een vergelijking van de verschillende typen van post-remissie behandeling. Patiënten in 
een grote intermediaire groep bleken een betere overleving te hebben na alloHSCT met 
minder intensieve conditionering dan met post-remissie chemotherapie. Die intermediaire 
groep bestond uit patiënten met AML met een lage ratio van FLT3-ITD en uit patiënten met 
een wild-type NPM1 zonder FLT3-ITD. Patiënten die behandeld werden met alloHSCT na 
een intensieve of myeloablatieve conditionering of een autologe HSCT hadden dezelfde 
overleving in deze intermediaire groep, hetgeen niet significant verschilde van post-remissie 
behandeling met chemotherapie. Derhalve kan alloHSCT worden beschouwd als de post-
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remissie behandeling van keuze voor patiënten met een moleculair intermediair risico AML. 
Hoofdstuk 5 gaat in op het anti-leukemie effect van alloHSCT bij patiënten met AML in 
eerste CR met of zonder restziekte ofwel “minimale residuale ziekte” (MRD) wat bepaald 
werd met flowcytometrisch onderzoek van beenmerg of perifeer bloedmonsters na 
het bereiken van die eerste CR. Het anti-leukemie effect werd berekend als de relatieve 
vermindering van de recidiefkans door alloHSCT te vergelijken met post-remissie 
behandeling met chemotherapie of autologe HSCT. Het anti-leukemie effect bleek exact 
hetzelfde te zijn in MRD positieve en MRD negatieve patiënten, wat suggereert dat donor 
T-cellen met name reageren op de immunologische eigenschappen van de leukemiecellen. 
Het anti-leukemie effect is blijkbaar minder afhankelijk van de genetische eigenschappen 
van de leukemiecellen. Deze observatie geeft ook aan dat alloHSCT zowel bij MRD positieve 
als MRD negatieve patiënten toegepast kan worden en dat de besluitvorming tot alloHSCT 
niet zozeer hoeft te berusten op de MRD status, maar meer op andere kenmerken zoals 
genetisch profiel van de leukemie en specifieke risico scores voor behandelingssterfte. 
Hoewel alloHSCT de post-remissie behandeling van keuze is voor patiënten met een 
ongunstig risicoprofiel van de AML, zijn er verschillende typen van donoren mogelijk om de 
transplantatie mee uit te voeren. Stamcellen van een broer of zus, die wat betreft de witte 
bloedgroep, ofwel de “humane leucocyten antigenen” (HLA), identiek is aan de ontvanger, 
genieten nog steeds de voorkeur. Daarnaast zijn er verschillende andere mogelijkheden als 
een HLA-identieke broer of zus ontbreekt. Alternatieve stamcelbronnen worden steeds vaker 
gebruikt en bestaan uit goed passende vrijwillige onverwante donoren, navelstrengbloed 
transplantatie of haplo-identieke familiedonoren. Bij haplo-identieke donoren worden 
meerdere HLA verschillen tussen patiënt en familielid geaccepteerd. Hoofstuk 6 vergelijkt 
de overleving na transplantatie middels deze verschillende typen alternatieve donoren 
met HLA-identieke broers of zussen bij patiënten met een ongunstig AML-risicoprofiel 
in eerste CR. De uitkomsten suggereren dat goed passende donoren bestaande uit HLA-
identieke familie donoren en goed passende vrijwillige onverwante donoren de voorkeur 
genieten boven navelstrengbloed transplantatie of onverwante donoren met 1 of meer HLA 
verschillen. De resultaten met haplo-identieke donoren zijn veelbelovend en benaderen 
de resultaten van HLA-passende familiedonoren of onverwante donoren. Desalniettemin 
zijn prospectieve studies nodig die alloHSCT met haplo-identieke donoren vergelijken met 
andere type donoren. Pas dan kan alloHSCT met haplo-identieke donoren zijn definitieve 
plaats krijgen in de hiërarchie van de alternatieve donoren voor patiënten met AML. 
Sterfte geassocieerd met de transplantatieprocedure ofwel behandelingssterfte kan 
worden voorspeld aan de hand van de ‘hematopoietic cell transplantation comorbidity 
index (HCT-CI)’ en de ‘European Group for Blood and Marrow Transplantation (EBMT) score’, 
welke scores bestaan uit verschillende parameters. In Hoofdstuk 7 worden parameters 
van deze samengestelde scores opnieuw geëvalueerd bij patiënten met AML in eerste 
CR die behandeld werden met alloHSCT na een minder intensieve voorbehandeling. 
Nederlandse Samenvatting
A
224
Beide reeds gevestigde scores bleken een relatief zwak voorspellende waarde te hebben 
in deze patiëntengroep. Vervolgens werden alle parameters opnieuw opgenomen in een 
statistisch model, wat uiteindelijk resulteerde in een selectie van slechts 16 parameters, die 
behandelingssterfte goed bleken te voorspellen. Deze parameters werden geïntegreerd in 
een nieuwe score die een sterkere voorspellende waarde bleek te hebben dan de HCT-CI 
en de EBMT-score. Het gebrek aan voorspellende waarde van de gevestigde scores voor 
behandelingssterfte en deze ontwikkeling van een verfijnde en meer toegewijde score 
benadrukt dat een herevaluatie van reeds gevestigde risico scores noodzakelijk blijft. 
Infectieuze complicaties zijn een belangrijke oorzaak van sterfte na alloHSCT. Wij hebben 
als eerste groep de incidentie en verschijnselen van hepatitis E virus infecties beschreven in 
patiënten die een alloHSCT kregen (Hoofstuk 8). De incidentie van hepatitis E virus infectie 
was 2.4% in onze studie, waarvan een deel van de patiënten een chronische hepatitis E 
virus infectie had ontwikkeld. De leverenzym afwijkingen bij deze patiënten werden initieel 
beschouwd als passende bij graft-versus-host ziekte of medicatie geïnduceerde leverschade. 
Hepatitis E virus infectie moet derhalve worden opgenomen in de differentiaal diagnose van 
alle patiënten die zich presenteren met ernstige leverenzymstoornissen na een alloHSCT. 
Ten slotte kan worden geconcludeerd dat een algemeen geldend ‘one size fits all’ model 
niet langer acceptabel is voor de besluitvorming aangaande post-remissie behandeling van 
patiënten met AML vanwege de vele variabelen die invloed hebben op de uiteindelijke 
overleving. Een meer toegespitste benadering voor de individuele patiënt met AML is 
dringend nodig. Derhalve wordt voorgesteld om bij de besluitvorming tot wel of geen 
transplantatie zowel het risico van leukemie-recidief als het risico op behandelingssterfte 
mee te wegen. Een dergelijke individuele benadering van post-remissie behandeling 
voor patiënten met AML in eerste CR wordt voorgesteld in Hoofdstuk 9. Deze individuele 
benadering dient tenminste het genetische risicoprofiel van de leukemie, de hoeveelheid 
restziekte, en het individuele risico op behandelingssterfte te omvatten. Daarnaast blijven 
prospectieve studies nodig om nieuwe parameters te evalueren, maar ook om oude 
parameters in een nieuwe context opnieuw tegen het licht te houden. 
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Dear Charlie, it is a great pleasure to have you as an opponent at my thesis defense. I have 
enjoyed our scientific conversations at the EBMT-Acute Leukemia Working Party meeting, 
particularly those supplemented with a glass of wine. Although our first collaboration has 
not resulted in a publication so far, I am looking forward to work with you in the future. 
Beste Edo, ik wil je hartelijk danken voor onze samenwerking die heeft geleid tot een mooie 
publicatie. 
Beste Annelies, dank dat ik tijdens mijn stage infectieziekten af en toe tussendoor wat tijd 
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